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BACKGROUND NOTE
This project describes the development and application of a series of computer
programmes which have as a final objective the simulation of screening programmes
for cervical cancer. For convenience, this set of programmes is referred to as
the «IARC Model*, the name deriving from the author's place of work at the time of
submission of this project description, although some of the earlier work was
undertaken whilst the author was employed by the Leeds Area Health Authority.
Several colleagues have contributed to the work described here, and their
contribution is recognised in the Acknowledgements.
The project developed from work which began in 1977 with the objective of
defining the precise patterns of screening activity in the Leeds and Wakefield Areas
of Yorkshire, and calculating parameters of the natural history of cervical cancer.
A research grant from the DHSS was awarded for this study from April 1978 - March 1980,
with the author as principal investigator. During this period, an extension of the
original research proposals was accepted - the use of the data collected in a simulation
model of screening. The period of the research grant was thus extended (until
November 1980), and Dr A.D. Clayden joined the author as co-director of the project
with Mr P. Hodgson as research assistant, from June 1979 onwards. A report of this
project was prepared for the DHSS in May, 1981 (The Yorkshire Cervical Cytology
Screening Project. Final Report), and described the development and application of
a simulation model based on that of Professor E.G. Knox, and the outline of a design
for a microsimulation model. The development of the microsimulation design derived
from a considerable volume of published work (described in section III) , principles
of design of clinical trials, the experience of Dr A.D. Clayden in modelling techniques,
and programmes written by Mr P. Hodgson.
After the author's move to IARC in Lyon, a new version of the microsimulation
model was developed. Mr P. Hodgson was employed as consultant in November 1981, and
in consultation with the author developed a new programme (SI), incorporating some
of the elements of the Yorkshire design, and at the same time many of the data files
were changed and updated. During the following two years this programme has been
extensively modified, and the version presented in Appendix 4 of this project
description (S20) represents the 20th major revision. Most of these changes have
been made by the author, but Mr M. Smans kindly assisted with the writing of some
of the programme subroutines of S20 concerned with output tables. It is therefore
no longer simple to identify the precise authorship of the 1800 lines of S20.
The programme GMT0.F0R (Appendix 1) is a distant descendent of the programmes
developed by Professor E.G. Knox, but it has been much modified (mainly by the author,
but also by Mr Hodgson), so that a precise attribution is difficult. Other programmes
and their data blocks used in the model (e.g. Appendices 2,3,7) are entirely the work
of the author.
The application of the Model in the formulation of parameters of the natural
history of cervical cancer and the exploration of screening policies represents
the author's own work, although discussion and consultation with various colleagues
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There is now plentiful evidence from correlational and case-control
studies of the effectiveness of cytological screening as a means of preventing
cervical cancer. However, there is obvious disagreement about the form which
screening programmes should take; the solutions recommended by different
advisory committees vary widely. The choice of programme is governed
(implicitly or explicitly) by cost-benefit considerations - how to achieve
maximum reduction in incidence (or mortality) for the resources deployed.
Simulation models are a convenient and rapid method of exploring the
outcome of differently formulated programmes, and of demonstrating the
importance and interrelationships of the variables concerned. There are
however two main disadvantages to this approach. The first relates to the
imperfect state of knowledge about the natural history of cervix cancer,
especially the ages of onset, rates of progression and regression, and
distribution of sojourn times in the preinvasive and preclinical stages of
cervical cancer. In practise, the different assumptions about natural history
can lead to large variations in the apparently optimum programme. The second
drawback is that many simulation models are either too simplistic or too
abstract, so that verification of results against observed experience is not
possible.
The model described reproduces the vital events and the population
structure of England and Wales between 1961 and 1991. Onto this population is
superimposed the natural history of cervical carcinoma, using data derived
from several recent studies, so that the changes in incidence which are
currently taking place can be reproduced. The technical solution adopted is a
"microsimulation" - each individual in the population is retained as a unit -
which allows factors such as disease onset and screening uptake to be
dependent upon personal characteristics and past events. Screening can be
offered as part of a routine programme, or incidentally - for example during
pregnancy or hospital attendance.
The model allows quantitative evaluation of the complex patterns of
screening activity that are currently observed in western countries. In
addition, the relative importance of the different components of screening
programmes, and assumptions about natural history can be studied. The model




Carcinoma of the cervix was the first malignant disease for which pro¬
grammes of mass screening were introduced. It is of course well known that
this was done without the benefit of any evaluation of the effectiveness of
the procedure. Perhaps it was regarded as self-evident that regular cytology
examinations would be beneficial, but it is also the case that the need for
evaluation of health care programmes was not widely recognised at that time
(the early 1950's), and the problems peculiar to the evaluation of screening
procedures were less well known. Whatever the reasons, the lack of any study
involving longitudinal follow-up of women randomly assigned to different
screening schedules has been a grave disadvantage in deciding whether the
procedure is effective, and if so, how it should best be implemented in the
community.
It is now clear that the incidence of invasive carcinoma of the cervix,
and consequent mortality, can be reduced by the introduction of cervical
cytology screening. The evidence upon which this statement is based is briefly
reviewed later. However, there are clearly widely divergent views about the
form which a programme for screening the female population should take. As in
all decisions on the planning of health care, the ultimate point at issue is
the most efficient use of resources. The relationships of the outcome of
different screening programmes to the input of resources can-theoretically be
studied in experimental trials; however, in reality the number of possible
screening policies which could be adopted is very great, and such trials would
have to be very large and of very long duration to yield useful results. It is
in such a situation that the use of simulation models is particularly useful
in carrying out "simulated experiments" in a matter of minutes rather then
years. It is becoming more usual to use this approach rather than relying upon
entirely intuitive judgments when proposing screening policies. However, it
has to be admitted that most of the models which are described in the
literature are rather unconvincing; they are either rather elaborate
mathematical abstractions designed to demonstrate the properties of sampling
(screening) from populations with theoretical natural histories of disease, or
their construction is so simplistic that it is difficult to examine all the
factors relevant to the disease process or the screening programme.
This project grew out of an attempt to advise on a reasonable screening
policy to adopt for a population of women in Great Britain. The nature of the
evidence about the disease process, and the properties of the screening
examination are first reviewed, and then the construction of a model which is
designed to study the outcome of screening policies in such a population over
a short time period is described. The properties of the simulation model are
demonstrated by using it to examine the outcome of very different, if rather
theoretical, policies. The use of the model demonstrates the potential of this
approach, and highlights the areas where the acquisition of more data is
essential for the rational planning of screening programmes.
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II CONTROL OF CERVICAL CANCER
1. EPIDEMIOLOGY OF CARCINOMA OF THE CERVIX
There are many excellent reviews of the epidemiology and natural history
of cervical cancer, and it is not proposed to reproduce them here (see Rotkin,
1973; Walton et al, 1976; Cramer, 1982). Some of the factors that are
essential to the later discussions on screening programmes will however be
reviewed.
1.1 INCIDENCE AND MORTALITY FROM CARCINOMA OF CERVIX
1.1.1 International data
There are striking variations in the incidence of clinical cancer of the
cervix in different parts of the world. Data is available for comparison from
the volumes of Cancer Incidence in Five Continents. Fig 2.1 illustrates some
of the large differences between age-standardised rates for the period around
1975.
Within these data there are variations in age-specific rates. Fig. 2.2
shows age-specific rates for the period around 1960 (when little screening for
carcinoma of cervix was in progress) . In the high risk areas there is a sharp
increase in incidence after age 30 and a peak in the fifth and sixth decades.
In lower risk areas the rise is more gradual, ana a maximum incidence is in
older age-groups.
In interpreting data from different centres it is important to bear in
mind that there are potential sources of artefactual differences which are
peculiar to cervical cancer. Firstly, the ICD classification system allows for
the coding of "Uterus-unspecified" as follows :





173 Malignant neoplasm of













179 Malignant neoplasm of uterus, part unspecified
180 Malignant neoplasm of cervix uteri
181 Malignant neoplasm of placenta
182 Malignant neoplasm of body of uterus
The proportion of cervix cancers put into the unspecified category may
vary considerably between centres. Secondly "carcinoma in situ" may be
included in the figures for cervical cancer. This will certainly distort the
age distribution of cases, and probably also inflate overall incidence.
Thirdly incidence rates are presented per 105 women ; however not all women
are at risk - hysterectomy is a very common operation and the prevalence of'
hysterectomy in western countries means that calculated rates will under¬
estimate the true rates (per 10^ at risk).
Mortality data is also available on an international basis. Table II. 1
reproduces recent age-standardised (World population) mortality rates for 56
countries submitting figures to WHO (Segi et al, 1981).
Particular care is required in interpreting these rates, partly because of
known under-registration of deaths in some countries, but also because of
differential allocation of cervix cancers to the "Uterus-unspecified"
categories as mentioned above. Once again it is clear that there are wide
variations in mortality rates, which apparently vary at least eightfold in
Europe, (between Spain and Denmark). Hill (1975) reviewed international
mortality data, for uterine cancer as a whole. Table II.2 shows mortality
rates for two time periods, and the probability of a decline in rates for
cervical carcinoma. Evidence of decline has been of particular interest in
evaluating the results of screening programmes (see section 3.2.3).
1.1.2 England and Wales data
The features of incidence and mortality from cervix cancer in England and
Wales will be dealt with in this section, since some of this data will be used
later in the simulation model.
Fig. 2.3 shows the age-specific mortality rates for cervix cancer for a
recent period (1976-80); rates reach a maximum around age 55-60 and are then
relatively constant.
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Table II.3 shows mortality rates for 10 year age-groups for the period
1955-1980. The most interesting features in this table are the steady overall
decline in mortality, especially since the early 1960's, but within this the
recent increase in death rates among young women (aged under 35). At age 35-44
a decline occurred up until about 1974 since when the rates have increased. In
the age group 45-54 there was a rise in mortality until 1968, since when rates
have declined, and above this age the decline has been more or less steady.
Hill and Adelstein (1967) pointed out that mortality rates varied by year of
birth, and a more recent analysis is shown in Fig. 2.4. Mortality rates show a
decline in successive birth cohorts up to the generation born around 1906,
rise to a maximum for the 1921 cohort before falling to a minimum in the 1936
cohort. There has been a progressive increase in successive birth cohorts
since then. These changes were attributed by Hill and Adelstein to increased
risk of disease in women who passed the period of late teens and early
twenties at times of social instability (wartime). The recent abrupt increase
in young women has given rise to considerable concern (Adelstein, 1981).
Cancer registration data are available for the whole of England and Wales
from 1962 onwards for invasive carcinoma of cervix, and for carcinoma in situ.
Fig. 2.5 shows age-specific incidence rates for invasive cancer at four
different time periods.
In Table II.4 are shown age-specific incidence rates for invasive
carcinoma of cervix; these show trends very similar to the mortality rates,
with recent rises in incidence in young women (under 35) , a rise in the
age-group 35-44 since 1974 and a fall at age 45-54 after a maximum rate in
1967.
The corresponding cohort curves are shown in Figure 2.6. There is a close
similarity to the mortality curves; maximum rates are seen in the 1921 cohort
and minima in that of 1931. There is a progressive rise in incidence rates in
birth cohorts born since then. Some of the rise in incidence in young women
might be attributable to the registration of micro-invasive cancers,
discovered at screening, in recent years. Calculations based on possible
numbers of such cases suggest that . this can account for only a small
proportion of this change, and a true increase in risk has occurred in recent
generations. Part of the apparent bimodality of the age-specific incidence
curves for 1976-78 (Fig. 2.5) is explained by the low rates at age 40-45
arising in women from the low risk 1931-36 birth cohorts. The remainder is
probably due to the effects of screening (see section 3.2.3). The supposition
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that such bimodality is caused by two distinct biological components of
cervical cancer (Ashley, 1966; Hakama & Penttinen, 1981) is not necessary.
Registration rates for carcinoma in-situ are given in Table II.5. These
rates will be dependent upon the number of smears which are taken - as this
increases, so the number of positive cases will increase and the 'incidence'
6 . .
rate per 10 women will increase. In addition, completeness of registration is
almost certainly less for in situ than for invasive cancer. Table II.6 relates
number of smears taken (Roberts 1982 - see section 3.2.2) to the number of
registrations and indicates that not only has there been an increase in the
number of examinations, but the rate of positivity has shown an increase -
especially under age 35. In view of the fact that with the progress of time a
larger proportion of smears are repeat examinations on the same women, a
reduction in proportion of positives might be anticipated. It is hard to
escape the conclusion that there is a true rise in incidence of in-situ cancer
in young women (Draper & Cook, 1983).
1.2 RISK FACTORS FOR CERVICAL CANCER
The factors which can be identified as being associated with increased or
decreased risks of cervical cancer have been reviewed by Rotkin (1973) , the
Walton report (1976), Hulka (1982) and Cramer (1982). They are briefly
summarized below.
Carcinoma of the cervix can easily be demonstrated to occur at increased
incidence in urban rather than rural residents, in blacks compared to whites
and in people of low social class compared to those of high. It is more common
in married women than single, and in widowed or divorced women than married
(Leek et al, 1978). The incidence of ' disease increases with the increasing
number of pregnancies, and with decreasing age at first pregnancy. A variety
of sexual behaviours are clearly associated with increased risk; early age at
first intercourse, multiple sexual partners and a history of veneral disease.
It is clear that these variables are highly correlated - thus there is
little or no independent effect of age at first marriage or age at first
pregnancy when the relationships are controlled for age at first intercourse.
Likewise marital status, number of marriages and history of venereal disease
are related to cervical cancer via the directly associated variable of number
of sexual partners. The importance of identifying directly associated
variables rather than indirect or confounding factors is obvious if the focus
is on the quest for aetiological agents. As will be discussed later, however,
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it is less important when cancer control programmes are considered, when an
indirectly associated variable, such as marital status, may serve to identify
groups at increased risk of disease.
Various other variables have been postulated in the past as important risk
factors, but their importance is now generally discounted; for example age at
menarche, coital frequency and age at menopause. Circumcision of the male
partner has been extensively investigated - the consensus view seems to be
that if it is a risk factor it is a weak one, and is possibly related to
penile hygiene. The possible role of the male partner in the disease aetiology
is also suggested by associations with the social class of the husband,
husbands whose jobs involve extensive travel, marital clusters of cervix
cancer (cases in two or more wives of the same men) and concordance of
cervical and penile cancer in married couples.
The role of contraception in aetiology is difficult to determine. Studies
are particularly hard to design and interpret because the use of different
contraceptive methods is closely related to the known risk factors for
cervical neoplasia (sexual activity). In addition to this, contraceptive users
are often subjected to frequent cytology testing during their attendances for
family planning services; thus the chance of their being found to have
preclinical disease is clearly much enhanced. Barrier methods of contraception
appear to reduce the risk of neoplastic disease, but there is considerable
controversy over the possible effects of oral contraception. Much of the early
work was reviewed by a scientific group of WHO (1978). The Oxford Family
Planning Study (Vessey et al, 1983) suggested that the incidence of neoplasia
(all degrees, from dysplasia to invasive disease) was 75% higher in oral
contraceptive users than IUD users, and that the relative risk was closely
related to the duration of use. This is the most convincing evidence to date
of a direct effect of steroid contraceptives on the cervix, but it is quite
possible that the effects observed were the result of confounding by sexual
factors.
The central role in aetiology which variables associated with coitus
clearly play has suggested several causative mechanisms. Two factors
associated with coitus itself are mechanical trauma and exposure to semen.
Coppleson & Reid (1978) suggested that there may be a carcinogenic factor
in sperm, and Singer et al (1976) further suggested that this could be related
to the seminal DNA interacting with that of the host to initiate epithelial
transformation.
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A more popular hypothesis to explain the link between cervical cancer and
early intercourse/multiple partners is the possible role of a ve.nereally
transmitted infection. The candidate most frequently advanced as the
responsible agent is the Herpes Virus type 2 (HSV2) . There have been a number
of studies which demonstrate an excess of antibodies to the virus in cervical
cancer compared to controls : Table II.7 from Cramer (1982) summarises the
results of ten such studies. In addition there are reports of herpes virus
genetic material in cervical cancer cells (Frenkel et al, 1972; Aurelian,
1974) and the virus has been shown to have oncogenic potential in other
species (Rapp & Duff, 1973). The evidence incriminating HSV2 as a possible
causative agent has been consistent, and has survived attempts to explain the
association as one confounded with other variables of sexual activity; it
seems unlikely that much more light will be shed by further retrospective
studies. Whatever its role the virus is almost certainly neither a necessary
or sufficient cause of cervical cancer.
Recently it has become apparent that infection of the cervical epithelium
with the human papillomavirus can give rise the cytological and histological
picture of dysplasia in the absence of visible condylomata (Meisels et al,
1981). It is not clear whether this infection has become more common recently
or, more likely, awareness of the rather subjective morphological features of
viral infection has increased its recognition. It is unknown whether the
dysplastic changes observed can progress to invasive cancer.
2. NATURAL HISTORY OF CARCINOMA OF THE CERVIX
2.1 THE NATURE OF PRECURSORS OF CLINICAL CANCER
Perhaps more has been written about the natural history of cervical cancer
than about any other tumour. This is because the disease occurs in a
relatively small area of squamocolumnar junction, and it is relatively
accessible to examination. This availability to cytological and histological
examination, and more recently the increasing use of, and experience in col¬
poscopy, has permitted the identification of a series of sequential changes
from normality to frank malignancy. Although the general pattern of such
change is now accepted, there is controversy over the precise rates of change
involved, and associated with this, the best nomenclature to use.
It was the widespread introduction of cytological examination of the
cervix (with biopsy of cervices showing abnormal patterns) which led to the
■
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identification of pathological conditions which were clearly related to
carcinoma of the cervix. This latter connection was surmised not only on the
basis of histological and epidemiological similarly, but as a result of early
work which demonstrated that many of the lesions so discovered would progress
with time to become clinically invasive cancer (Petersen, 1956). There was,
moreover, quite a distinct morphological gradation amongst these precancerous
intraepithelial lesions, ranging from a relatively slight disturbance of the
epithelial structure to the presence of small anaplastic cancer cells. These
latter lesions were termed "carcinoma in situ", whilst for those showing only
slight morphological abnormalities the term "Dysplasia" came to b>e used. This
latter is, then, rather a diagnosis of exlusion, being used for disturbances
of differentiation not amounting to carcinoma in situ; it is, furthermore,
frequently subdivided into mild, moderate and severe types.
These conditions are associated with the exfoliation of abnormal cells,
and smears made from these cells show a continuous gradation of changes. This
is a clear quantitative relationship between the histology of the cervix and
the cytological appearances observed (Maisel et al, 1963), so that the latter
may be reported in terms of the probable underlying histological changes.
Alternatively the cytological appearance is given some kind of numerical
grading, for example from I to V.
The validity of cytology and quantitative relationships between these
pathological states (rates of incidence, regression & progression) are dealt
with in more detail later (Section 2.3).
There seems no doubt that Dysplastic lesions can progress to in-situ
cancer and similarly that regression to normality is possible (Stern & Neely,
1963; Fox, 1967; Richart & Barron, 1969; Sedlis et al, 1970; Nasiell et al,
1975) . The more severe the degree of abnormality the more likely is
progression and vice versa.
Carcinoma in-situ is clearly a precursor of invasive cancer, follow up of
cases which are untreated is followed in a significant proportion by invasive
cancer (Petersen, 1956; Kottmeier, 1953; Kinlen & Springs, 1978). Apart from
direct follow up of in-situ cases there are other pieces of evidence
suggesting that this condition is a precursor of invasive carcinoma. Thus
carcinoma in-situ is frequently observed histologically at the margins of
invasive cancer, retrospective examination of biopsies of women subsequently
developing invasive cancer have been shown to demonstrate in-situ lesions
(Galvin et al, 1952), and careful serial sections of biopsies of cases of
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carcinoma in-situ has been shown to reveal foci of micro-invasion in up to a
quarter of cases (Friedell et al, 1958).
The question of whether carcinoma in-situ undergoes spontaneous regression
is more difficult to resolve because of problems inherent in the methods
available. Cases followed by serial biopsy are subject to the therapeutic
effect of the biopsy, cases diagnosed and followed by cytology only may have
been false positive on initial cytology or false negative on follow up.
Koss (1970) maintains that spontaneous regression in the absence of treatment
is a rare event. However, ethical constraints mean that there is now little
prospect of resolving the issue from longitudinal follow up of untreated
cases. The evidence available from population data suggest that the observed
prevalence of cis cannot be explained other than by allowing for the
probablity of regression.
The definitions of dysplasia and carcinoma in-situ already cited show that
the distinction between them is entirely arbitrary. In order to emphasise this
it has been proposed that the range of lesions be termed 'Cervical
Intraepithelial Neoplasia' (Richart & Barron, 1969; Koss, 1978) with grading
within indicated by the numerals I (slight morphological change) to IV
(carcinoma in-situ). This has the advantage of emphasising the unity of these
lesions, and from preventing a simple dichotomy of treatment of the patients
so diagnosed on the basis of an arbitrary division. However, it adds very
little to the understanding of the disease or the planning of screening, and
when used below it is merely as a synomym for "both dysplasia and carcinoma
in-situ".
2.2 RISK FACTORS FOR 'CERVICAL INTRAEPITHELIAL NEOPLASIA'
The relationship of dysplasia and in-situ lesions to invasive cancer is
shown by the similarity of the variables which have been identified as risk
factors. The usual method of study is by comparison of cases of CIN and
matched controls who have been attenders at screening programmes. The results
following are mainly from studies by Stern, 1969; Hulka & Zyzanski, 1971;
Thomas, 1973; Cooper & Hillier, 1975; Harris et al, 1980; Sweetnam et al,
1981; Parkin et al, 1982a.
Although dysplasia and carcinoma in-situ are, by definition, preclinical
lesions it has often been noted that their presence frequently coincides with
gynaecological symptoms. This could presumably be due to the co-existence of
CIN and other gynaecological abnormalities responsible for the symptoms, the
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association being due to the similarity of the aetiological factors involved.
Abnormal cervical pathology is associated with marital status, being more
common in married than single women and more prevalent still in the formerly
married, or those with a history of marital instability. Age at marriage and
number of marriages are also associated factors. An association between parity
(or gravidity) and CIN can usually be reduced by controlling for age and
marital status (although the study of Barron & Richart (1971) in Barbados
found an independent effect of number of pregnancies) . Race (negro vs white),
social class and variables connected with these (income, education, smoking)
have also been shown to be linked to abnormal cytology or pathology of the
cervix.
As with studies of the risk factors for clinical invasive cancer, there is
a need to distinguish variables possibly linked closely with causative agents,
and those which are confounding or secondarily associated. It seems that the
same factors are involved, most of the variables being more or less related to
coital practices, particularly early onset of intercourse, and multiple
partners (Meisels et al, 1977; Harris et al, 1980).
Abnormal cervical cytology is noted more frequently than expected during
pregnancy and the puerperium, and hence the rates of abnormality are higher
than average in women attending ante and post-natal clinics (Parkin et al,
1982a).This may reflect the possibility that pregnant women are in higher risk
categories (eg more sexually active) than the non-pregnant who attend clinics
for cytological examination. It is generally held that pregnancy itself does
not cause epithelial abnormalities, but the eversion of the endocervix
provides a greater area for dysplastic change during or soon after pregnancy
(Coppleson & Reid, 1966; Jones et al, 1968). Dysplastic changes noted during
pregnancy may be relatively transient (Lurain & Gallup, 1979).
As in the case of invasive cancer, the role of contraception is difficult
to determine. Increased rates of abnormality of the cervix are reported in
users of oral contraceptives (Stern & Clark, 1970; WHO, 1978; Vessey et al,
1983) - however this may be related to sexual activity, and hence to reduced
levels of abnormality in comparison groups. These latter may include users of
barrier methods of contraception; diaphragm users have been shown to have low
rates of preclinical abnormalities (Wright et al, 1978). The significant
relationship with length of use of oral contraceptives found by Harris et al
(1980) persisted after adjustement for number of sexual partners, and when
users of the pill are compared with users of other non barrier methods of
contraception. In this study, smoking appears as an independent risk factor.
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Th e possible role of HSV2 in the aetiology of cervix cancer has been
discussed, and Table II.7 summarises the results of case-control, studies of
positive serology; relative risks are higher for clinical disease than for
CIN. An association between cervical pathology and Trichomonas infection has
frequently been reported (Thomas, 1973; Parkin et al, 1982a). The association
may be due to the more direct link of sexual activity, but it has been
suggested that Trichomonas infection can lead directly to dysplastic lesions.
2.3 QUANTITATIVE RELATIONSHIPS IN THE NATURAL HISTORY
The evidence which has led to the general acceptance of the sequence of
histological changes in the natural history of cervical cancer has already
been described. It will become clear that such a general outline is quite
inadequate if it is desired to influence the development of disease by
intervening to interrupt this sequence - by a screening programme for
instance. Planning such programmes demands quantitative data on the inter¬
relationships involved.
The type of questions involved are : -
- At what rate do histological abnormalities arise in the population ?
- How is this rate influenced by risk factors (age at coitus, first
pregnancy etc) ? ie the size of the relative risk.
- What is the rate of development of the preclinical stages, and is this
also dependent on factors such as age, parity etc ?
This last question, on rate of development, is a crucial one. The
parameters of interest are really the distribution of sojourn times in the
different preclinical states (dysplasia, carcinoma in situ, occult invasive
cancer), and how these distributions are "influenced by other variables. It is
not surprising perhaps that the questions that have been answered (or, more
accurately, for which answers have been proposed) are much simplified
versions. Much effort has been expended to identify mean duration of these
states, although this is a meaningless statistic without some knowledge of the
range or shape of the distribution curve. Questions such as the percentage of
carcinomas in situ which will eventually become invasive, or the percentage of
invasive cancers which do not appear to pass through an in situ stage are also
merely indicating something about this distribution.
In studying the natural history, there are three methods which have been
used to throw some light upon the natural history of precursor lesions.
1. The study of the life history of the lesions themselves in individual
women (sometimes referred to as 'pathological evidence').
2. Inferring relationships between the different stages of disease from
observations on cross-sectional rates of incidence and prevalence in
populations. This latter approach requires the formulation of some kind of
statistical model of the disease process.
3. The longitudinal follow up of women subjected to cytological screening
to determine the rate of disease onset in those screening negative.
2.3.1 Studies of individual cases
The emphasis in such studies is to follow up a group of women with
preclinical disease to determine outcome, and to quantify rates of progression
or regression of lesions of differing grades of severity. A major drawback of
such studies has been that the methods available either lack validity
(cytology) or interfere with what is being observed (biopsy). Attempts to
diagnose and follow up cases entirely by cytology have the problem of false
positive and negative tests. It is impossible to decide whether transition
from positive to negative findings represent a true change, or whether the
first or second biopsy were false ! Attempts have been made to circumvent this
by requiring several sequential smears to show the same cytological pattern
before the 'diagnosis' is regarded as firm, but such a procedure precludes the
possibility of detecting rapid fluctuations in disease status. The alternative
approach requires that lesions are confirmed by histology of biopsy specimens;
here the obvious critique is that the biopsy may remove the original lesion,
or that the healing process following biopsy may also cure any adjacent
preclinical disease. There is no way to adequately answer such critiques, even
using modern methods of punch biopsy under colposcopic control, and the result
has been a widespread belief that intra-epithelial neoplasia can never
disappear spontaneously in the absence of external trauma.
A further problem in deriving quantitative estimates from such follow up
studies is that the cases observed will not be representative of the pre¬
clinical disease which arises in a population, because of length-biased
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sampling. For example, suppose that among incident in situ cases, 20% will
progress to invasion in two years, 30% in twenty years, and 50% will remain
unchanged (for, say, 40 years); then the relative likelihood that these three
types will be detected by a single screening test is 2:20:40. The proportion
actually observed will thus be 1.5%, 22.7% and 75.8% respectively - thus even
though 20% of incident cases have a short in-situ phase, it appears from
prevalent cases found on screening that this proportion is minimal.
Richart and Barron (1969) followed 557 patients with dysplasia. They found
low rates of regression to normality, but their criterion for inclusion in the
series wa.s three consecutive dysplasia smears. This would certainly have the
effect of enhancing the accuracy of the diagnosis of dysplasia (by eliminating
false positives) but at the same time it eliminates the possibility of
including patients with potentially transient lesions. Using various
assumptions (transition independent of age, independent of time, no movement
out of carcinoma in situ) they were able to estimate transition rates from
dysplasia to carcinoma in situ; approximately 30% had so progressed in three
years. The progression rates were closely related to the severity of the
lesion, as judged by the grade of the smear class. These authors review the
earlier literature on the outcome of patients with dysplasia. The majority of
these studies make no reference to the time base involved, so that rates of
progression or regression cannot be estimated.
Stern and Neely (1964) followed 130 women with dysplasia at intervals for
up to 9 years by repeated cytology, supplemented by periodic punch biopsies ;
i
criteria for diagnosis could be based on either. Because of the repeated
examination, each patient could contribute more than one interval observation
of progression and/or regression. They calculated progression rates from
dysplasia to carcinoma in situ of 6.4% per year, with higher rates of
progression in women under 45 years of age than those over 45. They also noted
high rates of regression (32% per year) but recurrence was common in this
group (33% per year). The authors note that these results would be markedly
dependent upon the failure to observe dysplasia cells during follow up
ir
examination (false negatives) giving rise to apparent regression and sub¬
sequent recurrence.
Hulka (1968) followed 480 women with 'atypical' cytological smears (which
were claimed to represent the pattern seen in mild/moderate dysplasia) and
noted that in periods up to 12 months 51.8% apparently regressed to
cytological normality whilst 14.2% progressed to 'suspicious' (representing
severe dysplasia, carcinoma in situ or invasive cancer). The results of the
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same series are presented in somewhat more detail in a later paper (Hulka &
Redmond, 1971). Rates of progression are not constant with time, but are high
during the initial period of follow up (6 months) and thereafter progres¬
sively fall. Progression rates are also influenced by age (higher at ages
30-44 than in younger or older women) and increase with increasing parity.
Progression rates were higher in atypical smears found at the first screening
(prevalent cases) than for those found during follow up of initially negative
tests (incident cases). This seems reasonable if it is postulated that the
prevalent cases would be at a more advanced stage of development, and that
atypical smears preceded by one or more negative tests are more likely to
represent transient lesions which regress spontaneously. The accuracy of the
data produced is entirely dependent upon the ability of the cervical smear to
reflect the underlying histology, and false positive or negative tests will
markedly influence apparent progression or regression. The data produced by
the authors suggests a far from perfect correlation between cytology and
histology ; of the 99 cases apparently progressing from atypical to
'suspicious' cytology, 42 had either negative histology, or changes of
mild/moderate dysplasia only.
Fox (1967) followed 278 women with cytological appearances of mild to
moderate dysplasia (diagnosis being based upon a single smear). 86 apparently
regressed (63 within 12 months) and 167 showed cytological appearances on
follow up which necessitated cone biopsy, final diagnosis being 164 with
severe dysplasia or carcinoma in situ.
In the series of 1712 cases reported by Nasiell et al (1975) mostly
followed without biopsy, regression was observed in 64% of mild 'dysplasias',
54% of 'moderate dysplasias' and 43% of 'severe dysplasias', the mean follow
up times being 2.1, 4.6 and 4.1 years respectively. The yearly probability of
progressing from moderate dysplasia to severe dysplasia or C.i.s. was
estimated to be 6-10%.
The fate of carcinoma in situ, if untreated, is even less well documented
than that of dysplasia, since the former condition is usually regarded as
sufficiently serious to demand complete excision (in the past this has usually
been by cone biopsy, but treatment by laser has become fashionable more
recently). Petersen (1956) in a well known series reported on 127 patients
with histological appearances equivalent to carcinoma in situ followed up
without treatment for a minimum of three years, after which period 11.4 % had
progressed to cancer and 24% showed regression of histological changes. It
should be noted that these patients had been initially detected because of
-13-
syraptoms (and hence some may have actually had invasive disease not seen on
biopsy), and that diagnosis and follow up involved biopsies which presumably
would enhance the prospects of cure (apparent regression) . The only British
series to yield comparable information is that of Kinlen and Spriggs (1978)
who followed 70 women with positive cervical smears (without distinction as to
histological category) who had escaped biopsy for a minimum of two years. Ten
patients had developed invasive cancer after a mean interval of 5.3 years.
Biopsies were obtained from 53 of the remainder ; 19 showed regression to
normal (this group was younger than the rest, regression was not observed over
the age of 40) and a further three had micro-invasive carcinoma.
2.3.2 Population methods of estimating natural history
Several types of population data are available which can be used to derive
estimates of natural history. The most widespread are mortality rates from
carcinoma of cervix (from vital statistics systems) and incidence rates for
clinical cancer of cervix which can be provided by population-based cancer
registries. Information on the postulated precursor conditions (dysplasia,
carcinoma in situ, preclinical invasive cancer) can only be derived from
surveys of the population, which in practice means that they are derived from
the results of screening programmes. The defects of this source of data are
mentioned later.
The simplest type of inference made from population data has been to
compare the mean ages of women found to have carcinoma in situ with the mean
age of onset of clinical cancer, the suggestion being that the interval
between estimates the duration of the preclinical lesion (eg Boyes et al,
1962; MacGregor and Baird, 1963). There are certain fallacies in such an
approach. Firstly two different types of measure are being used - one is of
onset (incidence) and the other of prevalence ; presumably the prevalent cases
of c.i.s. would be at various stages in their evolution. The second problem is
that the data sources are entirely different, and since the mean ages derived
will be weighted by the age composition of these populations, the estimates of
difference would be accordingly biassed. \
The first clear statement of how population data can be used to derive
parameters of natural history was made by Dunn (1953) and restated somewhat
more clearly by Knox (1966) who also outlined the further studies that would
be needed to provide such data.
It is necessary to point out at this stage that practically all population
studies make use of cross-sectional data on age specific incidence and
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prevalence to infer something about what might happen to individuals, or
single cohorts of women. The fallacy of such an approach is well known in
epidemiological reasoning. However the fact is that there are no data on a
single cohort which might be used instead. The nearest approach to this is the
British Columbia study (Boyes et al, 1982) which examines data from two birth
cohorts observed over a 20 year period.
The second feature of such studies is that they all rely, implicitly or
explicitly, upon some model of the natural history of cancer of the cervix. In
general, in order to keep the number of parameters to those which can be
estimated from available data, rather simplified models of the natural history
have to be adopted. This is an acceptable approach provided that the data
available from populations under study is compatible with the simple model to
be used ; this is not always the case, as will be described.
The papers by Durin (1953) and Knox (1966) outline how, if age-specific
incidence and mortality of clinical cancer, and prevalence of preclinical
stages are known, then some knowledge of incidence of preclinical disease
means that the parameters of interest can be estimated. Dunn is mainly
concerned with estimating mean duration of carcinoma in situ, and how this
might vary with age, the necessary assumption being that all such lesions
would ultimately progress to clinical disease. Knox on the other hand stresses
the use of the data to estimate the proportion of in-situ lesions that
progress (or regress), and also the proportion of invasive lesions that arise
between screening examinations. This latter statistic in conjunction with
estimates of mean duration would begin to indicate the information that is
truly required, that is the distribution of sojourn times in lesions
progressing to invasive disease.
At the time these papers were written there was little available data on
the prevalence or incidence of preclinical carcinoma of the cervix. Knox's
paper described the ideal study vhich could provide the data needed. This
involved investigating a (preferably random) group of 100,000 women with three
successive smears. The first examination would allow estimation of prevalence
rates, whilst the second, carried out very soon afterwards, would allow error
rates to be calculated and corrections made to the prevalence figures. The
third examination, after intervals ranging from 1.5 to 2.5 years, provides
data for estimating incidence. Not surprisingly, a study of such size and
complexity has never been performed. Instead there are available results
derived from screening programmes in various centres.
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Th e first problem raised by the use of such groups is the non-random
nature of the population examined. It is well known that women who attend
screening programmes are not a random section of the female population, and
many of the respects in which they differ are related to cervical cancer and
its precursors (Section 3.2). It has been noted that quite a large proportion
of women attending for cytology examination may have gynaecological symptoms
(Parkin et al, 1982 a) ; if interest is in preclinical precursors of carcinoma
of cervix then patients with symptoms due to such underlying disease (but not
to other diseases) should be excluded - hardly a practicable proposition.
A second problem is that screening programmes are designed specifically to
interrupt the natural history of cancer by identifying and removing possibly
precancerous lesions. Studies of natural history have not always allowed for
this; for example estimates of prevalence of preclinical disease will depend
upon the previous intensity of screening in the population. In addition the
phenomena of "length bias" (Feinleib & Zelen, 1969) means that, where the
preclinical lesions concerned have differing rates of growth and progression,
lesions which are detected in a population that is more or less unscreened
will be relatively benign or slow-growing compared with those discovered
during an ongoing screening programme.
Screening programmes involve cytological examination, followed by further
investigation if the cytological pattern appears to be abnormal. The lack of
validity of cytology as a predictor of underlying pathology of the cervix is
fully discussed in Section 3.2.1. Estimates of numbers of pathological lesions
present are based only on subjects with abnormal cytology, and will under¬
estimate the true numbers since false negative cytology examinations will not
be biopsied. Furthermore, attempts to infer the course of pathological
abnormalities of the cervix by serial cytology examinations will be misleading
to the degree that false-negative and false-positive tests will be included.
The extent of investigation of cytologically abnormal subjects is, in
pratice, related to the degree of abnormality observed, so that women with
apparently mild changes may be followed up by cytology alone,and may fail to -
attend such appointments# since there is some correlation between cytological
patterns and underlying histology, it is not safe to assume that the distri¬
bution of pathological changes in cytologically abnormal subjects biopsied vs
not biopsied is the same. Nevertheless some such assumption must be made in
practice.
PREVALENCE OF DISEASE
For reasons discussed, presenting prevalence data for populations subject
to repeated screening is meaningless. Similarly crude rates - eg at all ages -
are worthless since they will be highly dependant on the ages of the group
examined.
Fig 2.7 and 2.8 show cross sectional prevalence data by age in previously
unscreened populations, two British and three North American. The North
American series and that from Yorkshire are based on women receiving first
examinations in screening programmes, and that from Cardiff derive from the
65% of ever-married women in the city, previously unscreened, who accepted an
invitation to be examined. None can be considered as a random sample,
therefore. In all these studies, the method of determining the numbers of
women with cervical pathology (smear test followed by confirmatory histology
on those abnormal) leads to prevalence figures being in fact the prevalence of
true positive tests. The true population prevalence can be estimated by
dividing by the sensitivity of the test (see section 3.2.1).
The low rate of histological follow up in cases with only lesser grades of
cytological change meant that the absolute values of the prevalence rates of
dysplasia for Cardiff were of little value. Nevertheless those workers have
produced particularly useful figures for the relative prevalence of different
pathologies in different subgroups of the population (see Fig 2.9).
Only one study has attempted to estimate age-specific prevalence in birth
cohorts. Boyes et al (1982) studied the results of screening on two birth
cohorts (born 1914-18 and 1929-33) between 1940 & 1969.
Although in theory this should have allowed comparison between the rates
of disease at ages 35-39 in the two cohorts, this in fact proved impossible
since the women screened in the early years of the programme gave atypical
results (they were often referred because of symptoms). Nevertheless the
prevalence (and incidence) rates in adjacent age-groups were similar, which
encouraged the authors to combine both sets of data as a single series.
Table II.8 shows prevalence data from this study, including the figures
corrected for false negative tests (the method of estimation of false negative
rates from this study will be described later) . The figures for carcinoma in
situ or worse include lesions which subsequently proved to be microinvasive or
occult cancer ; however such cases were a minority (< 10% under age 40, 15%
-22-
over age 40) and the prevalence of c.i.s. is considerably higher in this
series than in any of those shown in Fig 2.8. Conversely the prevalence of
dysplasia is rather low. This may be largely due to the exclusion of smears
showing mild (class 2) abnormalities which were not biopsied (not normal
procedure during the study period) or followed up for long periods without
resolution ; thus any true dysplasias likely to regress would probably have
done so. Differences in terminology may also be present.
INCIDENCE OF DISEASE
Incidence of cervical intraepithelial neoplasia should be calculated from
new cases occuring in a population known to be free of disease. Figs 2.10 and
2.11 present estimates of incidence of dysplasia and carcinoma in-situ in
relation to age. The date, of Dunn & Martin (1967) and Bibbo et al (1971) allow
the calculation of rates of new true-positives in women with more than one
previous negative cytology examination. However the rates of Fidler et al
(1968) and Parkin et al (1982 b) are based on new true-positives in women
"with at least one" previous negative cytology examination. If only one
previous test has been performed, the population will contain lesions missed
on that occasion (false negatives). Since at all but the youngest age groups
prevalent cases are more frequent than incident the actual number of 'missed'
cases may be quite high in relation to truly incident ones. Parkin et al (1982
b) comment that in their series the majority of women examined were likely to
have had more than one preceding test, hence such bias was probably small.
The estimated incidence rates from the British Columbia cohort study
(Boyes et al, 1982) are shown in Table II.8. Two approaches were used to
eliminate the effect of false negatives from initial screenings artificially
inflating incidence. The first involves calculating the rates using only the
data least affected by false negatives (second smears 3 years or more after
the first, 3rd smears with intervals over 23 months and subsequent smears with
intervals over 11 months), the second uses estimated false negative rates to
make the necessary adjustments.
In the context of using statistical models to derive transition rates
between preclinical states, or to clinical disease, it is important to be
certain exactly what is meant by incidence of carcinoma in situ. In all of the
series quoted the calculations are based on new cases in a population known to
be normal (assuming the problem of false negatives is allowed for). If a
screening programme detects lesions at an earlier stage than c.i.s., and some
form of therapy is instituted, the incidence rates for c.i.s. derived as above
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cannot be usued to estimate the probability of progressing from normal to
preclinical disease. .Moreover, where more than one preclinical stage is
recognised which are sequentially related, the incidence rates of each will be
influenced by the interval elapsing between the first (normal) and second
examinations. Population based data cannot be used to resolve the question of
the proportion of dysplasias that progress to carcinoma in situ.
Fig 2.12 shows the relationship between prevalence of clinical/preclinical
disease and incidence of preclinical lesions based on the British Columbia
data of Fidler et al (1968) . The lower curve is the cumulative incidence of
clinical cancer (for British Columbia 1955-1957). Above this line is added the
prevalence of in situ cancer detected on screening in 1960-66. (Age specific
prevalence for micro-invasive and occult invasive disease is not given and may
in fact be included in the in situ figures; even if not, these only make up
about 10 % of preclinical carcinoma detected, so that the inclusion of these
conditions would only raise the upper prevalence line slightly). The
cumulative incidence of in situ cancer plotted on the same curve excedes the
summed prevalence curves by a factor of about two. Superficially this suggests
that only about half of the incident in situ cases will progress to clinical
cancer.
Other possible explanations for this discrepancy exist. Firstly, because
incident data was calculated in women having had at least one negative smear
(rather than two or more) , the presence of false negatives at the initial
screening may have lowered prevalence and raised incidence rates. Secondly, it
is possible that a cohort effect is present, that the younger women with
incident in situ carcinoma in this population will suffer higher rates of
clinical cancer in future.
A similar comparison was carried out by Dunn & Martin (1967) using data
from the San Diego County cytology registry. These workers derive incidence
and prevalence rates for dysplasia in addition to in situ and invasive
carcinoma. Incidence of dysplasia and in situ disease once again greatly
excede incidence of clinical cancer plus prevalent preclinical lesions
suggesting that regression occurs, and they suggest that "one would feel
intuitively that this would happen most frequently in dysplasia where
histological commitment appears less certain". They noted that incident cases
of in situ disease excede cases first appearing as invasive lesions in the
ratio 10:1; this suggests that only a small proportion of in-situ disease
progresses rapidly to invasion, but lack of suitable time data precludes
accurate quantitative estimation.
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Dunn (1953) pointed oat that, regardless of the fate of the lesions,
average duration can be estimated by the formula :
Age specific prevalence rates
^ Age specific incidence rates
The data of Dunn & Martin (1967) suggest an average duration of dysplasia
of 3.8 years and carcinoma in situ of 8.1 years ; Fidler et al (1968), using
the same technique, estimate average duration of carcinoma in situ to be 6-9.5
years.
The careful analysis of data from two cohorts of women examined in British
Columbia shows that the gap between incident and prevalent disease cannot be
explained either by carry over of false negatives or by a cohort effect (Boyes
et al, 1982). In this study the ratio between prevalence of c.i.s. plus
cumulated incidence of clinical cancer and the cumulated incidence of c.i.s.
is 0.67 by age 47 (see Fig 2.13), and the proportion of c.i.s. that progresses
to clinical cancer is 26% by age 50-53. (These figures are 0.86 and 53% if
incidence rates are calculated from first abnormality rather than mid-point).
Including figures for dysplasia leads to only a small increase in prevalent
disease plus clinical cancer, but a large rise in the cumulative incidence
(see Fig 2.13). This seems to imply that regression is particularly frequent
in dysplasia.
Kashgarian and Dunn (1970) present data from the Memphis Shelby county
screening project. The model of cervical cancer which they consider envisages
progression from normal to atypia, to intraepithelial carcinoma, to pre¬
clinical invasive cancer and then to clinical invasive cancer. In the analysis
of the data, however, cellular atypia is ignored. Prevalence of intra¬
epithelial carcinoma and preclinical invasive disease in an unscreened
population are presented (with some hypothetical reductions to allow for
screening of women with symptoms of cancer ; although how such symptoms were
defined is not stated). Incidence of in situ and preclinical invasive cancer
are computed from new cases in women with two previous negative smears, and
incidence of clinical cancer for some years before screening is presented. The
age specific incidence rates of clinical cancer of cervix are 2-3 times higher
than the British Columbia or England and Wales rates, and there was an
extremely high prevalence of invasive cancer found on screening - indeed it
was found more frequently than carcinoma in situ, the rates of which were
similar to those in Fig 2.9.
The cumulative incidence of intraepithelial plus occult invasive cancer
was quite close to that of observed clinical disease and prevalent cases
except in the older age-groups (see Fig 2.14) . It seems likely that the pre¬
valence and incidence rates calculated for the older age groups are inaccurate
because of small numbers and that computed rates of preinvasive disease are
underestimates because of the removal of cases showing 'atypia' after the
initial two screenings. Estimations of average duration from summed age-
specific rates suggest in situ disease lasting 10.7 years, and invasive
preclinical disease 5 years.
Barron & Richart (1970) present data on prevalence of abnormal cervical
smears in a small population in Barbados. With two rather unlikely assumptions
(that cytological grade represents underlying histology, and that regression
of lesions is impossible) they point out that the relative prevalence of each
grade of lesion would be proportional to its mean duration. The ratio of
transit times so estimated was similar to that observed in their US follow up
study (Richart & Barron, 1969).
In a later paper Barron et al (1978) use the British Columbia data of
Fidler et al (1968) to estimate the duration of carcinoma in situ. Unfor¬
tunately the model of the disease process which is used by these workers
involves a great many simplifying assumptions, so that the results quoted may
bear correspondingly little relationship to reality (average duration of
c.i.s. 3-10 years).
Albert (1981) describes a more complex model of disease which allows for
regression of carcinoma in situ. He uses the British Columbia data in this
model, and by what seems to be an iterative procedure produces best estimates
for the transition rates of interest. Unfortunately details of the precise
methodology are unavailable. The model ignores all abnormalities which may
exist before carcinoma in situ, they are subsumed in the "Disease Free" state;
it is thus highly questionable whether the British Columbia data on incidence
of carcinoma in situ are appropriate (this is based on transitions from normal
cytology to in situ disease). Moreover, since in reality dysplastic lesions
are identified on screening and subjected at the very least to more intensive
follow up than normals, the estimates of the proportion of occult invasive
cancers which derive directly from the "Disease Free" state (1/3) are highly
questionable.
The reason that simplified models of natural history have been so widely
used is however clear when the results of trying to derive parameters for more
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complex formulations are considered. Coppleson and Brown (1975) described the
natural history thus : -
<3 b c
Normal i. Dysplasia *C.i.s. ^ invasive cancer
^^
d
They used the data of Bibbo et al (1971) on incidence and prevalence of
dysplasia and C.i.s. together with age-specific rates of invasive cancer from
the US Third National Cancer Survey.
With five sets of transition rates to be derived it was not possible to
determine a unique 'best fit' natural history using population data alone.
Since the only transition rates which can be estimated from the data are
normal to dysplasia (a), and c.i.s. to invasive cancer (c), there are a whole
range of values for b, d and e which are compatible with the observed
prevalences! Knox (1973) had already pointed out the same problem in
describing his own simulation model, and employed several theoretical natural
histories typified as either 'dynamic' (permitting high regression rates) or
'progressive' (regression rates minimal).
2.3.3 Longitudinal studies of screened populations
The only observational data likely to yield information of practical value
is the follow up of participants in screening programmes to study the rates of
onset of invasive cancer at varying intervals after a negative screening test
(Walter and Day, 1983).
Immediately after a negative test, the incidence of clinical cancer is
reduced to a level corresponding to the false negative rate of the test. There
will then be a slow rise in incidence as cases with short preclinical sojourn
times become manifest. If a second test is performed, the incidence cases
thereafter will then consist of persons with two false screening results,
those arising between the two tests with one false result, and new cases since
the second test. Incidence data available after varying numbers of tests will
thus allow estimation of the unknown parameters of interest : false negative
rate and distribution of sojourn times prior to onset of invasion.
The essential data for this kind of study is the past screening history of
women found to have invasive cancer, and relatively large numbers of subjects
are required. No information will be forthcoming on the dynamics within the
preinvasive stages - however from a practical point of view this is of much
less consequence than modelling approaches which ignore the existence of early
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lesions. In practice, some form of intervention, even if only a more rigorous
follow up, is likely for such cases, so that the 'natural' history is, in
effect, interrupted. In planning screening programmes the essential knowledge
concerns the rates of development of all detectable preclinical lesions, and
the test characteristics.
3. PREVENTION OF CARCINOMA OF CERVIX
3.1 PRIMARY PREVENTION
Primary preventive measures for disease take the form either of reducing
exposure to risk factors, or increasing host resistance to them. Current
evidence suggests that the most important risk factors are related to early
onset of sexual activity and multiple sexual partners, possibly due to
transmission of an infective agent (viral). It seems highly unlikely that any
attempt to alter the sexual mores of society on public health grounds would
meet with any success whatsoever. Experience in attempting to reduce cigarette
smoking, where the relative risk of cancer is much higher, gives no grounds
for optimism. Genital hygiene is sometimes cited as a potential preventive
measure; apart from the imprecise meaning of this term, there is no evidence
whatever that cleanliness, though desirable on many other grounds, would be
preventive for cervix cancer. There is however some evidence, mentioned above,
that barrier methods of contraception reduce the risk of precursor lesions,
their use might be encouraged in preference to oral contraceptives especially
during early sexual life.
The suspicion that viral infection plays a role in the genesis of cervical
cancer has lead to hopes that the development of vaccines may allow prevention
by increasing host resistance. It seems likely that a vaccine against herpes
genitalis will be developed relatively soon, especially since this condition
is becoming a major public health problem in the USA. There are many problems
involved in evaluating the effectiveness of vaccines in preventing cancer, and
trials would have to be very large (Higginson et al, 1971). Furthermore,
herpes virus is almost certainly neither a necessary nor sufficient cause of
cervical cancer, and complete protection from vaccination is highly unlikely,
although incidence may well be reduced. The possible role played by human
papillomavirus infection in the aetiology of dysplasia has been discussed in
1.2; a great deal more epidemiological and laboratory research on the
carcinogenic potential of this virus is required before any trials of
intervention could be considered.
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3.2 SCREENING FOR CERVICAL CANCER
The description of the natural history of cervix cancer in section II.2
indicates the lengthy duration of histological abnormalities of the cervix
which precedes the onset of invasive cancer. The development of the
Papanicolaou technique for examination of cytological material obtained from
the cervix provided a method which could be used for the widespread screening
of women underlying abnormalities. The potential for prevention of invasive
cervical cancer seemed so clear that widespread screening was gradually
introduced in many countries in the 1950's and 1960's. There has been no formal
evaluation of the effectiveness of screening, with the result that there has
been a continuing debate as to its precise value (e.g. Knox, 1968; Foltz &
Kelsey, 1980).
3.2.1 Screening tests and their validity
Hie available screening tests all aim to obtain cellular material from the
cervix. This can be achieved by a cervical spatular scrape (usually with the
knuckle-ended Ayre's spatula:.), or a vaginal aspirate taken with a cyto-
pipette. The latter method seems to provide a poor yield of abnormal cells
when compared to the scrape (Wied, 1955). The sole advantage lies in the fact
that subjects can obtain their own specimens; however, this is more than
offset by inadequate sampling, poor motivation and organisational problems of
arranging follow-up (Anderson & Gunn, 1966; Reagan & Lin, 1967). The cervical
scrape administered by trained personnel still fulfills the requirement of
being a simple, cheap and acceptable method of sorting out the apparently
diseased (who probably have the condition under investigation) from the
apparently well (who probably do not). Screening tests are not intended to be
diagnostic, indeed the frequency with which a test result is later confirmed
by an acceptable diagnostic procedure is termed the validity of the test.
The results of a screening procedure can be conveniently summarised in the
form of a 2 X 2 table (Thorner & Remein, 1961).
TRUE DIAGNOSIS





b (false positives) a + b
d (true negatives) c + d
a + c b + d a + b + c + d
(= N)
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Frequently used measures of validity are the sensitivity of the test, i.e.
its ability to yield a positive finding when disease is present (aXa+c) in
above schema) , and the specificity, the tests ability to give a negative
result when disease is absent (b/(b + d)).
For some reason there is considerable confusion in the literature in re¬
porting validity of cervical cytology screening. In addition to the above
definitions, May (1974) proposed the following terminology : -
True positive rate (True prevalence) P U +
True rate of false positives fp bXfc + d)






Pseudo rate of false positives
r
P = b/fa + b)
Pseudo rate of false negatives
r
n = CXc + d)
Apparent rate of false negatives
r
an = C/(a + b)
When the prevalence of disease in the population is relatively low, b + d
C
will be quite close to N, and the false positive rate (*"p) can be approximated
by b/N.
The true positive rate (p) cannot be deduced from the results of screening
alone, which only produces an apparent rate of positives, Pa (a + b/N);
however it is common for screening programmes to cite their results in this
way, as the proportion of women examined who showed abnormal or suspicious
i
cytology. In order to derive P, the number of true positives (or false
positives) AND the number of false negatives (or true negatives) must be
known, and these cannot be identified immediately but only after careful
investigation and long term follow up. It is not correct to calculate false
positive and false negative rates using the test results as the denominator.
The identification of false-positive results entails the follow up of
subjects with positive cytological findings on screening. This is ideally done
by histological examination of biopsy material, but for milder grades of
cytological abnormality, follow up has- often entailed recall for subsequent
cytological examination. The results may be expressed as the proportion of
positive smears which prove to be false-positive on follow up (the pseudo-rate
of false positives, p) , or as the predictive value of a positive cytology
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test (1- rp) . Although the true false-positive rate (fp) cannot be directly
calculated, it is approximated by /N, which is given by :
Vn = rp x Pa = (b|a + ^ x (a + fc^N)
The value of Pa and rp are likely to be related, since the proportion of
smears in a screening programme which are judged 'abnormal" is subjective, and
depends on the proportion of borderline (class 2, dysplastic), smears which
are so classified- Where smears with mild grades of cytological abnormality
are followed up, a correspondingly high proportion will prove to have
insignificant underlying pathology, or will be transient in nature. This is a
specific example of the interrelationship of yield, sensitivity and
specificity and the choice of cut-off points in screening tests. Data from
screening programmes in Britain are given in the table below : -


















Cis (or worse) 0.5 %


















Figures from British Columbia (Boyes et al, 1982) suggest false positive
rates of 0.28 - 0.36 per 100 for dysplasia or worse, but on this study smears
showing grade 2 cytology were only included if the changes persisted. If all
class 2 smears had been included, the false positive rate would have been
considerably higher.
False negative error in cervical cytology screening can arise in two
different ways. The first of these is laboratory error, in which although
abnormal cells are present in the smear, they are not recognised by the
cytotechnologist. Laboratory quality control is aimed at reducing such error
to a minimum. In practice its extent can be estimated by reviewing previous
smears for women who have a detected abnormality.
The other component of false negative error is the absence of abnormal
cells on the slide, even though a lesion is present in the cervix. This might
arise due to non-exfoliation of atypical cells at the time of examination or
to faulty technique in taking the specimen or making the slide. It is more
difficult to measure, since this requires re-examination of a random group of
women screening negative to determine how many truly had histological
abnormality. Results are usually presented as the apparent rate of false
r
negatives ( an) , and values of 5-30% are reported (see review by Husain,
1976), the finding in Manchester for example was 14.9% (Husain et al, 1974).
As discussed by May (1974) the relationship between the true false negative
f r
rate ( n) and an is determined by the proportion of positive tests which are
r r
false positives ( p) . Using data from Sedlis et al (1964) he shows that an p
value of 70% converts an ran value of 30% to a true rate of false negatives of
59%. The data of Yule (1973) which includes an rp of 4% and a ran of 17.9%
yields a true rate of false negatives of 18.5%.
A different approach to the estimation of false negative error was
proposed by Knox (1966). Incidence is calculated from new cases arising in an
interval following a negative screening test. However, in the presence of
false negatives, these incident cases will be inflated by cases missed by the
first examination. The shorter the interval between the tests, the greater the
proportion of apparent incident cases which are "missed" false negatives.
Furthermore, after several smears have been taken any positive case is likely
to be a genuine new case, since the chances of a lesion being missed diminish
on successive examinations. Data which present incidence rates based on
second, third etc smears, and with different intervals between tests can
therefore be used to estimate false negative rates. A necessary assumption in
the calculations is that the chance of error is about the same at each
examination, and is independent of whether an error has already been made
previously. Coppleson & Brown (1974) used data presented by Christopherson
(1966) and Koss (1970) on rates of histologically proved abnormality in a
series of examinations on the same group of women. They calculated a true rate
of false negative tests of 20-45%. Boyes et al (1982) used a similar method -
however by reviewing the previous smears of new incident cases they were able
to eliminate laboratory error, so their-calculation on apparent incidence with
different intervals and smear ranks provided estimates of the residual
(non-laboratory) false negative error. This was 9.6% for cis (or worse) and
10.8% for dysplasia (or worse). There was a suggestion that the proportion of
false-negatives decreases with advancing age. Their estimate of laboratory




Screening programs which aim to examine whole populations of women have
been introduced in a great many parts of the world. It is not possible to
review these in great detail. The development of screening in England & Wales
will first be reviewed, then some of the better known programmes elsewhere
will be briefly described.
3.2.2.1 Screening in England and Wales
It is probably being rather generous to describe the development of
cervical cytology screening in England and Wales as a national
'programme'. For the most part the services which have developed vary
considerably from one place to another. Official policy was first
described in 1966 (Ministry of Health, 1966) as allowing for the
screening of women aged 35 and over at five yearly intervals, and
Hospital Boards were made responsible for providing the necessary
laboratory facilities. A standard form, HMR 101/5 (Fig 2.15) was provided
as the basis of a recall scheme. This was of five-copy form, the various
copies being retained by (i) the taker of the smear (ii) the subjects
general practitioner (if different) (iii) the examining laboratory (iv)
the health authority (v) the NHS Central Register. It was up to the
latter organisation, which filed all forms received in chronological
order, to operate a recall scheme. This was done by returning the copy
relating to the original smear to the local health authority (usually the
executive council/family practitioner committee) of the woman concerned,
providing that no evidence of an 'interim' smear, within 5 years of the
last, could be detected. The age for the first test was later modified to
include women who had had a third pregnancy. Only tests taken according
to these criteria were counted as items of service which were eligible
for reimbursement for the general practitioners taking the smear. Many
health authorities operated their own recall schemes which became
superimposed upon this national pattern, and the arrangements for the
centralised recall scheme have now been withdrawn (DHSS, 1981) . Each
health authority is expected to make its own arrangements for call and
recall of women for screening.
Within this rather vague outline, it is perhaps not surprising that the
actual service delivered has varied considerably between different areas;
in addition, the nature of service delivered bears little relationship to
a regular five yearly examination of women over 35.
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A review of routine statistics generated by the pathology laboratories
participating in cervical cytology testing, and by the NHS Central
Register was presented by Roberts (1982). There has been a rise in the
annual number of examinations carried out from about 7 X 10^ in 1965 to
2.9 million in 1980. Most of this increase has resulted from smears taken
by general practitioners (see Table II.9). The age-breakdown of the
examinees is also shown - it is notable that only a minority of smears
are taken from women aged 35 and over. Information on the results of
smears is notified to DHSS on forms completed by pathology laboratories
and hence a 'detection rate' (positive cases per 1000 total smears) can
be estimated. Table 11.10 shows estimated numbers of tests and the
detection rate by age and place of testing for 1980.
Statistics derived from forms HMR 101/5 are likely to underestimate the
amount of cytological testing performed, since a proportion of smears are
not accompanied by this form. Special studies are required to obtain a
complete picture of activity, and to elucidate the nature of the
population being tested in more detail. The study in Yorkshire in 1976-77
(Parkin et al, 1981) had this purpose in mind (Table 11.11). It was found
that approximately one third of tests were from various hospital sources,
mainly from gynaecology departments, or tests taken in association with
pregnancy (an estimated 80% of women having a child are tested before or
soon after delivery). One third of the women reported 'symptoms' at the
time the smear was taken, although more common in gynaecology patients it
was not confined to this group. The separation of smears into 'routine
tests' and 'diagnostic tests' is certainly not clear-cut on the basis of
place of examination. In any case the notion of a 'diagnostic' smear is a
curious one; most of the pathological conditions sought by cytology
('cervical intra-epithelial neoplasia') are asymptomatic, and a pap-smear
is certainly not an appropriate investigation if symptomatic carcinoma is
entertained as a diagnosis. The taking of smears from symptomatic
subjects is probably better considered as an example of selective
screening; such women have a higher rate of abnormal cytology than
asymptomatic subjects (see below) which probably reflects common risk
factors for various gynaecological diseases. Attendance in relation to
age and marital status is shown in Table 11.12. The overall average
attendance rate of 10.6% is the percentage of women aged 15 or more
living in the study area having a test in one calendar year. Within this
overall rate are larger variations by age and marital status. Between 20%
& 25% of married women aged 20-39 attended in one year, but attendance
rates fall off with age, and are lower for single women and widows/-
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divorcees than for married women. In order to achieve five-yearly testing
of the population, the minimum attendance rate must be 20% per annum -
however this supposes that no repeat tests are carried out, which was far
from being the case; 17.5% of the examinations were repeats of tests on
the same person during the 2 years of the study. Attendance was clearly
related to social class; there was a higher than expected proportion of
attenders in social classes I and II than in IV and V.
The screening programme in Manchester has been described in a number of
publications (Sansom et al, 1970, 1971) as far as testing of
'asymptomatic women" - i.e. excluding hospital tests - are concerned. As
in the Yorkshire study, the majority of tests were on women aged less
than 35, and social classes IV and V are underrepresented in women
receiving tests. The results of a planned policy of recall for repeat
tests after 3 months, 1 year, 2 years and 3 years has also been evaluated
(Sansom et al, 1975).
In addition to the DHSS policy described above, two other series of
recommendations have been formulated for England and Wales.
(1) The British Society for Clinical Cytology published a series of
recommendations in 1977 (Spriggs & Husain, 1977) .
i) Age for beginning screening : 25 for women presenting for
contraception, pregnancy or venereal disease; 30 if sexually
active and not already tested,
ii) Intervals of five years over age 35 (or three yearly if resources
permit). A first smear in a woman aged over 35 should be followed
by a second smear within a year to guard against false-negative
smear.
iii) Screening should cease at age 70 (but no age limit for first test).
(2) A working party was set up by the DHSS Committee on Gynaecological
Cytology in 1980 to consider possible changes in the current policy on
age and frequency of screening. This was largely a response to increased
mortality rates and the increasing numbers of positive smears in younger
women. The recommendations of this committee have been published (Draper,
1982). They are summarised below.
i) Smears should be taken at ages 35,40,45,50,55,60 and 65.
ii) No further smears need be taken for women aged over 65 who have had
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at least two recent negative smears (e.g. ages 60 and 65) and who
have never had a positive or doubtful smear,
iii) A smear should be taken early in the course of each pregnancy,
iv) A smear should be taken at age 22, or next visit thereafter, for
women attending for family planning advice, and who have not
previously been screened,
v) A smear at age 30, for women attending for family planning advice,
and who have not had a test during the previous five years,
vi) A smear should be taken on one occasion (or perhaps two) from any
other woman aged 25-35 who is, or has been, sexually active and
who requests a test,
vii) Smears taken at gynaecological clinics and STD clinics are
considered useful (but two smears during the same diagnostic
process are considered inappropriate).
3.2.2.2 Screening programmes elsewhere
ABERDEEN
A screening programme, originaly aimed at married women aged 25-60, was
started in Aberdeen in 1960, personal invitations to attend being sent by
post (McGregor et al, 1971; McGregor, 1976). Rescreening on a five-yearly
basis has subsequently been continued and smears are also taken at family
planning sessions and during pregnancy. It is claimed that by 1969 almost
90% of women aged 25-60 had been screened at least once. McGregor and
Teper (1978) compared mortality rates for the Grampian region (including
Aberdeen) and Tayside, with those for the rest of Scotland where, it was
stated, there is no established screening programme. Death rates in the
screened areas appear to be lower than in the unscreened (although the
significance - if any - of the differences is not reported).
CANADA
The 'Walton Report', published in 1976, reviewed in part II available
data for the Canadian provinces in terms of the intensity of screening
(number of cytologic examinations as a percentage of the female
population), the proportion of tests which were first examinations and
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the outcome in terms of change in incidence and mortality rates. The
recommendations made by this report were that screening for women 'at
risk' (i.e. sexually active) should be :
i) An initial smear at age 18.
ii) If initial smear satisfactory and negative, a second smear after
about one year (to allow for false negative examinations at first
screening).
iii) If initial smears negative, three yearly tests to age 35, then
five yearly to age 60. If all tests have been negative, screening
should then cease.
In addition, it was suggested that annual screening should be undertaken
for a high risk subgroup, defined as women with early onset of sexual
activity and multiple male partners. To this end cytologic specimens were
to be taken at family planning clinics, student health clinics, youth
clinics, venereal disease clinics, prenatal clinics and at medical
facilities where women are examined before admission to penal institutions.
These recommendations have been reviewed and revised in a further report
of the Canadian Task Force (1982). It seems that the task force considered
most women born after 1945 to belong to the previously defined 'high risk'
subgroup (and expanded this subgroup to include women whose husbands or
sexual partners had had multiple partners). Accordingly the recommenda¬
tions were changed, the concept of a 'high risk' group abandoned, and
annual screening recommended for all women between the ages of 18 and 35
who have had sexual intercourse. After the age of 35, five yearly
screening is suggested (although women over 35 considered as high risk, by
themselves or their physicians, are not to be discouraged from having
smears more frequently). These recommendations are based in part upon
results of a computer simulation exercise undertaken by Yu et al (1982) -
see Section III.
FINLAND
The screening programme in Finland was introduced in the early 1960's.
Every woman receives a personal invitation to be screened starting at age
30 or 35 and then at five year intervals until age 55. Response rates to
invitation for screening are over 90% (Hakama & Rasanen-Virtanen, 1976).
This programme which is run by the Finnish Cancer Society accounts for
less than one third of the smears taken in Finland (Timonen et al, 1974).
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The effect of screening on incidence of cervical cancer in Finland and the
other Nordic countries has been evaluated by Hakama (1982) - see Section
3.2.3.
ICELAND
Screening started in 1964, and from 1969 onward the policy is to examine
women aged 25-70 at intervals of 2-3 years (Johanneson, 1978). There
appears to have been a favourable impact on incidence on mortality rates.
NORWAY
In Norway, an organised screening programme was introduced in Ostfold
county in 1959. This took the form of invitations to attend for screenings
(intervals 2,3 and 3 years) for women aged 25-59. The programme yielded
information on attendance rates for screening, and rates of onset of
clinical cancer in women who did or did not attend. No generalised routine
screening programme has been introduced in Norway.
EAST GERMANY
In 1973 programmes were set up in Berlin and Rostock to study the effect
of different organisations (Ebeling et al, 1981). In Rostock personal
invitations were sent via a computerised system, whilst in Berlin
cytological examination was carried out during routine gynaecological
examinations with no personalised invitation. In both cities the objective
was to screen all women aged 20-65 every 2 years. It seems that the degree
of coverage achieved was about the same for the two systems. A fall in
incidence of clinical cancer, most notably in the age-group 40-59, has
been observed.
USA
For many years the general recommendation in the USA was to screen at
annual intervals after the age of 18 years. Recently a consensus statement
was issued by a group convened by the NIH (NIH, 1980) which recommended: -
i) Virgins should not be screened for cervix cancer,
ii) Screening should begin 'soon after the onset of sexual activity',
iii) The first smear should be repeated after an interval of one year,
iv) Rescreening should be carried out at intervals of 1-3 years (the
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precise figure to be decided jointly by the woman and her medical
care provider).
v) Mo further screening if two negative smears are obtained after age
60.
There have been several studies from the US reporting the results of
screening programmes, usually in terms of changes in incidence and
mortality rates. However, it is often very difficult to identify the
precise nature of screening carried out.
In Toledo (Burns et al, 1968) an attempt was made to invite all women over
30 for examination once per year by their own physicians - participation
was well below this target, but a decrease in invasive cancer was clearly
observed.
In Louisville (Kentucky) a programme was instituted in 1956 which
attempted to examine all females over the age of 20, and by 1967 it was
estimated that over 90% of the population had been examined at least once.
A decrease in mortality rates for Jefferson county (including Louisville)
was contrasted with the absence of change in the rest of the state where,
it is presumed, less screening was carried out (Christopherson et al,
1970).
In Olmsted County (Minnesota) , it was estimated that up to 63% of the
female population were examined at least once between 1960 and 1967 and
the average number of tests per woman was 2.7 (though there was no
organised programme as such). A fall in invasive cancer incidence and
mortality were observed for the same period (Dickinson et al, 1972a).
3.2.3 Evaluation of screening
Ideally the value of screening for carcinoma of cervix should be
demonstrated by a controlled trial, comparing incidence of clinical cancer in
the screened group with the unscreened. No such trial has ever been mounted,
so that the evidence available is less direct.
It is clear that women who do not attend screening programmes have much
higher rates of invasive disease and are detected at later stages than those
who do (Fidler et al, 1968; McGregor, 1976). However, women who do not attend
screening programmes are very frequently those at higher risk of disease, and
disease rates in the unscreened population are found to be higher than those
seen before the introduction of screening (Hakama & Rasanen-Virtanen, 1976).
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This self-selection bias makes interpretation of results in screened vs
non-screened difficult and unconvincing.
Cross-sectional studies attempt to relate the intensity of screening in
different areas with incidence or mortality of cervical cancer. The study of
Hill (1975) suggested that in countries where a decline in mortality rates was
probable, almost all had implemented screening programmes (this paper is
frequently cited as evidence of a universal decline of mortality rates prior
to screening, but in fact does not show this). Within the United States Cramer
(1974) found a positive correlation between the decline in mortality rates
and the annual rate of screening in each of the states. Miller et al (1976)
related an index of screening intensity (smears/1000 women/year) with changes
in mortality from uterine cancer for Canadian provinces and for counties or
census subdivisions. Hie results suggest that greater levels of screening are
associated with larger declines in mortality, even when various socio-
demographic variables for the geographic units are controlled for.
Guzick (1978) has reviewed the many studies which report trends in
incidence or mortality from cervix cancer in relation to the introduction of
screening programmes. For almost all centres, incidence has declined since the
introduction of screening (it was usually steady, or rising, beforehand), and
mortality rates also decline, usually some years later than fall in incidence.
Tables 11.13 and 11.14 are reproduced from this review.
Undoubtedly the best analysis of this kind is that reported by Hakama
(1982) who presents incidence data from the Nordic countries in relation to
screening. In these countries cervical cancer incidence was slowly rising
during the 1950's and 1960's. Nationwide screening programmes were introduced
in Finland and Iceland in the 1960's (all eligible women received personal
invitations) and the majority of women had been screened within a few years of
their introduction. In Sweden the programme was introduced more gradually
(county by county), in Denmark only some counties have been covered by
organised mass screening, whilst in Norway the only organised mass screening
has been in Ostfold county. The effect of screening on the trends on cancer
incidence' are clearly seen in Figure 2.16. Within those countries showing the
clearest changes, the age-groups subjected to screening (30-59) show a fall in
incidence which is not apparent in the older age-groups (Fig 2.17). A much
clearer effect is seen when the cohort curves for each country are examined.
In Norway there is a progressive rise in incidence at all ages for successive
birth cohorts (up to 1948). In Finland, Sweden and Denmark, however, the
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cohort curves for those generations subjected to screening appear to be lower
than expected in relation to earlier generations.
Similar changes are seen in the cohort curves for cancer incidence in
England and Wales (Parkin et al, 1984). Until the 1921 cohort the curves
appear regular and parallel, there is then an abrupt fall in the 1926-1936
cohorts, after which the rates again begin to show a rise (Fig 2.18). Using
data on registrations of in-situ cancers, an attempt was made in this paper to
estimate how much of the change seen is due to changing risk of disease in the
different generations, and how much is the result of screening. The curves in
Fig 2.19 represent the incidence rates as they would have been, assuming no
screening, and that half of the detected in-situ cancers would have progressed
to clinical cancer, the mean lead time being 8 years (several different
distributions of lead times in the detected cases were tested, but made little
overall difference to the pattern observed) . The cohort curves in this figure
are much more plausible in terms of changes between the succeeding genera¬
tions; they are more clearly parallel, and show a maximum incidence at about
50-55 years. They are rather similar to the pattern observed in Norway, which,
as already stated, has had little organised mass screening whereas the curves
actually observed (Fig 2.18) show changes similar, though less marked, to
those in Finland, Sweden and Denmark. Using this simple model of probable
events in the absence of screening, Parkin et al (1984) estimated the reduc¬
tion of incidence attributable to screening in England and Wales (Table 11.15).
A rather different approach to evaluation of the effectiveness of
screening is to utilise the methodology of the case-control study to estimate
the protective effect of screening tests. The principles involved have been
discussed by Morrison (1982) . Clarke and Anderson (1979) investigated the
screening histories of 212 cases of cervix cancer and 1060 age-matched
neighbourhood controls. The outcome measure was the degree of protection
conferred by a screening test in the five years preceding the year of
diagnosis - unscreened women had a relative risk of 2.7 compared to those
screened. A recent study in Geneva (Raymond et al, 1983) tends to confirm
these findings - the protection conferred by one or more negative tests up to
10 years before diagnosis (or the finding of a positive smear) was estimated
to be 3.2.
3.2.4 Problems to be solved
It seems quite clear from the numerous studies cited in the preceding
section that cervical cytology screening has been effective in reducing
incidence and mortality from invasive cancer. The main problem remains,
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however, the decision on the nature of service to implement. Section 3.2.2 has
outlined the very great variety of policies that have been suggested or
implemented. They are defined in terms of ages for testing, frequency or
intervals between tests, adjustment of protocols to allow for high risk groups
and the organisational setting for tests. Essentially the choice of programme
involves a decision on how the maximum benefit from screening (defined as
invasive cancers avoided, or life-years saved, perhaps) can be obtained from a
given input of resources. This is a decision based on analysis of cost vs.
effectiveness. (In the wider context of health care planning, the decision
must be made as to the appropriate resources to devote to screening for cervix
cancer as opposed to a totally different health programme; this need not
concern us here). The value of a screening programme is likely to vary
considerably depending on the precise pattern of service delivery adopted. For
this reason the simple checklist approach to deciding the value of screening -
for example the well known criteria of Wilson and Junger (1968), over¬
simplifies the issue by dichotomising the decision (screening useful/not
useful). The simultaneous evaluation of many different variables on a
quantitative basis requires some form of modelling approach. This is
considered in section III, but it is useful here to briefly review the factors
which have to be considered in the practical planning of a screening service.
Screening of the population always involves selection of subgroups for
examination. In the context of cervical cancer screening these are usually
defined in terms of age-groups (and, of course, sex!). The choice of age-
groups for screening depends, logically, upon a knowledge of the natural
history of disease. At the very least the prevalence of the condition sought
by the screening test in different age-groups should be known. In practice,
since screening will not be a single event, but a process repeated at
intervals during the life of an individual, knowledge of natural history
should include age-specific incidence rates of the conditions sought, and
their duration, and how this varies with age. The review of natural history in
II.2.3 has indicated the lack of detailed knowledge in this area.
As well as age, screening policies may use other risk factors to define
groups suitable for selective screening. It has already been noted that the
variables associated with an increased risk of clinical cancer are associated
also with higher risk of dysplasia and carcinoma in-situ. The variables used
as criteria for defining different policies do not have to be directly
causative. From a practical point of view this is of little consequence beside
the requirement that the relative subgroups can be easily identified. It
should be noted that selective screening need not imply an 'all or none'
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policy - screening only a particular subgroup of the population. Indeed, as
far as cervical carcinoma is concerned none of the known risk factors which
could reasonably be used have a high enough relative risk, or are sufficiently
prevalent, to justify screening only a subset of the population (Hakama et al,
1979), but it is easy to envisage policies which include the more frequent
screening of certain subgroups. Several demographic variables are associated
with increased disease risk (e.g. social class/occupation, marital status,
parity), as is current contraceptive practice. Hammond et al (1968) found that
women with 'complaints' (e.g. spotting, bleeding or vaginal discharge) were at
2-3 fold risk of cervical cancer (invasive or in-situ) for more than ten years
after two consecutive negative smears. This is in accordance with the
increased prevalence and incidence rates of precursor lesions in symptomatic
women (section II. 2.2) and such women form an obvious category for more
intensive surveillance.
As well as being related to disease risk, it is clear that there are a
number of individual factors which are associated with attendance at screening
programmes, marital status and social class, for example, (Parkin et al,
1981). These are both, as already described, associated with risk of disease.
Several studies suggest that non-attenders at screening programmes are a
particularly high risk group, having incidence rates which are higher than
those expected on the basis of incidence observed before the introduction of
screening (Hakama & Rasanen-Virtanen, 1976; Boyes et al, 1981). This is not
entirely surprising since non-attenders would be likely to be less health
conscious and more exposed to risk factors for cancer of the cervix. Thus, the
probability of attending for screening examinations is not equally distributed
in the population, attendance for future examinations can be to some extent
predicted from past screening history. These are important to consider when
predicting the outcome of a screening service, and in the practical planning
of service delivery.
Much of the literature on cervical screening concentrates on describing
the mass-screening programmes which have been added onto the health care
system. In reality, as described, a considerable amount of testing goes on
independently of such programmes - in gynaecology departments, V.D. clinics or
associated with pregnancy, for example. Although in the planning or evaluation
of screening projects it is convenient to ignore such tests (they are often
dismissed as 'diagnostic' investigations) they may form a substantial
proportion of the total examinations carried out. The women examined in these
settings frequently have higher rates of abnormality than the self-selected
group who attend screening clinics. Such testing probably has a substantial
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.effect on the natural history of the disease in the community, and
furthermore, tests taken at the time of other health-care activities represent
only a marginal increase to the cost of the encounter. An examination at a
screening clinic solely devoted to asymptomatic testing is likely to be more
expensive. For these reasons the existence of 'incidental' testing should be
taken into consideration when screening programmes are being planned (the
latest recommendations for England and Wales (Draper et al, 1982) appear to go
some way towards this).
The effects of lack of validity in the screening test itself have been
discussed in 3.2.1. The improvement of sensitivity and specificity of the
smear depend upon adequate technique in the taking and examination of the
specimen, essentially questions of quality control. It is worth noting that
the published data on false positives and predictive values usually come from
academic centres, and laboratories with interested and motivated staff. The
reality in a service setting may be lower sensitivity and specificity than
commonly reported. In addition to this, an area that has been little discussed
is the efficiency of follow-up and treatment when an abnormality has been
identified. Policies here appear to vary considerably; in general, coloscopy
and biopsy (perhaps preceded by a repeat smear) may be recommended for severe
cytological abnormality, minor dysplastic changes may be followed by a series
of smears repeated at intervals. It is unlikely that such follow up is
perfect, patients are likely to be untraced or unwilling to return. Kinlen &
Spriggs (1978) were able to report the outcome in 101 women with severe (grade
IV-V) cytological abnormalities who escaped follow-up for at least two years,
and the drop-out .rate for minor abnormalities is likely to be much greater.
Even after treatment by cone-biopsy recurrence of abnormal epithelium has been
reported (Kirkup et al, 1979), although this probably represents inadequate
treatment of the initial lesion.
The design of screening programmes should also take into account secular
trends in disease risk. It has been discussed in section II that in England
and Wales there appear to be quite marked changes in the risk of cervix cancer
(and presumably of its precursors) according to birth cohort. Screening
programmes should probably consider therefore whether intensity of examination




A model is merely a well-defined, well organised picture or description of
some aspect of the real world in which we are interested. This is indeed the
meaning of the word in everyday usage, and, although models may be qualitative
in character, scientific study usually requires the use of mathematical models
with a large quantitative component.
Four functions of models are commonly defined (Last 1982).
Predictive models are used to estimate the expected outcomes from one or
another response to a situation - for example population projections based on
different assumptions about fertility.
Organising functions of models include the synthesis of a complex of
related factors into coherent forms. In order to handle these complexities,
the variables used in the model must be conceived in a way that makes them
accessible to quantification, qualification and manipulation.
The mediating function reveals common ground between formulations that
appear distinct or disparate at first sight, but where the disparity is the
result of a narrow or individualistic viewpoint.
The analysing (or explanatory) function involves models that pose
different choices among the possible relations between variables. These are
models in which the same manifestations or results are obtained as the result
of different causal sequences. These different pathways demonstrate where
future studies are likely to be profitable in obtaining information on the
most likely causal pathway.
Early applications of mathematical models in the health care field were
concerned with modelling infectious disease processes, and the relatively
simple relationships involved often allowed these to be expressed in
mathematical terms (Bailey, 1975). Ideally, the expression of relationships
into an exact formula leads to the identification of a mathematical solution.
However more realistic and complicated models lead to extremely difficult
mathematical problems which may prove intractable or uneconomic to solve. The
advent of the computer has meant that there is less need to obtain elegant
mathematical solutions, and simulation techniques are much more easily
-45-
applied. The objective of a simulation model is quite different from the
analytical model, which sets out to summarise a set of observed relationships
as a concise algebraic equation and identify a generalisable solution.
Simulation is used to express the process rather than summarise the result,
and comparisons between the outcome of the process and available observations
are used to validate the adequacy of the model.
Many simulation models in health sciences work on the principle of the
Markov chain, which requires specification of a series of defined states, and
a set of transitions between them. A 'deterministic' model is one in which the
results or model output can be predicted directly from the input, and the
transfers carried out are proportional to the number of units in the initial
state. For example, if we have 100 units in A and a transfer rate from A to B
or 0.5, exactly 50 units will be transferred.
A 'Stochastic' model is one in which a probability element is incorporated
into mathematical formulae. In the example above, transfer of units from A to
B would be a random process, with the probability that any particular
individual will transfer being 0.5. The model output is expressed in the form
of a probability (or probability distribution), so that, for example, the
number of individuals in a particular state lies in a given range with a
particular probability.
An intermediate type of model (the 'Monte Carlo' model) uses probability
to generate the effect of chance or randomness on the situation being
described by using a deterministic model structure and allowing the chance
factors to influence, for example, the magnitude of transfer rates for
individual units. The difference between this type of model and a fully
stochastic model is that the latter is able to produce generalisable solutions
and give confidence ranges as an output, which Monte Carlo models can only do
by running the model a number of times.
2. THE USES OF MODELS IN STUDIES OF SCREENING
Simulation models have many advantages in exploring the outcome of complex
processes. At the very least they force the investigator to clearly identify
and quantify the premises from which he is working (which was termed the
'organising function' above).A simulation model of a screening programme will
therefore require precise, quantitative statements about natural history of
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the disease and the screening test characteristics. The relative importance of
the various premises to the outcome of the simulation can readily be explored,
a process termed 'sensitivity analysis'. Some assumptions about the disease or
the process of screening which might seem a priori of great importance may be
found to be irrelevant to. the outcome. The challenge that the simulation is
not realistic because of the false premises used (for example, about rates of
attendance for screening) is readily met by performing a simulation with
alternative assumptions. It may be that some of the values needed for the
model may only be present as possible ranges, or orders of magnitude. A range
of outcomes can be produced in order to express the effects of such
uncertainty - in effect producing a 'confidence interval' in addition to point
estimates.
Another advantage of the modelling approach is that it allows the checking
of model assumptions against observed data - the numerical values of the
parameters used - for example incidence of disease, prevalence at different
ages etc. should be consistent with those observed. Simulations using real
data should produce results which seem consistent with those observed in
screening programmes. In fact, the construction of a simulation model involves
the use of data on observed phenomena to help explain the processes involved
in the natural history of disease (a 'positivist' approach) , as well as the
use of various assumptions about the natural history and the screening process
to predict possible outcomes (a 'structuralist' approach).
The construction of a computer simulation model has an added advantage in
that programming is generally done in one or other high-level computer
language. The advantage of these is their structured, unambiguous format which
requires that all the relationships modelled must be explicit and quantifiable.
The major objective underlying the use of mathematical and computer
simulation models of screening programmes has been to serve a predictive
purpose. They have primarily been developed to answer questions concerning the
outcome of screening populations following the implementation of different
screening policies. Traditionally, of course, this is the role of the
controlled trial. It is, however, now probably impossible to carry out trials
of screening in real populations, both for ethical and technical reasons.
Although there is theoretically no ethical dilemma, in that the effectiveness
of screening is still controversial, in reality any such trial proposed would
be deemed unacceptable. The technical problems in designing a realistic trial
are also formidable. The large number of variables which require consideration
(eg ages and frequency of screening characteristics of target populations)
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would make such trials impossibly large (or numerous) and lengthy. It is quite
likely that after a large number of such trials, a high proportion of research
workers and clinicians would remain unconvinced of the results because of
differences in the populations of women, the manner of screening, type of
treatments etc. Doing a large number of trials carries with it the increased
risk of two similar trials showing different results by chance - leading to
calls for further trials. 'Artificial' experiments using simulation are
eminently practicable, however, and have the advantages already alluded to, of
being repeatable with different assumptions or incorporating new data, for
example on improved screening techniques or treatment for clinical disease.
The value of the modelling approach was stated succintly by Neuhauser in a
minority report to an 'NIH Consensus Statement' on cervical cancer screening
(NIH 1980). Hie Statement consists of suggested policies for screening, which
is presumably based on the collective guesses of the experts gathered together
at NIH in July, 1980.
The minority report concludes : "Computer-based models should be widely
available in interactive form allowing providers and patients to vary the
assumptions and consider the results. These models should be used in high
school courses and in health science museums. Cn the surface the controversial
issue is the frequency of screening. The real issue, however, is the role of
computer models in clinical decision making. These powerful techniques are new
to medicine, and not enough doctors are being educated in their use. This pap
smear debate will be viewed as one of the historical landmarks in this
transformation in clinical reasoning".
The analytic function of such models has been less extensively explored.
For carcinoma of the cervix, as will be discussed, there is considerable
debate about the precise natural history of the disease process. Dunn (1953)
was the first to extensively analyse in a quantitative fashion the type of
information that could be gathered from screening, and now this might be used
to define parameters in the natural history. The approach was taken further by
Knox (1966) who estimated sample size and follow up period required in order
to clarify the simple parameters of prevalence and incidence of preclinical
disease, and sensitivity of the screening test.
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3. REVIEW OF PREVIOUS WORK
An early use of mathematical modelling to study cervical cytology
screening was that of Dickinson & colleagues (Dickinson et al 1972, Dickinson
1972) . They used life table survival analysis on groups of patients found to
have cervical cancer (including stage 0) before and after the introduction of
screening, and applied an equation formulated by Berkson & Gage (1952) to
estimate cure rate and mortality risks in the two groups. The increased
expectation of life in the patients detected when screening was in progress
was used to evaluate the costs and benefits of screening during this period.
Eddy & Schwartz (1982) refer to this type of modelling as a 'Surface
Model' - it is used to tabulate observations and estimate the consequences of
an existing screening program. There is no attempt made to describe the
underlying disease process, or the dynamics of screening which led to the
observed events. "Deep Models" incorporate knowledge or assumptions on such
parameters, and are hence able to examine potential outcome of a variety of
possible policies which might be implemented. The other models reviewed are
all of this type.
The earliest work was that of Knox (1973, 1976) who developed a general-
isable computer simulation model for examining the outcome of screening
policies. The model was deterministic in type, and simulates events occuring
in a cohort of 10,000 women as they age from 15 to 95, the size of the cohort
being decremented each year of simulation in accordance with the expected
number of deaths, (mortality rates were obtained from a current life table).
The natural history of the disease is simulated by specifying up to 26
pathological "states" (including normal, dead of this disease, dead of other
causes) between which the population is divided. Up to 50 different types of
transition are allowed between these different states, the rate of transition
being expressed as the proportion of individuals who move from one state to
the other during each year of the simulation. A degree of sophistication is
introduced by making these transfer rates dependant upon age (for transfers
from the normal state) OR on duration' in the starting state (for other
transitions).
Hie screening process is simulated by a series of specifications: the
pathological states to which screening is to be applied, the probability that
an abnormality will be detected, and the state to which the proportion found
'positive' will be transferred. Note that the sensitivity of the screening
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test is thus required to be quantified for each abnormal state specified in
the model, since it is the proportion in each such state that are detected by
the test. The specificity of the screening test is in fact entered as false
positive rate (1-specificity), ie the proportion of normals who are found to
be positive and transferred out of the normal state.
The final series of specifications for the model Knox calls 'resource
deployment', and are the ages at which screening is to be "offered" to the
cohort (up to 30 individual ages) and the percentage of the population who
"accept". The uptake of screening programmes real life varies according to
factors such as age, marital status, social class etc. (Sansom et al, 1970,
1971; Parkin et al, 1981). Knox's model addresses this by making uptake of
screening dependent upon state (reasoning that the risk factors for cervical
cancer, and its precursor conditions, are the same as those that determine
attendance rates, or acceptance of screening).
Knox used the model firstly to explore the range of different natural
histories that were compatible with observed local data on cervical cancer
incidence and the prevalence of preclinical conditions (actually the pre¬
valence data for carcinoma in situ observed in British Columbia (Fidler et al,
1968) and incidence of clinical cancer in Birmingham were used). A range of
possible options were found to be feasible, and, two broad categories of
natural history; 'progressive' and 'dynamic' (the latter allowing for
regression of carcinoma in situ to normal), used for exploring screening
options. Various criteria are possible for evaluating outcome of screening
programmes, these include the percentage of deaths averted (compared to
background, no screening situation), the number of tests carried out per
averted death, and the number of positive tests per averted death. When a
programme of screening involving few tests per lifetime was simulated, he
found that these outcome measures were not very sensitive to the different
assumptions about natural history, but this became much more critical when
between five and ten screenings were carried out per lifetime. The marginal
returns of screening - that is the number of tests needed for each extra death
saved - became progressively smaller with increasing investment in screening.
Decisions about the apparent optimum ages for ten tests per lifetime were
sensitive to the choice of outcome measure; lives saved, life years saved, or
life years weighted in favour of the young.
Knox's work has recently been repeated by a group in Canada (Yu Shun-Zhang
et al, 1982) who used the identical computer program. Some simplifying
assumptions were made : for example only one preclinical pathological state
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(carcinoma in situ or worse) was modelled, and the possibility of detection,
surveillance and intervention before this ignored. The natural history
incorporated into the model was based initially on incidence data of carcinoma
in situ (or worse) in British Columbia (Boyes et al, 1982). However these
rates were tripled and the maximum incidence advanced five years to allow for
"an earlier and possibly more rapidly progressive natural history than that
... in the cohort born in 1929-33". In addition, onsets of preinvasive disease
were limited to ages under 55. Rates of progression to clinical cancer,
regression and mortality were adjusted to produce incidence and mortality
rates of invasive disease consistent with this hypothesis but it is not clear
whether such rates are compatible with observed data, nor whether model
predictions of prevalence of in situ disease are compatible with those
actually observed in British Columbia. The results are presented in terms of
ages at which the cohort should be screened in order to produce different
potential years of life saved, given different levels of input (number of
tests), test sensitivity and attendance.
Coppleson and Brown (1975, 1976) describe the development and use of a
simulation model similar to that of Knox. Cnly four states (normal, dysplasia,
carcinoma in situ and invasive cancer) are used with a series of transition
rates between them. The basic data chosen for their model were prevalence data
of dysplasia and carcinoma in situ (Bibbo et al, 1971) and incidence data of
clinical cancer from the Third National Cancer Survey in the US (Cutler &
Young, 1975). They found that a range of possible transition rates were
consistent with these data, but that it was necessary to postulate transition
rates dependent upon age (hence implying that the sojourn times are related to
age, duration in state, or both). The preferred set of transition rates which
they chose to examine screening options incorporated the maximum possible rate
of regression from dysplasia to normal, and the minimum possible rates of
transfer out of the state of carcinoma in situ.
They studied the outcome of different screening policies (specified as
different ages for screening) using cancers avoided, life years saved and
weighted life years as measures. The optimum ages for screening were dependent
upon the outcome criteria chosen (although the relationship between total
tests per lifetime and percent of the maximum possible saving achieved was
not). They also examined the effect of different false negative error rates
(1-sensitivity of test) on the percentage of possible savings that can be
achieved by a given number of tests per lifetime, and the marginal costs
(further tests needed) of finding each case according to the number of
screenings already done with different false negative error rates. Finally,
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they undertook a simple cost-effectiveness exercise by imputing a dollar cost
to each test and examining the theoretical financial consequences of different
outcomes for a stationary population. Unlike the analyses of Knox, no
correction is made for differential compliance with screening, and no attempt
was made to study the effects of other assumptions about natural history.
The Knox model has been adapted and used by a group of workers in the
Netherlands (Habbema et al, 1979). They first attempted to overcome one of the
major defects of the model, that it allows only for the testing of a single
birth cohort at different ages, by performing eight separate runs on different
birth cohorts. This allows a more realistic prediction of results in the Dutch
population where screening policies introduced in a given year will be
available for different lengths of time for separate cohorts. The group have
produced some results of sensitivity analyses where the possible effects of
Dutch screening policies are examined in terms of incidence and mortality of
invasive cancer given different assumptions about natural history (duration
and possibility of regression of carcinoma in situ) and test sensitivity.
A later publication by the same group (Oortmarssen et al, 1981) describes
the development of a different approach which aims to overcome some of the
other drawbacks of the single cohort deterministic type of model. A model
using a micro-level Monte Carlo simulation is described, in which the
individual lifehistories of a single birth cohort are simulated. For each
individual the age at death (from a life table) is determined, and also the
age at hysterectomy (from a probability table, source unspecified). The onset
of disease and transfers between the states of disease declared as the natural
history is a stochastic process which depends upon sets of transition
probabilities and dwelling time distributions for the different states. These
parameters are derived more or less empirically, and several theoretical
natural histories developed. Onto this background simulation of natural
history can be superimposed screening for disease, and this can be either
"routine" screening (eg at gynaecological attendance) , or as part of a mass
screening policy. The latter is simulated by specifying ages at test offer,
acceptance rates, detection rates (test characteristics) and the outcome for
individuals detected as positive. A wide variety of options is available for
treating this latter category.
Model output is essentially a comparison of various parameters in the
whole cohort between the background conditions (what would happen to each
individual if no intervention had taken place) , and the outcome for the same
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individuals in the presence of screening. Hoe indices used include disease
cases saved, lives saved, life-years saved, number of false-positives etc.
The advantage of this micro-simulation approach is that it permits the
modelling of interactions between factors; for example age-specific prognosis
distributions, correlations between sojourn times in successive disease
states, the non-independance of attendance probabilities at subsequent
screens, and between test errors on subsequent screens. The model also
addresses the possibility of having different risk strata in the population,
and permitting the evaluation of different mass screening programmes against a
background of "routine" testing.
However the basic philosophy of the single cohort approach is essential
for this model - a knowledge of what would have happened to each individual if
they had not died, had a hysterectomy, or been found positive on screening.
The difficulties in this approach were highlighted in these workers' earlier
paper, specifically in validating simulation results against those observed in
a population with changing disease patterns in different cohorts. Although not
explicitly stated, there must also be problems in defining realistic tran¬
sitional probabilities for hysterectomy and attendance at routine screening,
since the only available data are likely to be cross sectional, and cover
short periods of time.
Albert et al (1978 a,b) describe a mathematical model for examining
screening programmes. Its main objective appears to be analytical, attempting
to define the natural history of cancer as a series of mathematical functions,
rather than relying on the specification of states in a Markovian process,
with transfer rates between them. Thus the natural history of cervix cancer is
described as the distribution of sojourn times in the preclinical state
(which, incidentally is assumed to be exponential, with a mean of 7-8 years
and independant of age). The model examines the outcome in a population of
women with an age distribution of the US 1960 population over a fifteen year
period.
The outcome measures used relate to the proportion of disease detected in
in-situ or micro-invasive states as compared to later stages, in the presence
or absence of screening; the model is unable to examine effects on mortality.
The effect of a policy of annual screening is tested, and compared with highly
theoretical policies based on formulae which provide the optimum distribution
of tests at different ages to secure maximum benefit for minimum investment.
The authors claim no more than to have produced an initial methodology for the
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examination of screening programmes in general. Some of the assumptions
required in order to supply inputs for the model appear highly questionable,
and no attempt to examine the sensitivity of the results to different
assumptions has been made.
In a highly technical and detailed monograph, Eddy (1980) describes the
formulation of a theory which is stated to be generalisable to the solution of
all screening problems. The specific discussion is limited to analysis of
screening for cancer of the breast, however. It seems that his model has been
applied to cervical cancer screening, since a diagram linking increased life
expectancy and cost is reproduced; however no detail is available.
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IV THE IARC SCREENING MODEL
1. CONSTRUCTION OF THE MODEL
1.1. Introduction
The development of the simulation model currently used was a progressive
process, the original starting point being the computer program written by
Professor E.G. Knox some 10 years ago. A brief description of this macro-
simulation approach has already been given (section III), and two developments
of this are currently being used.
a) A conversion to an interactive menu-driven format. This program (MACRO)
\
has been used for teaching and demonstration purposes. Its simple output and
ready adaptability allows demonstration of the effects of frequency of
testing, ages of testing, acceptance of screening and test sensitivity with
different assumptions about natural history.
b) A simplified version (GENMAK) has been used to explore possible natural
histories. The main simulation model utilises sets of transition rates between
states ; some of these are available from published data (eg incidence of
dysplasia, mortality from clinical cancer), others can be derived as possibil¬
ities compatible with observed incidence and prevalence of disease.
The Knox model, in studying transfers between states every year in a
single cohort, cannot distinguish between the variables of age and time. In
the natural history of the disease, for example, the rates of onset,
progression or regression of pathological conditions can be made dependant
upon age, or (with more difficulty) on duration of disease, but not upon both.
This is a major drawback. It is most obvious in any attempt to simulate
survival of clinical cancer. Survival curves (adjusted for normal mortality)
are strongly dependant upon the age at diagnosis. However within each age-
group survival probability also depends on duration since diagnosis; hence the
curves of relative survival are not simply exponential, but show a steep fall
in year one, and then progressively flatten out. This variation by age and
duration may also be important at other points in the natural history; the
probability that different progression rates pertain at different ages has
already been described.
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It is, in fact, a general property of the Markov process that probability
of transfer from a state is independent of the time already spent on it. One
way to circumvent this is to define the states in the simulation as a
combination of pathological entity and duration. In one version of GENMAK the
programme GMTO this approach has been used, so that up to 2100 states are used
- as an array of 21 (pathological conditions) X 100 (durations). Transfer
rates are declared for any combination of these 2100 states. This solution
becomes impracticable if it is wished to make events in the simulation depend
upon several other variables.
The incidence of preclinical and clinical cervical neoplasia have been
shown to be related, albeit indirectly, to a variety of variables which
include age, parity, marital status, social status, contraceptive use. Some or
all of these may be of value in specifiying screening programs. In order to
incorporate these into a macro-simulation model the technical problems involve
the use of transfer specifications between the elements of multi-dimensional
arrays. Although such problems are theoretically soluble, the second drawback
of macro-simulation - inability to make events dependant upon past history -
is not.
Past history or experience of individuals is important for example in
attempting to simulate screening programs. The macro-simulation model mimicks
screening by defining ages at which screening tests will be offered, and
specifying the percentage of the population at these ages that will accept. If
some of 'the population are not screened (ie are "refusers") they will not
receive another "offer" until the next specified age, at which time the
acceptance rate will be again the same as that for the general population. In
reality both these premises are highly unlikely ; persons not receiving a test
at the specified time are likely to receive further invitations during the
interval before the next routine examination is due, and individuals who do
not accept screening are likely to comprise a subset of the population with a
greater than average probability of refusing subsequent offers also.
Another major disadvantage of the simulation models described in section
III is their limitation to the examination of events in a single birth cohort.
The results of such an exercise are interesting, but will be far removed from
observing the results of screening programs in real populations which are
composed, of course, of all generations. The simulation of screening involves
the 'offering' of testing to the cohort at defined ages, however in reality
screening policies are likely to be introduced (or modified) at a single date
or point in time, and hence affect the varying cohorts of the population in
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different ways. In addition there is good evidence of a strong birth-cohort
effect on the natural history of cervical cancer in England and Wales and the
Nordic countries.
Another element that is important to incorporate into a model of screening
programs is 'incidental screening' - for example in relation to family
planning, childbirth, hospitalisation. Although this is often conveniently
ignored, it often makes up a large proportion of the examinations performed
(Parkin et al, 1981). It is hard to conceive how this type of activity could
be simulated in parallel with routine screening programs using the macro-
simulation approach.
For all the above reasons the fundamentally different approach of
microsimulation was chosen as the basis for the current model. The general
outline of this approach is described below, followed by more detailed
description of the varying elements of the simulation with the specifications
of the data and the sources used. Technical details of the computer programs
are contained in section IV.2.
1.2. General Format of the Model
The model studies events occurring in a population of women over a defined
period of time. The time period chosen is arbitrary but in all the examples
below a 3C year period has been studied in order to avoid projections too far
into the future when there are obviously likely to be many uncertainties. The
population studied is one with realistic demographic characteristics; once
again the choice is arbitrary, all the work described below has been carried
out on a population that has the demographic makeup of that of England and
Wales.
Like the Knox model, the simulation involves examining year by year
transitions occurring between defined, mutually exclusive states. These
include various more or less arbitrary steps in the natural history of disease
(including death from cancer), as well as states of normality and death from
other causes. However, instead of examining the proportions of a group which
transfer each year, the IARC model studies transitions occurring to individual
members of the population. Each individual has a set of characteristics
pertinent to the study of screening. As already suggested in the preceding
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section it was desired to make transfers between states dependent upon a
variety of factors other than age :
- Duration in the current state
- Marital status
- Childbearing
- Past history of screening
Offers of screening and their acceptance by individuals in the population
can also be dependent upon these factors.
Each individual in the population is characterised by their values for a
set of variables related to these characteristics. There is no theoretical
limit to the number of variables which may be defined for each individual ;
however since the model will involve examining each individual every year, the
addition of variables will add to the time and computing load involved.
The following represent the variables in a relatively simple version :
DEMOGRAPHIC VARIABLES
1. Age : As year of life, ie 31 = age 30 last birthday
2. Marital status : Single, married or formerly married
3. Parity : Nil, one birth, two or more births
4. Fertility status : Fertile/infertile
NATURAL HISTORY
1. Present state : Disease state, includes normal/dead
2. Duration in present state
3. Previous state
SCREENING HISTORY
1. Clock : Years to elapse before next screening due
The basis of the model is the annual examination of individuals to
determine whether the value of these variables change. The simplest change is
the Age variable, this will be incremented by one every year providing the
individual survives each year. The probability of dying can be obtained from a
life table, and is, of course, conditional upon age. Thus the basic data which
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is used by the model consist of conditional probabilities ; in this example
the probability of death given age and current state (the probability will, of
course, be greater for subjects with cancer)-
The other main feature of this model is that it is stochastic in nature,
the events which occur are determined by chance within the probabilities
defined. For instance, using the mortality example it might be that the data
specifies the probability of dying for a woman, aged 60 during the ensuing year
as 1 %. How is the occurrence or non-occurrence of death to be simulated ? The
model uses a random number generator which would produce a random digit
betweeen 1 and 1000 ; if the digit produced was 10 or less, the person in
question would be deemed to have died, and the value of the relevant variable
changed accordingly. If she survives she would be eligible for other
transitions within the model, and of course the value of the age variable
would be incremented by 1.
This approach has intuitive appeal in that it is very close to reality in
the way it treats individuals as units, rather than carrying out operations on
fractions of populations. However it suffers from a drawback of real life too:
the use of random chance in the model means that no two simulation runs will
ever be exactly identical even with the same data as input. The results will,
in fact, obey the laws of probability, and conventional inferential statistics
are required to decide whether the differences observed between different
simulation runs are in fact real, or merely due to chance. For the same
reasons, simulation exercises involving large populations are likely to result
in more precision in the results (ie narrow confidence limits) than those
involving small samples.
There are additional advantages in a model v^iich results in the recording
of events in individual members of the population, one is the ability to use
the model for retrospective analyses. As described in the introduction, the
case-control approach to the study of screening is likely to be increasingly
used in future. The output from the stochastic model, consisting as it does of
individuals with defined characteristics, can be utilised for simulating
case-control studies. This is a further check on the validity of the model and
the assumptions which it incorporates.
1.3. Simulation of Demographic Events
As already described, the model aims to simulate events in a population
with the demographic characteristics of that of England and Wales. The
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starting point for the simulation is 1951 when complete data on this
population was available from the census.
The first stage in a simulation run is to choose a size of population to
be studied. Two considerations govern this choice. Firstly the microsimulation
model is expensive in computer time, and, because each individual must be
examined for her characteristics before a decision on transfer is taken, the
amount of processing time needed is proportional to the size of the starting
population. The second consideration is related to the fact that, because the
model works on individuals, the outcomes of simulation runs are like real life
experiments; no two outcomes on the same size of population will be identical.
Consequently, the size of population simulated should be large enough to
obtain reliable results.
Once the population size is fixed, it is distributed by age, marital
status and parity to match the England and Wales 1961 distributions. Table
(IV. 1) shows the age distribution used - each individual is assigned an age in
accordance with this distribution. The next step is to distribute the
population by marital status. Table (IV. 1) also shows the distribution of
marital states at each individual year of age for the 1961 England and Wales
population. The actual procedure involves examining each member of the
population in turn, and allocating a marital status according to the
probabilities pertaining to the relevant age, the actual decision being left
to chance.
The third step of the 'start up procedure' involves distributing the
starting population by parity. Questions on the parity of married and formerly
married females were included in the 1961 and 1971 censuses, and tabulations
of the data are available. However there is no comparable information on
parity of single (never married) females by age. Some data are available on
trends in illegimate births (Werner, 1982) and a question on parity was
included in the General Household Survey for 1979 (See Table IV. 2). These
allow some 'guestimates' of parity of single women, which are included in
Table TV.3. The procedure for allocating parity status to individuals
involves, once again, random chance within the probabilities defined for the
relevant age and marital status.
The demographic events which can occur in this population over the 30
years of the simulation are births, marriages and deaths. The procedure
involves examination of every individual for each year, and a decision is
taken whether or not a change in status occurs. Once again this is done by
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comparing a randomly generated number against a set of conditional proba¬
bilities.
Step one is a decision on survival. The appropriate probabilities are life
table death rates (P deathjage). For the first 20 year period the life-table
death rates for England and Wales for 1970-72 are used (Table IV. 4). The
second step is to stimulate transitions between marital states. Three marital
states are used ; single, married and formerly married (widowed or divorced)
and three transitions are possible between these states (marriages,
remarriages, divorces/widowhoods). The transition probabilities were obtained
from age-specific rates of marriage, remarriage, divorce and widowhood for two
separate periods, 19.61-1970 (Table IV.5) and 1971-1980 (Table IV.6). Two sets
of data are used because of changing patterns of nuptiality. Inspection of the
tables reveals a rather later age of marriage in the second decade, and of
course, rising rates of divorce leading to increased rates of transition from
married to formerly married in the younger age groups. The latter parts of the
simulation (1981 onwards) involve projections of rates. The full data for the
model involves the use of transition rates for individual years of age; these
have been estimated by linear interpolation and the full data set (FILE
14.DAT) is shown in Appendix 5 and as Table IV.7.
The third demographic event to be simulated is fertility. An attempt has
been made to define age-marital state-parity specific fertility rates.
Fertility rates in the population are notoriously subject to short term
fluctuations, and the British population has shown quite mhrked and rapid
changes in the last two decades. Ideally a set of fertility data appropriate
for each individual year of simulation could be incorporated; however this
would lead to an inordinately cumbersome set of data files, and a compromise
of adopting average rates for the decades 1961-70, 1971-80, 1981-90 has been
adopted. As will be seen in the Results section, this leads to some slight
deviations in the simulated population structure from that observed, but these
are small and do not affect the main objective of the model, that is to study
the effects of screening.
Table IV.8 and IV.9 show the data used to calculate age-parity specific
fertility rates for 1961-70 and 1971-80 for married women, and the results
obtained. Fertility data for unmarried females is not broken down into single
vs. formerly married, nor is it possible to produce estimates by parity of
mother. The model therefore has to utilise the data for the two decades as
shown in Table IV.10, and assume equal rates for single and formerly married,
and at all parities. The full data set used by the model utilises rates for
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single years of age. These were obtained by graphical interpolation in similar
fashion to the calculations of Tables TV.9 and IV. 10. The full data is shown
in FILE 13.DATA, in Appendix 5.
It is worth noting that the data for marital and parity transitions are
presented as central rates (r) of fertility, marriage etc. These are converted




The actual occurrence of a birth to an individual depends, once again,
upon comparison of a randomly generated number against the appropriate age-
marital state - parity specific probabilities.
The births which result are used to define new entrants to the population
as infants in their first year of life (Age = 1). Since the population being
simulated consists only of females, the proportion of births which are girls
requires to be known, and is shown for different maternal parities in Table
IV. 8 and IV. 9.
In practice the application of childbearing probabilities to the entire
population leads to a progressive deviation of the parity distribution from
that expected on the basis of real or projected demographic data. With
increasing years of simulation the proportions approximate to a Poisson
distribution, with a deficit of para 0 women. This was overcome by specifying
a proportion (P^) of the starting population and new births deemed to be
infertile. A reasonable estimate of this proportion is 0.05 (WHO, 1975). An
adjustment is required during the start up procedure to ensure that all
infertile individuals are placed in the Para 0 category. In addition, an
appropriate adjustment must be made to the chilbearing probabilities for Para
0 women, since the probability of childbearing is only applicable to fertile
women.
1.4 Hysterectomy
From the viewpoint of the simulation model a further event of great
significance in a woman's life history is a hysterectomy (for conditions other
than cancer of the cervix), since she is then no longer at risk of this
disease. The rate of operation for hysterectomy has shown a steady increase in
the last two decades, so that prevalence of hysterectomy is rising, and there
are also marked cohort efforts.
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In order to calculate rates of hysterectomy, data was obtained from the
Hospital In-Patient Enquiry (HIPE) which collects information on 10% of all
hospital discharges in England and Wales. The number of hysterectomies
involving removal of the cervix which were performed in 1966 and 1976 for
conditions other than malignant neoplasms of the cervix uteri were calculated
for each five year age group (see table IV.11). Somewhat similar data, for
different time periods, had been used by Alderson & Donnan (1978), and by
extrapolating their hysterectomy rates backwards in time they were able to
estimate the prevalence of hysterectomy at different time periods. Table IV. 12
shows prevalence of hysterectomy by age in 1961 as presented in their paper.
Similar estimates of prevalence by age for 1966 and 1976 have been used to
correct the denominator populations in Table IV. 11, so that the final
hysterectomy rates calculated are actually probabilities of hysterectomy in
women who still have a uterus. The sets of rates for 1966 and 1976 are used to
approximate hysterectomy rates for the decades 1961-70 and 1971-80 respec¬
tively.
Hysterectomy is handled by the model as one of the 'States of Disease'
(see below), since it clearly excludes the possibility of any other stage in
the natural history being present in the individual. Transfers can occur from
normality, or from preclinical stages of cervical cancer (but not clinical
disease). The model allows for transfer probabilities from preclinical
carcinoma of cervix to hysterectomy to be multiples of the basic rate (from
normality), in accordance with the possibility that preclinical cancer and
other conditions which necessitate hysterectomy share common risk factors. It
is also possible to specify transition probabilities dependent on parity and
marital status. However, the data to permit this do not exist so the data used
in FILE 15 DAT (see Appendix 5) uses a single age-specific set of hysterectomy
rates.
Individuals who have had a hysterectomy no longer participate in
childbearing.
1.5 Simulation of the Disease Process
The disease process is simulated by defining a series of mutually
exclusive 'states' in which an individual is situated at any particular
moment. The natural history of the disease is mimicked by postulating
transitions between these states, the rates of which are conditional upon
other characteristics of the individual.
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After defining the size of population to be simulated, the second
specification required is the number of states involved in the simulation.
These must include a 'Normal' state, and states to represent dead (of causes
other than cervix cancer), and hysterectomy (for other than clinical cancer of
cervix), as described above. Other states are used to define the disease
process, and the possible transfers between these states are then included in
the data files.
The simplest natural history, and the transitions involved between the
states used to define it is shown in Fig. 4.1. Although there are obvious
advantages in specifying the simplest natural history possible - a minimal
number of transfer probabilities require to be defined for one thing -
unfortunately the resultant model is a poor reflection of reality. Preclinical
disease exists in a variety of grades of severity from the presence of minimal
cellular changes to occult invasive cancer, and these different grades have
different probabilities of detection on screening, and are treated and
followed up in different ways.
As already discussed in section II.2 preinvasive neoplasia can be regarded
as a single condition 'Cervical Intra-Epithelial Neoplasia' of varying grades
of severity. However this terminology is relatively new, and most of the
literature on natural history of cervix cancer still uses the terms
'dysplasia' and 'carcinoma in situ'. Despite the dichotomisation of what is
clearly a continuum of pathological change, this old terminology does have an
advantage in a simulation model. It allows the 'dysplasia' category to include
histological patterns which may or may not be precursors of cervical cancer.
The transient nature of much of what is detected as 'dysplastic change' can be
modelled, whilst the workload involved in diagnosing and following up such
cases is recorded.
The states which have been used in the examples below, and the possible
transitions between them, are shown in Fig. 4.2.
1.5.1 Prevalence of disease states in the starting population
The first step in simulating natural history, once the disease states have
been defined, is to define the prevalence of each in the population at the
beginning of simulation (1961). Clearly this does not apply to the two 'dead'
states, and the data used for defining prevalence of hysterectomy has already
been defined above.
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1.5.1.1 Prevalence of preclinical disease is available from a variety of
series describing the results of screening programmes. Prevalence rates of
dysplasia and carcinoma in situ for several such series are shown in Figs
2.7 and 2.8. It should be recalled that the prevalence rates presented are
actually based on the prevalence of true-positive screenings, and the true
prevalence rate can be derived by dividing by the sensitivity of the
screening test.
A set of age-specific prevalence rates for the preclinical states
dysplasia (2), carcinoma in situ (3) and occult invasive cancer (4) are
shown in Table IV.13.
1.5.1.2 Prevalence of clinical cancer Table IV. 13 also shows prevalence
rates for clinical cancer. By "prevalent cases of carcinoma of cervix" is
meant women currently alive who have been diagnosed as having carcinoma of
cervix at sometime in the past. This data is not available, and a
reasonable estimate must be produced.
The approach used was to use the simple deterministic model GENMAK (see
Appendix 1). The data input were age-specific incidence rates of clinical
cancer of cervix for England and Wales from a period before the widespread
introduction of screening, and estimates of age-duration-specific survival
data for the same period. Suitable incidence data are shown in Table IV. 14.
Age-specific survival data for carcinoma of cervix in England and Wales are
available for cases registered in 1971-1973 (see 1.5.2. below), and estimates
of survival rates around 1960 can be made from crude (all ages) survival
curves from this period. Hie simulation output is the number of cases in each
of the declared states, from this the prevalence of cases of cervix cancer, by
age, can readily be derived, and these are given as 5 year age-specific rates
in Table IV.13.
Hie population to be simulated by the model is made up of individuals with
a variety of defined demographic characteristics (age, parity and marital
state) . So far prevalence has been presented as if it were dependant only upon
age. However it is known that prevalence of preclinical conditions is inde¬
pendently associated with other variables and data on age-standardised
prevalence ratios for parity and marital status are available (Parkin et al,
1982 a ; Sweetnam et al, 1981). The data used in calculating starting pre¬
valence are shown in Table IV. 15. It was not possible to use the data of
Sweetnam et al, which provides prevalence ratios for dysplasia, c.i.s. and
invasive cancer separately, since it was available only for ever-married
-65- '
females, however the ratios for married : formerly married in their data (Fig
2.9) are close to those in Table TV.15. The prevalence ratios shown in the
table were thus applied to all states of disease (dysplasia, cis,
microinvasive, clinical cancer). Hie ratios presented were simply multiplied
to provide nine parity marital status specific prevalence ratios (although
this is probably not accurate, there is no alternative approach possible due
to limitations of data) .
A special program (CRESTPREV - See Appendix 2) takes the 5-year age
specific prevalence data, the parity-marital status specific prevalence ratios
and, using the age-parity-marital status composition of the starting
population as weights, produces a full set of starting prevalence data in
FILE4.DAT (Appendix 5).
The model once again uses a random number generator to determine an
individuals starting state, given the probabilities of the different states
conditioned upon age, marital status and parity.
1.5.2 Derivation of transition rates between disease states
It has already been pointed out that the choice of disease states for use
in the model is an arbitrary one. Hie more states defined, the easier it
becomes to model disease and screening processes ; for example Knox (1973)
defines 26 different states. However the more states that are used, the more
difficult it becomes to determine realistic rates of transfer between them.
Although a major virtue of the use of simulation models is the ability to
explore a variety of assumptions about input parameters, it is also true that
the major criticism is the lack of realistic data that can be incorporated.
Hence it is advisable to try to define disease states such that reasonable
estimates of their prevalence and the rates of progression and regression
between them can be obtained.
Fig. 4.2 represents the choice of disease states used in the examples
described. Hie data used to derive rates of hysterectomy and mortality from
causes other than cervical cancer have already been outlined.
One other set of transition rates are known with a fair degree of
certainty, those from clinical cancer to death from carcinoma of cervix. Such
rates are equivalent to relative survival rates from clinical cancer, rates
for England and Wales are shown in Fig. 4.3. It should be noted that survival
curves such as these do not show a constant rate of decline - ie the
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probability of deat± is not constant each year. The risk of death is highest
in the first year after diagnosis and declines thereafter. Such curves can
only be modelled by specifying rates which are dependent upon duration in the
starting state.
It has been suggested that other rates of transition may be dependent upon
the duration of the state or disease condition (see section II.2).
It should be remembered that what is being modelled is an essentially
continuous process; the extension of cellular abnormalities to involve the
entire thickness of the cervical epithelium and subsequent invasion, and pro¬
gressively increasing cellular atypia. When this is simulated by a set of
discrete 'states', it seems unlikely that the transition between them would be
entirely independent of the duration of abnormality. Certainly there is no
reason to suppose that the distribution of sojourn times in such preclinical
stages of disease can be simply modelled by rates of ingress and egress
depending solely upon age. A constant rate of exit from a state would lead to
the distribution of sojourn times following a negative exponential; to date
there is no evidence for or against such a distribution, but it seems
intuitively less likely than, say, a log-normal distribution. For these
reasons the model allows transition rates to be dependent both upon age and
upon duration in the initial state.
Data derived from the survival curves of Fig. 4.3 are included in the
transition data shown in Tables IV.16-IV.18.
Two other sets of data can be used directly to approximate transition
rates, these are the incidence rate of dysplasia and the incidence of clinical
cancer. Dysplasia incidence can be used to approximate the transition rate
from normality to dysplasia. Estimates of incidence of dysplasia have been
presented in II.2.3 ; such figures are derived from serial observations on
groups of women attending screening programmes. As already discussed, the
figures represent incidence of true positive tests, and the true incidence of
dysplasia can be estimated by dividing by the sensitivity of the screening
test; this is probably about 70-80% (see section II.3.2).
The incidence of dysplasia which is estimated thus from observation of
serially screened populations will represent the net increase of dysplastic
cervices resulting from conversions from, and regressions to normality. Hie
true annual transition rate from normality to dysplasia will thus be higher
than the observed incidence depending on the rate of regression (dysplasia to
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nonnal) and the actual intervals between screenings on which the estimates of
incidence were based. Neither of these are known, so the transition rates
cannot be estimated precisely. The rates shown in Tables IV.16-IV.18 are
approximations based on the two lower curves of Fig 2.10.
The other observed data which can be used to estimate transition rates are
the incidence rates of clinical cancer. These indicate the annual number of
cases passing from the preclinical states (in Fig. 4.2 this is always micro¬
invasive or occult invasive disease) to clinical disease. Clinical cancer
incidence figures for populations of England and Wales prior to the
introduction of screening programmes are shown in Table IV.14.
The use of the data on incidence of dysplasia and clinical cancer, along
with prevalence of preclinical disease and clinical cancer (see section 1.5.1
above) to derive sets of transition rates, is illustrated in Appendix 3.
1.6 Simulation of Screening
The descriptions of screening programmes in section II have indicated that
in reality these are really rather complex. Recommendations are usually
formulated in terms of ages and frequencies for examination of asymptomatic
women ; for example the age recommended for the first examination, the
intervals between subsequent tests, and the age after which screening can be
ceased. These recommendations are based upon a mixture of intuition,
qualitative judgement, some results of quantitative modelling, and political
pressures. However, such recommendations usually assume that no screening
activity exists apart from the programme envisaged. This is far from true -
large numbers of smears are taken at a variety of contacts with the health
care system. These cannot be ignored as incidental or inconsequential, since
the women examined may be particularly high risk groups (using contraception,
having gynaecological symptoms) such tests form an important part of the
preventive strategy for carcinoma of the cervix.
Since the micro-simulation model follows individual subjects, it is
possible to simulate contacts with the health care system and the screening
which can arise on such occasions. The easiest of these is the screening
activity which occurs in ante-natal and post-natal clinics. Since the model
simulates childbirth events to each individual, it is very simple to incor¬
porate the performance of a screening test during a childbirth year. Data on
individual frequency of other events is more difficult to incorporate, but it
is theoretically possible to model contacts with family planning services and
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inpatient or outpatient visits to gynaecology and veneral disease departments.
Screening can occur at all or a designated proportion of such contacts.
Routine asymptomatic screening is simulated by defining the programme
which is offered to individuals, their acceptance of the offer, and the
characteristics of the screening test. The data for defining a programme is
included in the model as FILE12. DAT. The screening programme can be made up
of many different policies. Each policy is contained in 3 lines of data which
define:
i) The years for which the policy will be in operation
ii) The interval between offers of screening tests
iii) The ages between which tests will be offered
iv) The marital-state of individuals to be offered screening
v) The parity " " "
vi) The percentage of women in each disease state who attend
for screening when it is offered
vii) The proportion in each disease state who are found to be
positive on screening, and moved to state "STPOS"
viii) The proportion in each disease state, who have been found to be
positive on screening and placed in STPOS, who revert to original
state the following year
It will be recalled that each individual has a set of associated variables
which include age, marital state, parity, current state, previous state and
duration since last screening (ICLOCK). The probability of attendance when
screening is offered can be made dependent upon age, marital status and parity
(by specifying separate policies) or upon current disease state. The
sensitivity and specificity of the screening test is modelled by defining the
proportion in each disease state who are found to be positive, and moved to
state STPOS, when screening is performed on those who attend. The proportion
in state 1 (normal) found to be positive is the false positive rate
(1-specificity), the proportion in the disease states (dysplasia, cis,
micro/occult invasive) found positive on screening is the sensitivity of the
test for these conditions. Data on test characteristics have been given in
section II.3.2.
When the screening test is found to be positive, the individuals current
state becomes STPOS and a record of what the previous state had been before
screening is naturally retained as the variable LSTAT. The fate of women in
this 'screened positive' state will naturally depend on their previous state.
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It is assumed that, in reality, some form of investigation of positive
screenees is undertaken depending on the severity of the cytological changes
observed. Naturally women who were false positive will not undergo any
prolonged observation or treatment, this is modelled by returning all of these
individuals to state 1 (normal) the following year. Women with marked
cytologic changes will undergo investigation by, for example, colposcopy and
biopsy, and the histologic changes appropriately treated. Such women can be
retained indefinetely in state STPOS ; in this case they take no further part
in the natural history of cancer, nor in screening, and can leave STPOS only
by having a hysterectomy or by dying from causes other than cancer. Finally,
women detected by screening may escape supervision, possibly because follow-up
was arranged by a recommendation for repeat smears which is not complied with,
or biopsy may be refused. In such cases the individuals return from STPOS to
their original disease state. The percentage of women with pathological
lesions detected by screening who escape supervision is modelled by
specifiying a percentage of STPOS women reverting to their original state each
year (see line 3 of the policy data in FILE12.DAT) . It is possible to modify
the model so that this probability depends on the time since the positive
screening test.
Women who attend for screening are not due for a further test until the
interval specified in the screening policy has elapsed. This is simulated by
the variable ICLOCK, which after a screening test has been carried out is set
to this interval. ICLOCK is decremented by 1 each subsequent year. Only when
the value of ICLOCK is zero is a woman eligible for screening. The variable
ICLOCK can be used to simulate 'refusers' of a screening programme; for
example the value can be set to other than zero for women who do not attend
the first offer of screening.
The model output records the total number of screening tests performed
each year, the number of false positives found, and the number of true
positives for each disease state.
2. THE COMPUTER PROGRAMS
2.1 The main simulation program and input data files
The computer program is written in FORTRAN ana is structured with liberal
comments to explain the sequence of operations that is being carried out. The
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program is reproduced in its entirety in Appendix 4, and the data files used
in Appendix 5.
This section will briefly outline the principles and structure of the
program as a guide to understanding.
The MAIN LOGIC SECTION defines the variables used and the size of the
arrays'. A call is made to FILE 33.DAT which defines one of the outputs
(FOR034). This output will contain a count of the numbers of individuals
defined by any of combination of variables (age, marital state, parity, state
etc) at any of the 30 years of the simulation. FILE 33.DAT is shown in
Appendix 5 and the output from this specification appears as FOR034 in
Appendix 6. Calls are made once to five subroutines which define the starting
population at the beginning of simulation (INIT, ST AGE, STMST, ST IPS, and ST
1ST). For each year of the simulation, three other subroutines are called :
TRANSF, SCREEN and AGEING.
Subroutine INIT reads in the data in FILE1.DAT which includes the number
of years for which simulation is to be carried out, the size of the starting
population and the total number of states (NUMST). When this total number is
defined, the following states can be allocated a number :
STOTH (dead of causes other than cancer) = NUMST
STHIS (dead of cancer of the cervix) = NUMST - 1
STHYST (hysterectomy - not for cancer) = NUMST - 2
STPOS (screening test positive) = NUMST - 3
In addition, the years for which a file containing the data on all the
individuals in the simulation is to be saved is recorded.
Subroutine ST AGE takes the starting population and distributes it
according to age, using probabilities derived from the population structure in
FILE1.DAT.
Subroutine ST MST takes the starting population and for each member
allocates a marital status with regard to age, the probabilities of marital
state conditional upon age are derived from FILE2.DAT.
Subroutine ST IPS takes the starting population and for each member
allocates a parity status, with regard to age and marital state. The relevant
probabilities are derived from FILE3.DAT.
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It will be remembered that, since the model is stochastic in nature, the
application of probability tables involves separate decisions for each
individual. This is achieved by calls to a subroutine RAND (I,J) which
produces a random integer I in the range 1 to J. This integer can be compared
with the number relevant to the individual from the probability table.
Subroutine ST 1ST allocates one of the states defined in INIT to the
starting population. The probability of each of the live abnormal states (ie
state 2 to STHYST (NUMST-2) is determined by combining the data on prevalence
of hysterectomy in the starting population (FILE1.DAT) with that on the
prevalence of clinical cervical cancer and its precursors (FILE4.DAT). The
latter defines disease state probabilities in terms of age, marital status and
parity. The duration in state has next to be allocated for those states (1-5)
from which exit is possible. For state 1 duration is made equal to age. For
dysplasia (2) and cis (3) the durations are allocated from files FILE92 and
FILE93 respectively. These represent cumulative probabilities of each duration
for individual year of age, and were derived during the formulation of
transition rate data as described in Appendix 3. For state 4, duration is
either 1 or 2 (with equal probability). The duration in state 5 (clinical
cancer) has been derived from the survival curve (all ages) , which for the
purposes of simulation will be sufficiently accurate, and is simpler than the
use of a data file containing separate estimates for each year of age.
Chce this initialisation procedure is complete the starting population is
completely defined in terms of age, marital status, parity, state and duration
in state, values for these variables being assigned to each individual.
The simulation proper now begins with calls to three subroutines for each
year of the simulation run.
TRANSF.; This subroutine carries out all the transitions between states on a
year by year basis. For each decade of the simulation (Year 1, 11 or 21), the
transfer data contained in FILE11.DAT is read. Each individual in the
population is then examined to see if they transfer to a different state.
There is the opportunity to undergo a second transfer in the same year;
however, the probability of doing so is halved (since, on average, the first
transfer would have occurred at mid year, and only a half year remains for the
second). The probability of subsequent transfers is progressively reduced by
dividing by two. As soon as a transfer takes place, the variables for current
state (1ST), last state (LSTAT) and time in present state (ITIMM) are updated
- the latter variable taking the value 0. A further set of transfers is
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possible - from STPOS (screened positive) back to the original state pre-
screening (LSTAT). These probabilities are defined in the screening data file
(FILE12.DAT). These transfers out of state STPOS are the first event simulated
each year (except for the first year, at the beginning of which no one has
been screened, and there are no individuals in STPOS).
SCREEN: This subroutine performs the simulation of routine screening. The data
defining the screening programme is read from FILE12.DAT, which contains a
series of policies, each of 3 lines of data. These policies may be relevant
only during certain years of the simulation run. If screening is to be done
during a given year, each individual is examined to see if they are eligible
for screening, given their age, marital and parity status, current disease
state and time since the last test was performed. Once an individual has had a
routine test, they are not deemed eligible for the next until the time
interval defined by the screening policy has elapsed ; this is achieved by
means of the variable ICLOCK.
If an individual is eligible for screening, a random number is generated
to see if she attended (the probability of attending given the current state
is defined in the data file). If the individual attends another random digit
determines whether she is found to be positive (the probability of which
depends upon current state, and is defined in the data file). If found to be
positive the variable present state (1ST) takes the value STPOS, and LSTAT,
ITIMM and ICLOCK are changed appropriately. ICLOCK is decremented by 1 each
succeeding year - when it takes the value of 0 the individual is eligible for
i
screening once again.
Non-attenders at screening can be dealt with in various ways - either
recalled for screening after a specified interval, or not offered a further
test until the next examination is due. This is done by adjusting ICLOCK.
An annual and running total is kept of the number of screening tests
carried out, and the number of non-attenders.
AGEING: This subroutine carries out all the vital events - births, marriages
and deaths - each year, as well as ageing the individuals in the population.
The data which are used are the probabilities of childbirth (in FILE13.DAT) ,
of changing marital state (in FILE14.DAT) and of death from causes other than
cancer (in FILE15.DAT). The latter file also has data on the probability of
having a hysterectomy. For each individual the actual occurrence of such
events is simulated by the generation of a random number for comparison
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against the probability relevant to the individual, given their age, marital
state, and parity.
The sequence of demographic events simulated is : -
1. Marital events
2. Births (unless infertile, or in STHYST (hysterectomy))
3. Hysterectomy
4. Deaths (from causes other than cervix cancer)
5. Ageing by one year of survivors
Each year the value of ICLOCK (time before next routine smear is due) is
decreased by 1 and the value of ITIMM (time in current state) is increased by
1.
Infants (aged 0-14) are handled rather differently, since none of the
demographic events except death, are relevant to them. Every year the number
of infants in each age group is checked to see if any deaths occur (using the
mortality data in FILE15.DAT) , if not they are moved up to the next age group.
Infants moving from age 14 to age 15 become adults, and are examined as such
the following year. The births that occurred earlier in the subroutine are
checked to see if they are female (the relevant probabilities depend on birth
number : 0.483 (first), 0.485 (second), 0.488 (third)). Female births become
infants aged 0, and are added to the simulation population.
2.2 Output files
During a simulation run, the main program generates 4 types of output.
Channel 6 is the default output channel. When the model is run in real
time at a terminal this can appear on the screen, or it can be assigned, as it
is when the simulation run is in batch, to a file.
For each year of the simulation output to channel 6 consists of a matrix
showing the transitions which occur between the defined states during the
year, and the number in each state at the end of the year. In addition, the
number of births occurring and the number of screening tests performed during
the year is recorded, together with the total population alive at the year
end. A running total of screening tests is also kept, both as the total number
performed and the number of 'positive' tests. It should be noted that the
number in state STOTH (ie dead from causes other than cancer) is not
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accumulated from year to year, this figure represents the annual deaths only,
whereas STHIS (dead from cancer) cumulates the total cancer deaths as the
simulation goes along. At the very beginning of a simulation run, data for
"Year 0" appears, representing the results of the start up subroutine ST 1ST
and showing the distribution of the population among the different states
before any transfers take place. An example of the output from a typical
simulation run is shown in Appendix 6.
In addition to this regular output, a cross-tabulation of numbers of
individuals by any combination of variables can be obtained at the end of any
particular year. This is done by specifying the years for which such files are
to be created in FILE 33.DAT and the variables, intervals etc required. For
each of these years, the data is read out to channel 34, into files which
become sequentially numbered.
The examples given show numbers of individuals by age-group and disease
state.
Three further output files are created which will allow the computation of
parameters of interest.
FOR008 lists deaths from cancer amongst the population.
FOR009 lists new cases of cervix cancer.
For both these files the variables for each individual is recorded as one
line of data, with year of simulation.
FOROIO is a block of data recording for each year of simulation the number
of person-years of life lived at each age.
2.3 Programs for analysis of ouput
The output described in FOR008, FOR009 and FOROIO is processed by a
program RATABLES (Appendix 7). This produces tables of incidence and mortality
rates by five and ten year age-groups for the time periods specified in the
data-block of the program.
In addition, a calculation is made of the person-years of life lost at
each year of simulation. This is carried out using the age of cases dying (in
FOR008) and a data block containing the normal expectation of life at each age
(from the 1970-72 life table) . The person-years lost are cumulated for each
year of simulation.
The output of RATABLES is printed as FOR020, an example of which is
reproduced in Appendix 7.
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V RESULTS OF SIMULATION
The format of the output generated by the simulation programmes is
illustrated in Appendix 6. In this section the data generated has been
summarised in tabular or graphical form, rather than reproducing multiple
examples of computer output.
Hie results will be reviewed under three headings; firstly the results of
simulation of demographic events, secondly the results of simulation of
cervical cancer natural history, and thirdly the results of simulation of
different screening programmes.
1. SIMULATION OF DEMOGRAPHIC EVENTS
Hie objective of the screening model is to investigate the effects of
different screening policies in a realistic population over relatively short
time periods. The population chosen was one having an identical composition to
that of England and Wales in 1961 (the census year) and simulation is possible
for a 30 year period. For the first 20 years of this period, input data for
the simulation of vital events have been taken from the observed rates in
England and Wales, for the third decade published estimates have been used
(see section IV). The objective of the simulation is to keep the structure of
the model population close to that observed, or predicted for England and
Wales. A precise concordance is not expected, since the modelling methods are
rather coarse - involving for example ten-year average (rather than annual)
rates and taking no account of migration.
Table V.l shows the changes in population size observed (and projected)
for England and Wales in the period 1961-1991 and the results of simulation
(average of several runs using data shown in Appendix 5). Table V.2 shows the
crude birth rates and death rates (females only) for England and Wales in
comparison with the simulated rates (from R20.LOG, Appendix 6). There is a
reasonable correspondence, except for a deficit of births at the beginning of
the second decade of simulation, and a slow rise in mortality (which in
practice appears to have remained rather constant). The latter effect may be
due to the use of a single life-table for the entire simulation period
(whereas expectation of life has in practice shown a slow increase over time) .
It does not seem to be the result of inaccurate modelling of the population
age-structure. The model results are compared with the observed England and
Wales population pyramids in Figure 5.1.
-77-
Fig 5.2 shows the observed and simulated age-specific marital composition
of the population. The main change with time is a shrinkage of the proportion
of never-married women, and an increase in size, especially at young ages
(25-55) of the formerly married group. The model predictions closely match the
changes observed over the period 1951-1981.
Fig 5.3 shows the proportions of married females of different parities.
Once again the model predictions are a reasonable approach to the observed
data. The results of the 1981 census are not available, and an estimate based
on the General Household Surveys of 1980-1982 is shown against the model
output for 1981.
2. SIMULATION OF DISEASE OCCURRENCE
Although not part of the disease process, the simulation includes the
modelling of hysterectomy (for conditions other than carcinoma of cervix and
its precursors) , since this will have an effect on the occurrence of disease
by changing the susceptible population.
Fig 5.4 shows the prevalence of hysterectomy, by age, at four different
time periods of a simulation run of 30 years. The model suggests quite a
marked rise in the prevalence of this condition, given the rates of
hysterectomy in the input data of FILE15.DAT. These prevalences are compatible
with those estimated independently from similar data sources (Table V.3).
t
Figs 5.5 and 5.6 illustrate the age-specific prevalence of dysplasia
(state 2) and carcinoma in situ (state 3) at 4 different times in the course
of simulation. Two different natural histories are used. In both the
transition rates are those shown in Table IV. 16, but in 11M the incidence of
dysplasia is made conditional upon age, marital status and parity (as
described in Appendix 3) , whilst in 11A, incidence is dependent upon age
alone. With 11A there is relatively little change in the prevalence of
preclinical disease over time. However with 11M there is an increase in
prevalence of both conditions with time. As already described, this reflects
the changes in (especially) marital status of the population, and reproduces
to some extent the underlying secular trends in disease rates.
Fig 5.7 shows the observed age-specific incidence rates of carcinoma of
cervix in England and Wales, for the period 1962-1965 (i.e. before the
introduction of screening could have markedly influenced the incidence). The
age-specific incidence rates for the first five years of a simulation are
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shown for comparison. The close concordance of the two curves is not
surprising, since the natural histories used by the model were developed so
that the observed incidence rates were reproduced as closely as possible
(Appendix 3). After this initial time period there is, however, a progressive
divergence between the results of simulation and the observed rates of
incidence and mortality (Fig 5.8). This is to be expected, since the England
and Wales rates shown are the net result of complex changes in risk of disease
by birth cohort and the effect of screening in preventing clinical cancer
(Parkin et al, 198$). The predicted rates shown are the results of simulation
using the two natural histories 11A and 11M referred to above. The result of
changes in marital/parity composition of the population on simulated
prevalence of preclinical states has already been described; here the end
result on incidence and mortality can be seen as a rising trend with history
11M (where incidence of dysplasia is conditional upon these two variables) and
almost constant incidence and mortality when history 1IA is used. Neither of
these simulations incorporate any screening activity, and so represent the
theoretical background of disease occurrence onto which screening will be
superimposed.
3. SIMULATION OF SCREENING
The number of combinations of natural histories, screening policies,
attendance rates, test characteristics etc which can be specified and
examined, is of course enormous, and in this section only a limited number of
these possibilities are presented. An additional problem is the determination
of which outcome parameters are of interest - the output from the model
provides a great amount of information on the simulated population, and this
must be summarised for ease of comparison.
The approach adopted below is to have available several simulation runs in
the absence of any screening activity, so that the average values of the
outcome parameters can be calculated. This solution has been used because the
model is stochastic in nature, and the results of simulation runs vary
somewhat, even though the input variables remain constant. The results
obtained when different screening policies are incorporated into the
simulation are then compared with this baseline. Three outcome parameters have
been examined in the examples which follow: the reduction in the number of new
cases of cancer, the reduction in the number of deaths from cervix cancer, and
the reduction in life-years lost due to cancer. These three parameters do not
necessarily change to similar degrees - much will depend, for example, upon
the age at which screening is concentrated. The relationships are complex
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(which is why a simulation model is necessary for their study), but in general
screening at younger ages that prevents incident cases of clinical cancer
might save more life-years than a policy with an equal detection rate
concentrated at later ages. These savings resulting from screening are
presented as absolute values (cases saved, lives saved, life-years saved) and
as percentage reductions from the baseline no-screening results. This allows a
direct comparison of the effects achieved on the different outcomes.
In health care studies life-years are not uncommonly used as outcome
measures, and the further refinement of calculating weighted life-years is
sometimes performed. This procedure gives more value to life-years saved at
younger ages than in the elderly, the logic being that social costs of death
in the young are greater than in the elderly. Although this approach may have
something to commend it, it is difficult to decide on an appropriate weighting
to use (personal judgement of what is appropriate may depend on the age of the
person making it!), and it has not been adopted here.
In comparing screening policies it is not sufficient merely to examine the
outcome in terms of the savings defined above. These must be compared with the
input of the screening programme (otherwise the 'optimum' programme in any
comparison is likely to be the one with the most intensive screening). The
costs of a programme are likely to be reflected by the actual number of tests
carried out, and by the work involved in the further examination and treatment
of individuals found "positive" at the screening test. In the analysis
presented below, therefore, programme input is given as total tests performed,
and the number of "positive" tests during the period of screening.
Several ratios relating input to output (or cost-effectiveness) are thus
presented from the combination of parameters described.
It would be possible to carry out a more formal cost-effectiveness study
using the output data from the simulation model. The framework for doing so
has been presented by Blumberg (1957) and recently restated by Simpson et al
(1978). This involves calculating the net value of screening, given the
numbers of individuals who screen true positive, false positive, true negative
and false negative, and the values imputed to these four states. True positive
and true negative tests have positive values, false positives and false
negatives have negative values (the consequence of unnecessary follow-up and
misplaced reassurance respectively). This more detailed approach has not been
used, in part because of the need to reach arbitrary decisions on the values
of screening outcomes (the different cost-effectiveness ratios resulting from
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different assumptions is a modelling exercise in its own right) , and in part
because the model generates ultimate outcomes (cases, deaths, life-years lost)
rather than just screening test results.
3.1 COMPARISON OF NATURAL HISTORIES
As described in section VI, three natural histories were examined. The
characteristics of these are set out in Appendix 3, Tables IV. 16-18 and Figs
4.4 and 4.5. In 11M, cis is a rather stable condition, regressions are reduced
to a low level. The median sojourn time of cis is 9.9 years, the distribution
being exponential in format. In UN cis is more transient, with a greater flux
in and out of dysplasia. The area under the sojourn time curve (Fig 4.5) is
correspondingly larger, the median sojourn shorter, but the distribution
remains exponential. In history 110 there is the same rate of flux between
dysplasia and cis as in UN, however the shape of the sojourn time
distribution is quite different; there are no long-duration cis cases,
although the median duration (9.5 years) is much the same as in 11M. Dysplasia
is a less transient condition also.
The actual numbers of cancer cases, deaths and years of life lost which
result from simulation of a 30 year period when no screening is carried out
vary slightly between the three different natural histories. For this reason,
the comparison of the effects of screening assuming these natural histories
examines percentage change (rather than absolute numbers). Table V.4 shows the
results of the same screening policy (examinations at ages 35,40,45,50,55,60,
65) , test characteristics (70% sensitivity, 99,5% specificity) and follow-up
loss (8% per year dysplasia, 4% per year cis, for 3 years) under the
assumptions of two different attendance rates (80%, 45%; probability for all
women equal) and the three different natural histories.
At both screening intensities it is noticeable that the differences in the
results for the three natural histories are really rather small.
At 80% attendance the savings in cases, deaths and life years appear to be
greatest for 110 and least with UN. Since the number of tests performed is
almost identical, the same effect is seen in the ratio of savings per 1000
tests. The number of positive tests is rather higher for history 110. This
might be anticipated from the shape of the curves of distribution of sojourn
times (Figs 4.4 and 4.5) which indicate a relatively large number of
dysplasias and carcinomas in-situ of short durations, so that prevalence of
these conditions is likely to be less reduced by regular screening than the
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more stable natural history of 11M. A higher prevalence would lead to more
positive tests on screening. The savings of deaths and life-years per positive
screening test is thus higher for 11M than 110.
When attendance at the 5 yearly screening examinations falls to 45%, the
results for natural history 110 (notably for deaths and life-years) appear
much worse. This too is presumably related to the sojourn time distribution -
since few cis cases have long sojourn times, at low rates of attendance, a
greater proportion will be able to transit onward to clinical cancer without
being detected.
Fig 5.9 plots the cumulative person-years of life lost for the 30 years
of simulation, comparing the three natural histories (11M, UN & 110) both in
the absence of screening and with the rather intensive policy (80% attendance
rate) summarised above. This diagram illustrates that the reduction in life-
years lost achieved by screening is not evenly spaced throughout the 30 years.
In the first 10 years there is relatively little effect; thereafter the
'saving' increases progressively with time. This is the kind of result which
would be expected, since screening interrupts the disease in the pre-clinical
stages - it is only some years later that some of the individuals so detected
(and successfully treated) would have died from clinical cancer if screening
had not been instituted. Evaluation of actual screening programmes should make
allowance for this lag time, and to expect an immediate effect in terms of
mortality is unreasonable.
In the following examples illustrating the effects of different screening
policies, a single natural history (11M) has been used for simplicity.
3.2 COMPARISON OF DIFFERENT PATTERNS OF ATTENDANCE
Table V.5 shows the results obtained by simulation in a population of
100,000 women over a 30 year period with the same screening policy as already
described in 3.1 above, and with annual rates of attendance ranging from 15%
to 90%. The probability of attending is equal for all individuals of the
specified ages.
For each apparently equal step in attendance rates, there is a progres¬
sively smaller saving in cases, deaths and life-years saved. The diminishing
return achieved by increasing attendance rate is seen more clearly in diagram¬
matic form in Fig 5.10 which plots the actual numbers of cases, deaths and
person-years of life lost at the different attendance rates. The tendency of
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the number of cases, deaths and life-years lost (and the savings in these
parameters) to reach a plateau indicates that, with a schedule of five-yearly
screenings, there will always be a proportion of clinical cancers which pass
through their pre-invasive stages in less than five years. In the present
example this relationship is complicated by a less than perfect detection of
abnormalities on screening (70% sensitivity) and the escape of a small
proportion of screen-detected cases from surveillance.
The number of screening tests carried out in the population is directly
proportional to the attendance rate. The ratio of savings per 1000 tests
therefore shows a reduction in yield with increasing attendance rates.
However, this decline is less steep for the ratios shown under 'savings per
positive test'. This is because the proportion of tests which are positive
falls as the intensity of screening increases (from 20 per 1000 at 15%
attendance to 16.3 per 1000 at 90% attendance). This is a consequence of a
reduction in prevalence of preclinical lesions in the population as the
intensity of screening increases.
In the results presented so far, the likelihood of attending for screening
at the ages schedules (35,40,45,50,55,60,65) has been equal for all
individuals in the population, at a probability defined by the attendance
rate. Because of the stochastic nature of the model, the population simulated
is examined as individuals, and transfer probabilities can be made dependent
upon personal variables. In Table V.6 the effects of making attendance for
screening dependent upon such variables are examined.
The simplest proposition is to suppose that 20% of women will never attend
a screening programme when it is offered, The other 80% may attend, their
attendance rate at each schedules test is 75%, so that the apparent rate of
attendance in the entire population is 60%. As might be expected the results
achieved (savings of cases, lives, life-years) are inferior to the situation,
represented by 60% attendance for the entire population, but the programme
costs (total tests, positive tests) are almost identical.
In section II.3.2 it has been described that attendance at screening
programmes is not a random event, but is related to such variables as age,
marital status and social class. It is quite clear, for instance, that women
who do not attend for screening are at higher risk of cervix cancer than those
who do attend. The second column of Table V.6 represents the situation where
attendance for screening tests is only half as likely in women with
abnormalities of the cervix (dysplasia, cis, micro-invasive/occult invasive
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disease). The overall attendance is 80%, and a comparison with the. position
where probability of attendance is the same for all individuals shows that the
'saving' are reduced by about one quarter. There are naturally considerably
fewer positive tests, of which a greater proportion are now false-positives.
The overall outcome is a reduction in savings per 1000 tests, but savings per
positive test are likely affected.
In the same table, the effect of making probability of attendance depend
upon marital state is shown. The ratios chosen are 5:9:2 for single :
married : formerly married. This was the approximate ratio seen in the Leeds -
Wakefield study (Parkin et al, 1981) - see Table 11.12. Cnce again overall
attendance in the whole population is close -to 80%. Because women in the
formerly-married group have elevated rates of onset of dysplasia (See Appendix
3) , so that prevalence of precursor conditions will be highest in this group,
their poorer attendance results in small reductions in savings and in positive
tests. The ratios savings per 1000 tests and savings per positive test are
slightly below those seen when a random 80% of women attend for screening.
Table 11.12 also shows that attendance for screening examinations tends to
decrease with age. Table V.6 (last column) shows a simulation of 30 years
screening where the rate of attendance falls from 60% at age 35 to 30% at age
65. This is compared with a similar overall rate of examination - 45% at all
ages. The savings of cases, deaths and life-years are less when screening
attendance falls off with age, even though there is a slightly increased
proportion of positive screening examinations. The explanation is probably the
higher prevalence of precursor lesions in younger women (Figs 5.5. and 5.6) so
that yield of positives is higher when attendance is greater at young ages,
but that this is offset by the more rapid progression of carcinoma in-situ in
older women (see Table IV.6) , so that failure to interrupt the course of such
lesions by screening has greater consequences in terms of clinical cancer.
3.3 TEST CHARACTERISTICS AND FOLLOW-UP
Table V.7 examines the effects of varying two parameters, success of
follow-up and test characteristics, on the results of the screening programme
summarised (examinations at exact ages 35,40,45,50,55,60,65; 80% of the
population attend on each occasion).
3.3.1 Follow-up intensity
It is known that in any screening programme a proportion of individuals
with precursor lesions who are found to have positive cytology will not be
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removed from the risk of developing clinical cancer. This may be because
follow-up is inadequate (the individuals do not attend for further screening
tests, or for diagnostic biopsy) or because such follow-up procedures (e.g.
regular 6 monthly cytology, or treatment by laser or cone biopsy) may
themselves be inadequate. In the policies examined in the results section the
usual assumption is that screen-detected dysplasias escape surveillance
(revert to dysplasia) at a rate of 8% per year for 3 years (equivalent to one
fifth of the cases detected) . For cis the loss is only half of this (since it
is assumed that the cytological features at screening would prompt more
intensive follow-up of the case). Table V.7 examines two other possibilities
which envisage more successful surveillance - a loss of only 2% of detected
dysplasia and 1% detected cis cases for a 3 year period (5% and 2.5% lost
overall), and a perfect system where, once detected by screening, the
individuals concerned have no further possibility of developing cancer.
The results show that, as the quality of follow-up deteriorates so too do
the savings achieved (cases, lives, life-years), and there is a small increase
in the number of tests carried out (fewer people are successfully treated or
under permanent surveillance) and in the proportion of screening tests that
are positive (since the prevalence of precursor lesions which are not treated
or under follow-up will increase) . Nevertheless, within the range examined
here the differences in savings achieved and in the ratio of savings to tests
are rather small.
3.3.2 Screening test characteristics
As discussed in section II.3.2 screening test performance can be described
in terms of sensitivity and specificity, and these bear a reciprocal
relationship to each other. In the programmes presented in this results
section a test sensitivity of 70% and specificity of 99.5% (5 per 1000 false
positive rate) has been assumed. These values are approximately equivalent to
those which have been estimated from the results of screening programmes
(section II.3.2.1). In Table V.7 two other possibilities are examined. Cne
envisages a higher sensitivity (90%) achieved presumably by the classification
as 'abnornal' of minor degrees of cytological change, which would lead to a
decrease in specificity (to 99%). The other alternative examines the opposite
effect of increasing specificity (to 99.9%) at the cost of a loss of
sensitivity (to 50%).
The results indicate that the savings in cases, lives and life-years
increase in direct proportion to the test sensitivity. Since the total number
of tests carried out will remain the same, the savings per 1000 total tests
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shows the same effect. The number of positive tests on screening shows an even
steeper increase, however, because the increasing sensitivity is accompanied
by a decreasing specificity, and this leads to large numbers of false
positives. The result is that the ratio of savings per positive test for the
three different sets of test characteristics, are in the opposite direction
from the savings per total tests.
Supposing that it were possible to choose the precise characteristics of
the screening test, the optimum could be selected by comparing the costs and
benefits of the different options. Cost could be derived from the relative
expense of negative screening tests (cost of taking and examining a smear) and
of true and false positive tests (which demand follow-up and possible
treatment). Benefit would be derived not only from the person-years of life
saved, but also from the number of cases of cancer avoided, since there is an
obvious benefit from avoiding treatment for clinical cancer, even though the
outcome is successful in terms of survival.
3.4 COMPARISON OF DIFFERENT SCREENING POLICIES
Table V.8 examines the outcome of several screening policies over a 30
year period.
The screening policy of five yearly examinations between the ages of 35
and 65 has been presented in two different ways. In column 1 is the policy
used many times already, of offering tests at exact ages 35,40,45,50,55,60,65.
i
The fourth column represents the effect of introducing a policy which calls
for all women to present for tests at five yearly intervals. The overall
number of examinations and positive tests with these two schedules is almost
identical, but their distribution over time is very different. Fig 5.11
illustrates this. For the 5 yearly schedule, in year one all 30,000 women aged
35-65 are tested, in the next four years only those attaining age 35 are
eligible. At year 6 all women aged 40-65, and those exactly 35 become eligible
for screening, and for the next four years so do women reaching ages 35 and
40. The oscillations gradually decrease so that the number of tests annually
tends to become constant. With the schedule testing women at exact ages, the
annual number of tests remains almost constant. The results of the 5-yearly
interval policy appear to be slightly better than that of tests at exact ages.
This may be because of more intensive examination at older ages in the first
year of the simulation.
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Columns 2 and 3 of Table V.8 illustrate possible modifications to the
exact ages policy to increase efficiency. Mot examining women who are either
single or who have had no children reduces the number of tests required in the
30 years of simulation by 20% (to 153,000), and increases the proportion of
screening tests which are positive (from 16.7 per 1000 to 18.2 per 1000) .
However, the decrease in savings of cancer cases, deaths and life-years lost
means that the outcomes to cost ratios are either the same as (savings per
1000 tests) or inferior to (savings per positive test) those obtained by
screening the whole population.
Since dysplasia is assumed to be a rather transient lesion, the great
majority of which regress to normality, the effect of ignoring screening tests
showing minor degrees of abnormality (consistent with dysplasia) has been
examined. There is a large reduction in positive tests (most of which are
false positives). However, failure ~to follow-up dysplasias leads to a
reduction in the savings achieved, so that although the ratios of savings per
positive test are improved, the ratios of savings per 1000 tests are worse.
Whether such a policy is worthwhile depends on the relative costs imputed to
negative tests and to true and false positives and a comparison with the
benefits obtained.
The final column examines the results obtained by examining women only at
the time of pregnancy. The rationale for such a policy would be the lower cost
of the tests (especially negative tests) since, as the tests can be taken
incidental to other health-service attendances, no special screening service
needs to be established. It can be seen that the savings with such a schedule
are much less than those achieved by the other policies. However, because of
the young age at which testing is performed, the saving of life-years is less
inferior than the other two parameters. The savings per 1000 tests and savings
per positive test are inferior to those achieved by regular examination at
older ages. However, if the cost of a negative test taken during ante-natal or
post-natal care was only half that taken at special screening clinics, then a
favourable cost-benefit ratio is seen for pregnancy screening if benefit is
equated with life-years saved, and the cost of follow-up and treatment of
positive tests is up to one-hundred times that of a negative test. Thus, even
though the yield is rather small, pregnancy screening may be a relatively
efficient way of deploying resources.
Table V.9 summarises five screening policies which have been recommended
for England and Wales, and which have been described in more detail in section
II.3.2.2.
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Table V. 10 illustrates the simulated outcome of applying these policies (1
to 5) to a population with the structure of that of England and Wales for the
thirty year period 1961-1990. For all these policies, very favourable rates of
attendance have been assumed; a random 80% of females attending all the
routine tests.
In the British Society of Clinical Cytology recommendations (3 and 4) the
onset of routine testing is after the age of 25 at the time of attendance for
pregnancy, contraceptive advice, or venereal disease. In the simulation a
start to screening at the time of pregnancy (childbirth) is readily modelled,
but there is no data available on the probability of attendance for contra-
ception/v.d. between ages 25 and 29. The arbitrary solution adopted was to
make the annual probability 0.2 for individuals with a normal cervix and 0.4
for individuals with precursor lesions (in keeping with the increased
prevalence of abnormality in contraceptive users and patients with venereal
disease). A similar problem exists in modelling the Committee on
Gynaecological Cytology recommendations (policy 5) . The solution adopted was
to postulate (generously) a 50% probability of receiving a first test at ages
22 and 23, and a 50% probability of being screened at age 30 if no test had
been taken in the preceding five years. Attendance in women with abnormal
cervices (dysplasia, cis, micro/occult invasive) was increased to 67% in
keeping with an increased risk of disease in contraceptive users (this rate
results in prevalence being double that in normal subjects).
The results indicate that the highest yield in terms of savings is
achieved with the policy involving 3 yearly routine tests (policy 4), but that
this involves the greatest number of screening tests. The yield, particularly
in terms of lives and life-years saved, is rather similar for policies 2,3 and
5. However, the input of screening tests is considerably different, so that
the savings per test ratios are much less favourable for the more intensive
policies. It should be pointed out that the costs per screening test are
probably not identical for all these policies, in particular with the C.G.C.
policy (number 5). Some 89,000 tests were taken during pregnancy and a further
26,000 during attendance for family planning, and such examinations taken
incidental to other procedures may be less costly than examination at special
screening sessions. Similarly, with the BSCC policies, a small proportion of
tests are carried out incidental to pregnancy, contraception or venereal
disease attendance (About 9500 . per year). Table V. II shows a rather crude
cost-effectiveness analysis of these five policies, using as a measure of
output the life-years saved over the first 30 years of screening. The unit of
cost is taken to be that of a routine screening test; examinations taken
-38-
incidental to another procedure are taken to cost half this amount. The cost
of follow-up of a false positive (usually involving repeat smears) is taken to
be five times, and the cost of diagnosing and treating true positives twenty
times that of a routine smear. The efficiency of the Committee for
Gynaecological Cytology policy (number 5) is considerably enhanced using this
approach when compared with the simple savings per test analysis of Table
V.10. Nevertheless the yield of screening appears to little superior to the




The model which has been developed meets many of the specifications which
were laid down during the discussion on the problems involved in evaluating
different screening policies. It is simple in conception and easy to
understand, since the approach adopted was to produce a model which was
lifelike, albeit clumsy, rather than abstract and sophisticated. Ihe
demographic basis of the model, following a total population for a relatively
short time period, is a much more satisfactory background for studying
screening that the single-cohort method. The disease process is simulated by
what is essentially a simple markov-process, but the lack of time-dependence
is avoided by the device of multiplying the number of disease states by a
set of durations to produce states of disease/duration, from which transfer
rates are specified. This allows a great deal of flexibility in defining
natural histories. Disease natural history can be modified by individual
characteristics (in the examples given, marital status and parity were used),
as can behaviour with regard to screening. Finally, the pattern of screening
activity which can be superimposed on the population is extremely flexible,
and is not limited to the highly theoretical policies which have been examined
in the past.
The input data from the model are based on real observation, wherever this
is feasible, so that it should be possible to verify the model output against
the actual population results. This has been done for the demographic
component, and to some extent for the natural history. However, to date there
has not been an attempt to verify whether the trends in disease observed in
England and Wales could be reproduced by simulating the screening activity
that has taken place. It is lack of accurate knowledge about this activity
that is a major limiting factor, nevertheless this is an area which merits
some future effort.
Hie other general area where validation studies are possible is that of
natural history. This is very important, since it is the more or less
arbitrary choice of natural history parameters that makes much simulation work
unconvincing (see, for example, Chamberlain, 1982). The specification of
natural histories in the present study was based on data on cross-sectional
prevalence and incidence rates, and on observational studies of pre-invasive
disease. The results of simulation did not appear to be very sensitive to the
choice of natural history. The joint IARC/WHO collaborative prograrmie on the
evaluation of screening programmes for cancer of the uterine cervix has
brought together available material from different screening programmes
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(mainly in Scandinavia) on the rates of disease onset at varying time-periods
after one or more negative screening tests. Interpretation of this material in
terms of natural history is not easy, but it offers the opportunity of testing
whether the same order of results can be achieved using simulations based on
the natural histories derived as described above.
The potential for simulating complex screening programmes with this type
of model has been demonstrated. It is the author's belief that it is not
possible or necessary to separate screening tests into incidental (sometimes
called "diagnostic") and routine ("mass" screening). Testing at the time of
other contacts with the health care system (eg pregnancy, gynaecology
attendance) is a fairly satisfactory and efficient way of reaching relatively
high risk groups who may otherwise not attend for screening. A screening
programme should seek to add a set of special screening examinations to this
background service. There is a need for good data on attendance rates and
population coverage of gynaecology,clinics and family planning services which
can be used by the simulation model to examine these possible options.
There is ample scope for improving the technical aspects of the type of
model described. A more efficient computer solution is almost certainly
possible which will retain the essential features of the model (a micro-
simulation which involves examination of the members of a mixed population
over a short time period). The stochastic nature of the model means that
outputs from simulations using identical parameters will not be the same, and
to produce stable results when rare events are under study large populations
i
have to be simulated. This uses large amounts of computer time (1 1/2 - 2
hours of C.P.U. time are needed on the VAX computer at IARC to study a
population of 100,000 for 30 years). Improvement on this is almost certainly
possible; but even without it the model provides a more feasible means of
studying the effects of different screening programmes than the use of
clinical trials)
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Aye adjusted I) ealh Rates of Canter by Site and Year (1970-1975)
Cervix uteri (female)
Country 1970 1971 1972 1973 1974 1975
Africa
1. Egypt 0.33 0.28
2. Mauritius 7.66 7.60 7.47 4.48 5.92
3. South Africa
America
4. Canada 5.70 5.39 4.95 4.46 4.37 3.68
5. Chile 15.53 15.34 16.68 16.10 15.37
6. Costa Rica 10.02 11.20 7.69 12.42 10.89 9.01
7. Cuba 5.41 4.86 4.72 4.63 5.66
8. Dominican Republic 3.90 3.28 4.81
9. Ecuador 4.04 5.14 7.27
10. El Salvador 6.55 4.97 4.94 3.61 4.43
11. Honduras 0.71 0.42 0.26
12. Martinique 4.97 4.79
13. Mexico 10.30 10.57 11.25 11.20
14. Nicaragua • 1.03
15. Panama 11.16 7.72 15.52 10.00 8.10
16. Paraguay 10.49 12.95
17. Puerto Rico 5.79 4.83 4.14 4.89 4.44
18. Trinidad & Tobago 16.43 15.32 17.97 11.39
19. United States 5.60 5.12 4.56 4.42 4.02
20. Uruguay 5.79 7.40 6.06 4.91 5.43
21. Venezuela 12.65 13.48 11.78 12.09 12.64 11.19
Asia
22. Hong Kong 7.88 8.51 8.47 8.15 7.78 7.23
23. Israel 1.10 0.83 1.54 1.86 1.78 2.16
24. Japan 2.54 2.41 2.50 2.20 2.32 2.34
25. Philippines 1.20 1.25 ' 1.19
26. Singapore 9.10 9.95 9.30 9.69 6.00
27. Thailand 0.70 0.56 0.53 0.84 0.80 0.71
Europe
28. Austria 4.68 4.95 5.21 5.34 5.21 4.78
29. Belgium 3.59 3.96 3.33 2.97 2.61
30. Bulgaria 2.98 2.55 2.98 3.21 3.00 2.84
31. Czechoslovakia 5.46 5.49 5.33 5.46 5.01 5.18
31 Denmark 8.99 10.53 8.42 8.47 8.62 8.11
33. Finland 4.53 5.03 3.79 3.16 3.28 2.98
34. France 2.44 2.55 2.48 2.52 2.57 2.40
35. Germany, F.R. 5.80 5.80 5.75 5.84 5.70 5.50
36. Greece 0.82 0.88 1.09 1.30 0.66 0.84
37. Hungary 6.46 6.10 6.72 6.48 6.50 6.50
38. Iceland 7.99 5.14 2.38 7.65 6.23
39. Ireland 4.16 3.42 4.18 4.25 2.64 3.91
40. Italy 1.58 1.50 1.33 1.31 1.15
41. Luxembourg 3.93 7.85 4.74 7.28 3.64
42. Malta 4.27 3.17 1.83
43. Netherlands 5.33 5.32 4.89 4.33 4.86 4.54
44. Norway 6.34 6.11 5.27 5.80 4.72 5.75
45. Poland 8.56 9.33 9.30 9.26 8.74 8.63
46. Portugal 8.68 8.05 7.01 6.49 6.76 4.98
47. Romania 9.31 9.63 9.55 9.87 10.20
48. Spain 0.82 0.69 0.83 * 0.67 0.82 0.82
49. Sweden 5.98 5.03 5.10 4.95 4.43 4.33
50. Switzerland 5.90 6.25 5.28 5.41 4.93 5.02
51. England &. Wales 6.08 6.06 5.73 5.87 5.27 5.53
52. Northern Ireland 5.06 4.00 5.06 5.13 3.63 5.02
53. Scotland 6.03 5.84 5.31 6.13 5.06 6.04
54. Yugoslavia 6.37 4.98 4.87 4.89 4.88 4.26
Oceania
55. Australia 5.16 4.80 5.01 4.83 4.50
56. New Zealand 5.67 5.84 5.18 5.24 5.56 5.23
%
Source : Segi et al (1981)
%
TABLE II.2
CHANGES IN MORTALITY FROM MALIGNANT NEOPLASM OF UTERUS AT AGES 3S-64,
19SS-S9, 1965-69
VARIATIONS DE LA MORTALITY PAR TUMEUR MALIGNE DE L'UTERUS
POUR LE GROUPE D'AGE 35-64 ANS, 1955-59, 1965-69






sion marquee de la
mortality par tumeur
maligne du col de
I'ut6rus
















Canada 17.5 13.3 — 24 26.1 - 19.1 — 27 •
Chile Chili 19.0 29.3 + 54 43.7 43.7 0 •
United States — Etats-Unis 19.0 13.5 — 29 29.1 19.8 — 32 •
Venezuela 25.2 29.2 + 16 69.9 56.8 — 19 •
ASIA — ASIE
Israel — Israel 2.0 2.4 + 20 12.3 9.5 — 23
•
Japan — Japon 7.0 7.2 + 3 39.8 25.9 — 35
•
EUROPE
Austria — Autriche 7.4 10.5 + 42 44.0 36.3 — 18
•
Belgium — Belgique 14.6 7.8 — 47 33.8 22.8 — 33
«
Czechoslovakia — Tchdcoslovaquie . . 14.8 14.0 — 5 32.1 24.8 — 23
•
Denmark — Danemark 24.8 27.5 + 11 39.9 35.5 — 11
•
Finland — Fintande 12.0 11.9 — 1 24.8 18.9 — 24
•
France 6.6 6.6 0 26.0 22.1 — 15
•
Germany, Fed. Rep. of
Allemagne, R6p. fed. d'
8.8 13.5 + 53 28.7 27.1 — 6 •
Hungary — Hongrie 6.4 12.6 + 97 47.3 35.5 — 25
•
Ireland — Irlande 5.9 8.6 + 46 19.6 16.8 — 14
•
Italy — Italie 4.3 4.0 — 7 30.1 26.9 — 11
•
Netherlands — Pays-Bas 13.9 13.1 — 6 21.9 20.3 — 7
•
Norway — Norvfege 16.7 13.4 — 20 22.6 18.5 — 18
•
Portugal 20.8 17.7 — 15 30.0 25.4 — 15
•
Sweden — Suede 10.6 13.9 + 31 22.2 19.8 — 11
•
Switzerland — Suisse 15.9 11.7 — 26 25.5 20.7 — 19
•
U.K.: England and Wales
R.-U.: Angleterre et Galles
15.2 15.1 — 1 21.7 20.7 — 5 •
U.K.: Northern Ireland
R.-U.: Irlande du Nord
11.7 12.3 + 5 21.9 18.4 — 16 •
U.K.: Scotland — R.-U.: Ecosse .... 15.2 15.5 + 2 25.6 21.2 — 17 «
OCEANIA — OCEANIE
Australia — Australie 12.1 11.6 — 4 19.4 15.8 — 19 •
New Zealand — Nlle-Zelande 15.9 13.1 — 18 22.5 18.2 — 19 •
Source : Hill (1975)
TABLEII.3























































































































































































Sources:1)CancerM rtalityEnglanda dW es1911-70.Studi sonMedicala dPopulat onSubj c sn2 UMBO,1975 2)Roberts(1982)
TABLE11.4
INCIDENCE(REGISTRATIONA ES)PE100,000,ENGLANDAWA ES (Excludesin-situlesions) AGEGROUP





































































































































































Sources:1)RegistrarGeneraltatistic lviev;fEnglandndW sSupplenentCanc (years1962-1970) 2)OPCS:CancerSt tistics,Regis rationsMB1nos1,2,4,5,7,0,9(y a1971-1978) 3)OPCS:CancerRegistrations1979,d80(est m t )MB18 /1
TABLE 11.5
REGISTRATIONS CF CARCINOMA IN SITU OF THE CERVIX
IN ENGLAND & WALES
RATES PER MILLION WOMEN
Age-group
YEAR
15-24 25-34 35-44 45-54 55-64 65+
1*65 e 103 198 109 32 14
1966 19 168 300 167 37 13
1967 23 230 406 242 52 15
1966 33 249 365 225 44 14
1969 36 260 313 201 51 15
1970 35 237 252 164 41 12
1971 35 256 244 148 40 9
1972 54 251 235 157 46 16
1973 53 309 277 132 54 12
1974 65 367 296 152 48 13
1975 73 419 316 149 47 16
1976 85 504 346 143 53 20
1977 88 549 402 151 53 15
1976 89 552 398 140 47 12
1979 82 627 417 145 51 17
I960 109 710 468 . 174 70 19
TABLEII.6











Rate per 1,000 smears
Smears 1000s
CIS Regns
Rate per 1,000 smears
Smears •000s
CIS Regns



































































































































































































%R4uiiv*rukcalc latedbyexposureoddsr tiowh reP aIp rcentlcas swithp i ivent bodiesndPcolperc ntfcontrols. Source:Cram r(1982)
TABLEII.8

































































































* .......■i\ MethodI:CalculationxcludesthedmostaffectedBycarryov rf(alsnegativ sfroiniliexamin lk ii( )
"* MethodiI:Datallowsforalsnegativernl'.cniniti ldsubs quen ',oxamin li(If.US'odyspl si9,(,"le c.i.s.);figurerepresentdati gofincid ncafirstalinorniatsm ar,oamidpointBetweensmears.
'ABLE II.9 Screening workload in Enaland and Wales
Table 1: Estimated total smears IthousandsI and {in parentheses! Table 2: Estimated total smears <thousandsI and Iin parenthesesl












































1967' 245 384 141 521 51 1342 1974 560 490 354 1072 2476
1968 313 378 168 551 58 1467 (2-5) (4-2) (5-6) (5-9) (4-7)
(6-3) 1975 592 482 380 1044 2498
1969 363 388 227 587 67 1632 (2-1) (4-5) (5-5) (6-2) (4-8)
(5-7) 1976 566 476 429 1097 2568
1970 419 431 284 620 82 1835 (2-4) (5-1) (6-1) (6-3) (5-2)
(4-7) 1977 616 458 385 1086 2545
1971 477 433 345 649 90 1995 (2-5) (6-0) (7-8) (7-1) (5-9)
(4-4) 1978 600 441 383 1163 2587
1972 539 473 376 640 96 2124 (2-8) (7-3) (9-3) (6-7) (6-3)
(4-5) 1979 632 467 406 1244 2749
1973 630 541 411 552 204 2338 (2-6) (7-2) (9-7) (6-7) (6-3)
(3-5) (2-4) (2-1) (9-8) (1-7) (4-3) 1980 701 469 404 1354 2928

















































































' Local Health Authority prior to 1974 NHS re-organization. t
1 1965, 1966 and part 1967 figures are based on a sample.
Notes to tables i mi i-
(1) Prior to 1973 information on source of smear was obtained from pathology laboratories; detection rates are not available. Since then the
number of smears examined by source and age have been estimated from a 20% sample of negative smears taken during January and
July of each year and returned to the National Health Service Central Register.
(2) The total number of positive cases is obtained from the laboratory return S8H 140.
(31 Because of rounding the sum of figures across a row may not equal the "All sources" figure.
Source : Roberts (1982)
TABLE II.IO
Estimated total smears by age and source. 1980
Area
Health Family
Age Smears General Authority Planning Hospital Other All
(years) Practitioners Clinics Clinics Clinics Clinics sources ,
Under Estimated total smears 270000 133000 150000 140000 8000 701000
25 Detection rate 2-0 1-2 2-2 7-1 12-8 3-0
25-29 Estimated total smears 189000 80000 73000 119000 7000 469000
Detection rate 5-9 4-3 8-2 15-5 17-2 8-6
30-34 Estimated total smears 170000 79000 52000 98000 5000 404000
Detection rate 8-6 6-0 11-9 19-8 20-2 11-4
35 and Estimated total smears 622000 417000 80000 212000 23000 1354000
over Detection rate 5-0 2-3 6-6 20-7 10-2 6-8
All Estimated total smears 1252000 708000 356000 570000 42000 2928000
ages Detection rate 5-0 2-7 5-9 16-0 13-1 6-8
(1) The number of smears examined by source and age group is estimated from a 20% sample of negative smears taken during January
1980 and July 1980 and returned to the National Health Service Central Register. The number of positive smears and the total number
of smears are from form SBH140.
(2) Detection rate = Positive cases per 1 000 total smears.
(3) Because of rounding the figures down a column or across a row may not equal the "All ages" or "All sources" figure.
TABLE 11.11
Cytology testing 1976-1977; place or examination
Persons examined
Tests performed Age Contraception
'lace of testing No. r;) No. Mean % under 35 Taking pill I.U.C.D. With symptoms*
jeneral practitioner 24.800 (25 5) 22.800 (27-8) 35-7 51-2 32 1 3 0 30-9
Tcalth authority clinics 18.910 (19 3) 18.040 (22 0) 41-2 28-9 20-4 1-5 17 0
:amily planning clinics 19.040 (19-6) 16.040 (19-6) 28-1 80-9 52-8 13 5 15-9
knte-natal clinics 10.870 (112) 9.550 (11-7) 25-7 92-8 0-2 0-2 —
'ost-natal clinics 2.240 (23) 1.730 (2-1) 27-8 87-7 15-9 2-4 —
jynaecology out-patients 16.030 (16 5 9.630 (118) 37-7 450 18-5 4-3 79-7





530 J (10) 800 (10) 39-3 40-1 20-9 (0) 14-3
Ipectal (V.D.) clinics 2.540 (2-6) 1.810 (2-2) 25-1 88-0 54 3 (0) 54-6
'nvate patients 1.080 (M) 1.050 (13) 41-8 37 5 (0) 3 9 100
Total 97,250 (99-9) 81.890 (100) 34-2 57-4 27 4 4-4 33-8
* Excludes pregnant and post-natal women. t (0) too few for reliable estimate.





Annual attendance rates (100)
TotalNo. (%) Single Married Widowed/divorced
15-19 6,350 (6-5) 65-8 6 2 24 (-) 7-5
20-24 17.610 (181) 407 194 24-4 31 6 22-3
25-29 18.000 (185) 23-6 17 0 22-7 16-3 21 6
30-34 15,370 (15 8) 16-6 9 2 21 5 10-4 200
35-39 11,440 (11 8) 14 0 8 8 18 7 118 17 7
40—49 16.250 (16 7) 150 4 5 13 5 10-6 12 8
50-59 8,540 (88) 17-1 2-9 7 0 3-4 6-3
60 + 3.690 (3-8) 28-9 0 04 2-4 0 8 14
All ages 97,250 (100 0) 23-9 8 2 13-5 2-9 10 6
TrendsiIncidenceofvasivCervicalan erp jr100,000F malePo ul t on




















































































































































































































































































































































"O.msieadral sarlorten-yeartwelve-yearspe iod ,C n cticutralfoliv -yearp riods,ndL ui villelefIhr -yearp io .Th sed rh wnilhmi points. **R«iesinauoa-sauaw llinv sivecervicalcancer. Sources:Rele ences10.273194 .8-56 Source:Guzi k(1978)
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'Ownsiaaoa dConnecticutr lesarl rth ee-yearlive-y ape iodash wntthmidp ints. Souvces:Relevances21.73951-60.
Ago 30-54 21 21
Source:Guzi k(1978)
TABLE 11.15
NUMBER OF CASES OF INVASIVE CERVICAL CANCER OBSERVED IN 1973,
AMD THE NUMBER THAT MIGHT HAVE BEEN EXPECTED IN THE ABSENCE OF SCREENING
AGE OBSERVED 'EXPECTED' PROPORTION NUMBER
'PREVENTED' 'PREVENTED'
20-24 45 57 0.21 12
25-29 163 241 0.32 78
30-34 282 438 0.36 156
35-39 281 458 0.39 177
40-44 233 393 C.41 16C
45-49 292 441 0.34 149
50-54 399 553 c.2e 154
55-59 549 673 C.1S 124
60-64 454 518 C. 12 64
65-69 441 474 0.C7 33
70-74 290 306 C.C5 16
75-79 213 222 C. 04 9
80+ 229 238 C.C4 9
TOTAL 3871 5012 0.23 1141
TABLE IV.1
1961 CENSUS : FEMALES BY AGS/MARITAL STATE
TH0USA21DS
Age S M FM Ml s M FV.
0 376.7 0 0 51. 37.8 253.3 29.0
1 358.3 0 0 52 40.7 261.6 33.0
2 354.2 0 0 53 41.4 250.5 35.3
3 345.7 0 0 54 42.1 241.6 37.5
4 331.3 0 0 55 41.7 228.8 39.6
5 320.0 0 0 56 43.1 225.1 43.7
6 314.4 0 0 57 42.3 214.7 46.6
7 322.3 0 0 53 41.9 209.5 51.^
8 316.4 0 0 59 41.3 198.5 54.6
9 316.6 0 0 60 42.0 195.5 63 .A
10 324.2 0 0 61 38.9 174.1 63.3
11 338.7 0 0 62 38.8 162.3 65.7
12 353.0 0 0 63 38.5 154.2 69.5
13 389.7 0 0 64 37.4 144.1 74.1
14 411.1 0 0 65 37.8 134.8 78.0
15 316.1 0 0 66 35.6 122.7 73.9
16 331.4 2.8 0 67 35.5 113.2 82.4
17 313.2 11.5 0 68 34.9 106.2 86.0
18 285.6 30.7 0 69 32.8 94.5 86.3
19 228.1 5806 0.1 70 32.7 87.1 "91.6
20 180.2 95.5 0.1 71 29.3 73.6 84.8
21 150.4 143.3 0.3 72 29.5 70.0 92.4
22 116.0 178.4 0.6 73 28.0 61.5 91.8
23 89.8 201.9 0.9 74 26.2 53.1 90.3
24 70.5 214.5 1.2 75 24.6 46.2 89.O
25 57.2 225.0 1.6 76 23.3 40.4 87.1
26 47.8 228.9 2.1 77 20.6 32.8 79.3
27 40.8 229.2 2.3 78 19.4 27.8 77.5
28 38.2 238.5 2.7 79 17.7 22.8 71.6
29 35.8 247.1 3.1 80 17.0 19.3 70.4
30 36.4 262.6 3.8 81 14.1 14.5 59.3
31 32.3 255.1 4.0 82 12.5 11.5 54.3
32 31.8 258.6 4.4 83 10.9 8.8 48.2
33 30.2 254.9 4.9 84 9.8 6.7 43.0
34 31.6 266.6 5o5 85 8.1 4.7 36.0
35 32.1 275.7 6.7 86 6,6 3.6 30.5
36 30.8 273.4 7.3 87 5.2 2.3 23.4
37 31.0 278.2 8.4 88 4.2 1.6 18.8
38 31.8 288.3 9.8 89 3.3 1.0 14.2
39 33.4 307.2 11.6 90 2.6 .7 11.2
40 36.4 330.3 14.1 91 1.8 .4 7.9
41 31.7 302.0 14.1 92 1.3 .3 5.9
42 25.8 229.3 12.1 93 1.0 .2 4.1
43 25.7 217.3 12.4 94 .7 .1 3.0
44 29.8 246.3 15.4 95 .5 .1 2.0
45 31.8 259.0 17.4 96 .3 .1 1.4
46 34.4 282.1 21.0 97 .2 0 0.8
47 34.6 278.2 22.2 98 .2 0 0.6
48 35.9 275.3 24.0 99 .1 0 0.4
49 36.3 267.3 25.0 10o 0 0 0.2
50 39.5 273.3 29.0
Census 1961 (England, and Wales) : Age, Marital Condition & General Tables
(General Register Office 1964 H.K.S.O.)#
TABLE IV.2
PARITY OF WOMEN 3Y MARITAL STATUS AMD AGE























18-19 289 48 5
0 279 (96.5) 26 (54.2) 0 (0.0)
Para
1 10 (3.5) 19 (39.6) 5 (100)
2 0 (0.0) 3 (6.2) 0 (0.0)
3+ 0 (0.0) 0 (0.0) 0 (0.0)
20-24 341 498 31
0 318 (93.3) 217 (43.6) 13 (41.9)
1 19 (5.6) 161 (32.3) 12 (38.7)Para
2 4 (1.2) 97 (19.5) 3 (9.7)
3+ 0 (0.0) 23 (4.6) 3 (9.7)
25-29 119 714 65
0 104 (87.4) 180 (25.2) 16 (24.6)
Para
1 12 (10.1) 203 (28.4) 15 (23.1)
2 2 (1.7) 255 (35.7) 24 (36.9)
3+ 1 (0.8) 76 (10.7) 10 (15.4)
30-34 64 895 79
0 55 (85.9) 94 (10.5) 9 (11.4)
1 6 (9.4) 171 (19.1) 26 (32.9)Para
2 3 (4.7) 400 (44.7) 28 (35.4)
3+ 0 (0.0) 230 (25.7) 16 (20.3)
35-39 38 708 77
0 27 (71.1) 60 (8.5) 4 (5.2)
i 1 5 (13.2) 101 (14.3) 10 (13.0)Para
2 2 (5.3) 276 (39.0) 33 (42.9)
3+ 4 (10.5) 271 (38.3) 30 (38.9)
40-44 31 682 72
0 28 (90.3) 63 (9.2) 2 (2.8)
1 2 (6.5) 62 (9.1) 11 (15.3)Para
2 1 (3.2) 259 (38.0) 17 (23.6)
3+ 0 (0.0) 298 (43.7) 42 (58.3)
45-49 25 591 60
0 23 (92.0) 51 (8.6) 12 (20.0)
1 1 (4.0) 89 (15.1) 7 (11.7)Para
2 0 (0.0) 203 (34.3) 15 (25.0)
3+ 1 (4.0) 248 (42.0) 26 (43.3)
ALL 907 4141 389
0 834 (92.0) 693 (16.7) 56 (14.4)
TD—j >»"-5 1 55 (6.1) 809 (19.5) 86 (22.1)raJLG.
2 12 (1.3) 1493 (36.1) 120 (30.8)
3+ 6 (0.6) 1146 (27.7) 127 (32.6)
• BL£ IV.3
PARITY DISTRIBUTIONS OF STARTING POPULATION
Age Sinaie Married Form, married Age Sinale Married -orm. married
Parity
2+ 1 2+ 2+
Parity
2+ 1 2+ 2+
L 1000 0 01000 0 01000' 0 0 61 890 100 10 239 234 417 205 236 559
£ 1000 0 01000 0 01000 0 0 62 890 100 10 239 234 417 205 23o 559
3 1 coo 0 01000 0 01000 0 0 63 890 100 10 239 234 417 205 236 559
i 1000 0 01000 0 01000 0 0 64 890 100 10 239 234 417 205 236 559
? 1000 0 01000 0 01000 0 0 65 890 100 10 239 234 417 205 236 559
0 1000 0 01000 0 01000 0 0 oo 890 100 10 233 234 543 190 216 594
r 1000 0 01000 0 01000 0 0 67 890 100 10 233 234 543 190 216 594
8 1000 0 01000 0 01000 0 0 68 890 100 10 233 234 543 190 216 594
9 1000 0 01000 0 01000 0 0 69 890 100 10 233 234 W*TU 190 216 594
) 1000 0 01000 0 01000 0 0 70 890 100 10 233 234 543 190 216 594
L 1000 0 01000 0 01000 0 0 71 890 100 10 227 204 569 178 199 623
1000 0 01000 0 01000 0 0 72 890 100 10 227 204 569 178 199 623
3 1000 0 01000 0 01000 0 0 73 890 100 10 227 204 569 178 199 623
* 1000 0 01000 0 01000 0 0 74 890 100 10 227 204 569 178 199 623
8 1000 0 01000 0 01000 0 0 75 890 100 10 227 204 569 17S 199 623
0 990 10 01000 0 01000 0 0 76 890 100 10 217 189 594 164 180 656
r 990 10 0 667 333 01000 0 0 77 890 100 10 217 133 594 164 ISO 656
8 990 10 0 571 410 191000 0 0 78 890 100 10 217 189 594 164 180 656
9 980 20 0 564 396 401000 0 0 79 890 100 10 217 189 594 164 180 656
> 970 30 0 560 370 701000 0 0 80 890 100 10 217 189 594 164 ISO 656
L 970 30 0 538 356 106 500 500 0 31 890 100 10 210 174 616 151 159 690
970 30 0 514 347 139 333 333 334 82 890 100 10 210 174 616 151 159 690
8 970 30 0 462 356 182 400 400 200 S3 890 100 10 210 174 616 151 159 690
i 970 30 0 408 359 233 250 500 250 84 890 100 10 210 174 616 151 159 690
8 960 40 0 358 354 288 333 417 250 85 890 100 10 210 174 616 151 159 690
o 950 50 0 309 343 348 344 375 281 86 890 100 10 210 174 616 151 159 690
7 920 70 10 266 329 405 316 368 316 87 890 100 10 210 174 616 151 159 690
e 920 70 10 239 326 435 273 364 363 88 890 100 10 210 174 616 151 159 690
9 920 70 10 204 297 499 269 346 385 89 890 100 10 210 174 616 151 159 690
j 910 SO 10 134 281 535 276 345 379 90 890 100 10 210 174 616 151 159 690
L 920 70 10 167 267 566 250 333 417 91 890 100 10 210 174 616 151 159 690
? 910 80 10 155 257 588 237 329 434 92 890 100 10 210 174 616 151 159 690
3 900 90 10 146 249 605 233 333 429 93 890 100 10 210 174 616 151 159 690
* 890 100 10 142 243 615 234 319 447 94 890 100 10 210 174 616 151 159 690
8 890 100 10 138 242 620 226 321 453 95 890 100 10 210 174 616 151 159 690
b 890 100 10 133 241 626 222 317 461 96 890 ICO 10 210 174 616 151 159 690
7 890 100 10 131 240 629 200 343 457 97 890 100 10 210 174 616 151 159 690
8 390 100 10 128 241 631 213 312 475 98 890 100 10 210 174 616 151 159 690
9 890 100 10 127 243 630 213 319 468 99 890 100 10 210 174 616 151 159 690
j 890 100 10 125 244 631 196 330 474 00 890 100 10 210 174 616 151 159 690
L 890 100 10 126 248 626 199 331 470
2 390 100 10 125 247 628 191 324 485
3 S90 100 10 128 247 625 197 308 495
Sourcea 390 100 10 132 250 618 135 311 504
5 890 100 10 139 255 606 196 304 500
b 890 100 10 143 254 603 192 299 509 Married/formerly married:
7 390 100 10 145 255 600 132 231 527
3 890 100 10 155 259 586 186 288 526 Census 1961 (E & W) Fertility Tables
9 890 100 10 162 263 575 198 289 513 GRO 1966 (HMSO)
j 390 100 10 169 264 567 192 282 526
1 390 100 10 196 271 533 203 273 524
Single2 830 100 10 196 271 533 203 273 524
3 890 100 10 196 271 533 203 273 524
data* 890 100 10 196 271 533 203 273 524 Estimates based on from GHS 1979
Werner (1982)390 100 10 196 271 533 203 273 524 -V
3 390 100 10 229 266 505 215 258 527
7 390 100 10 229 266 505 215 258 527
0 390 100 10 229 266 505 215 258 527
9 890 100 10 229 266 505 215 258 527
j 890 100 10 229 266 505 215 253 527
TABLE IV.A











































































































OPCS I'bnitor D.S, No.2 (1979)
2, Figures represent values i.e.
Proportion of those attaining exact age x who die in ensuing year
I Alii I IV.5
HATES Of MARRIAGE, REMARRIAGE b WIIXJWHOUD/DIVOICE
1961 - 1970
(rates per 1000)
AGE S-*M M-»FM* FM—M
16 20 )
17 50 ) 1
18 104 • )
19 169 )
20 222 ) )
21 298 ) ) 4Sfl
22 287 ) 5 ) 458
23 266 ) )
24 234 ) )
25 203 ) )
26 173 ) )
27 149 ) 8 ) 357
28 129 ) )
29 112 ) )
30-34 73 7 214
35-39 38 7 120
40-44 21 8 74
45-49 14 10 40
50-54 8 14 27
55-59 ) 21 )
60-64 ) 32 )
65-69 ) 47 )
70-74 ) 2 66 ) 3
75-79 ) ) )
80-84 ) ) 106 )
85 + ) ) )
* Includes divorces based only on 1964-67 rates
Source
Marriage and Divorce Statistics 1974. OPCS Monitor FM2 no 1
(HMS0, 1977)
HATES OF MARRIAGE. REMARRIAGE & WIDOWHOOD/DIVORGL
1971-1980
(rates per 1000)
AGE S-*M M-+FM FM-»M
16 14 ) -
17 43 ) 2
18 106 )
19 149 )
20 182 ) )
21 213 ) )
22 227 ) 17 ) 509
23 215 ) )
24 198 ) )
25 170 ) )
26 162 ) )
27 147 ) 21 ) 310
28 131 ) )
29 117 ) )
30-34 84 18 201
35-39 42 15 )
40-44 23 14 )
43-49 15 14 ) AS
50-54 10 16 )
55-59 ) 23 )
60-64 ) 31 )
65-69 ) 45 )
70-74 ) 2 66 ) 4
75-79 ) 93 )
80-84 ) 121 )
85+ ) 165 )
Source
Marriage and Divorce Statistics 1980. OPCS MONITOR FM2 no 7 (HMSO
1981)
TRANSITIONR TESBETW EM RI ALSTAT











































































































































































































































































































































































































































































































































































































































































































































































































































































































































FERTILITY RATES : MARRIED WOMEN 1961-1970
1. AVERAGE ANNUAL BIRTHS BY AGE/PARITY 1961-70
AGE PARA 0 PARA 1 PARA 2 +
16-19 47,320 10,450 1,080
20-24 135,660 86,370 35,470
23-29 69,880 91,040 79,560
30-34 21,680 38,750 70,970
33-39 7,260 12,870 42,580
40-49 1,610 2570 14,150
Source : Registrar Generals Review of England and Wales, Part II,
Population - 1961 - 1970 (Table HH)
2. MEAN POPULATION (ENGLAND & WALES 1966) BY AGE/PARITY
AGE PARA 0 PARA 1 PARA 2 +
16-19 74,050 60,390 9350
20-24 389,250 315,980 210,660
25-29 257,250 341,000 598,250
30-34 148,230 259,400 827,630
35-39 143,900 261,650 902,680
40-49 336,650 646,400 1,710,200
Sources :: Population : Census 1966 : Summary Tables
Parity : Census 1961 & 1971 : fertility Tables
3. MEAN AGE-PARITY SPECIFIC FERTILITY RATES (BIRTHS PER 1000
WOMEN)
AGE PARA 0 PARA 1 PARA 2 +
16-19 640 174 115
20-24 348 273 168
25-29 272 267 133
30-34 146 150 86
35-39 50 49 47
40-49 5 4 8
% Females births CD 49% ■O CD
I V. 9
FERTILITY RATES : MARRIED WOMEN 1971-J98U
1. AVERAGE ANNUAL BIRTHS BY AGE/PARITY 1971-80
AGE PARA 0 PARA 1 PARA 2 +
16-19 35,370 7,920 590
2G-24 99,540 60,650 20,830
25-29 79,450 90,720 47,470
30-34 21,400 36,930 39,760
35-39 4,470 7,130 17,810
40-49 860 1,210 5,310
Source :: Birth Statistics, Series FM1 nos 1-7 (Tables 4.1, 4.:





















Sources : Population estimates by marital status : Marriage and
Divorce Statistics 1976, FM 2 no 3.
Parity of married women : GHS data for 1975-77 (unpublished
tables : GRO 51)
3. MEAN AGE-PARITY SPECIFIC FERTILITY RATES (BIRTHS PER 1000
WOMEN)
AGE PARA 0 PARA 1 PARA 2
16-19 544 136 (325)
20-24 215 240 111
25-29 202 233 65
30-34 112 153 42
35-39 32 39 20
40-49 3 3 3
% Female Births 48% 49% 48%
FERTILITY RATES : UNMARRIED FEMALES
Figures are all Illegitimate Live Births (both sexes)










Source : Birth Statistics (1980). OPCS Monitor FM1 No. 7 (HMSO
1982)
HYSTERECTOMYPROBABILITIES 1966&7
Datasources: 1.Annualnumberoftothysterectomies( otf rcanc r):IIIPE 2.Populationatrisk:1966census,7estimates 3.Prevalenceofhystere tomybyg:estima sfrAld son4Donn(1970) 1966
1976
AGE
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Source: From data of Alderson 4 Donnan (1978)
Figures in parenthesis are extrapolations
TABLE IV. 13
PREVALENCE OF STATES 2-5
(PER 10,000)
AGE 1 STATE
GROUP 2 3 £
0-4 0 0 0
5-9 0 0 0
10-14 0 0 0
15-19 40 3 0
20-24 120 18 0
25-29 147 49 1
30-34 130 76 3
35-39 108 90 5
40-44 88 88 8
45-49 67 79 9
50-54 61 68 10
55-59 60 58 9
60-64 59 51 8
65-69 58 45 8
70-74 57 40 7
75-79 56 36 7
80-84 55 33 7
85-89 54 30 6
90-94 53 28 6






















INCIDENCE OF CLINICAL CERVIX CANCER
ANNUAL REGISTRATIONS PER 100,000 WOMEN
















ALL AGES 18^0 16.9
Sources :
England & Wales : Registrar Generals Statistical Review of
England & Wales for 1965. Supplement on Cancer (Table 8) 1970
G. R.0,
Four English Regions : Doll et al (1966). Cancer Incidence in




Single 84 88 94
56 89 96
Married 90 95 101
61 98 106
Formerly 145 158 168
Married 138 220 238
Upper figures : Standard prevalence ratios (dysplasia - microinvasive) 1
Lower figures : Age-adjusted relative risk (dysplasia - microinvasive) 2
1 Parkin et al (1981) Public Health 96_, 3-14

















































TRANSITION PATES : DATA 11M
Columns
3 4 5 6 7
IS 20 0 99 0. 17
21 25 0 99 0. 50
26 30 0 99 0. 45
31 35 0 99 0. 37
36 40 0 99 0. 31
41 45 0 99 0. 25
46 50 0 99 0. 19
51100 0 99 0. 12
16 50 0 99 25. 00
51100 0 99 12. 50
16100 0 99 5. 0
16 50 0 99 1. 0
51100 0 99 0. 5
16 20 0' 99 0. 5 >
21 25 0 99 1. 0 >
26 30 0 99 1. 5 >
31 35 0 99 2. 0 >
36 40 0 99 3. 0 >
41 50 0 99 5. 0 >
51 60 0 99 7. 0 >
61 70 0 99 8. 0 >
71 ao 0 99 9. 0 >
31100 0 99 10. 0 >
16100 1 1 0. 0
16100 2 99 100. 0
16 30 1 1 10. 0 j
lo 30 2 3 4. 0 1
16 30 4 5 2. 0 1
31 40 1 1 12. 0 1
31 40 2 3 5. 0 1
31 40 4 5 3. 0 1
41 50 1 1 13. 0 1
41 50
M
cL 3 8. 0 j
41 50 4 4. 0 1
51 60 1 1 22. 0 1
51 60 OCm 3 12. 0 1
51 60 4 5 5. 0 3
61 70 1 1 27. 0 1
61 70 2 3 14. 0 J
61 70 4 5 6. 0 u
71 SO 1 1 41. 0 1
71 SO 2 3 IS. 0 1
71 SO 4 5 6. 0 I
31100 1 1 55. 0 1
31100 2 nW 20. 0 1
SHOO 4 5 6. 0










5 )' duration in state in column 1
6 )






















































TRANSITION RATES : DATA UN
2 16 20 0 99 0. 17
2 21 25 0 99 0. 50
2 26 30 0 99 0. 45
2 31 35 0 99 0. 37
2 36 40 0 99 0. 31 of
2 41 45 0 99 0. 25
tz. 46 50 0 99 0. 19
2 51100 0 99 0. 12
1 16 50 0 99 25. 00
1 51100 0 99 12. 50
3 16 85 0 1 2. 0 *c
3 16 85 <=. 99 10. 0 *r
c- 16 60 l 99 5. 0
6110O I 99 2. 5 *
4 16 20 0 99 0. 5 >
4 21 25 0 99 1. 0 >
4 26 30 0 99 1. 5 >
4 31 35 0 99 2. 0 >
4 36 40 0 99 3. 0 >
4 41 50 0 99 5. 0 >
4 51 60 0 99 7. 0 >
4 61 70 0 99 8. 0 >
4 71 SO 0 99 9. 0 >
4 81100 0 99 10. 0 >
5 16100 1 1 0. 0
5 16100 2 99 100. 0
S 16 30 1 1 10. 0 3
S 16 30 2 *"3W 4. 0 3
S 16 30 4 5 2. o 3
s 31 40 1 1 12. 0 3
s 31 40 2 3 5. 0 3
s 31 40 4 5 3. 0 3
8 41 50 1 1 18. 0 3
a 41 50 2 3 8. o :
8 41 50 4 5 4. 0 3
8 51 60 1 1 22. 0 3
8 51 60 2 3 12. 0 3
8 51 60 4 5 5. 0 3
8 61 70 1 1 27. 0 3
8 61 70 2 3 14. 0 3
8 61 70 4 5 6. 0 3
8 71 80 1 1 41. 0 3
8 71 SO 2 3 IB. 0 3
8 71 80 4 5 6. 0 3
8 SHOO 1 1 55. 0 3
8 81100 -ie. 3 20. 0 3
s 31100 4 5 6. 0 3
O








TRANSITION RATES : DATA 110
1 £=. 16 20 0 99 0. 17
1 <=. 21 25 0 99 0. 50
1 2 26 30 0 99 0. 45
1 2 31 35 0 99 0. 37
1 C. 36 40 0 99 0. 31
1 2 41 45 0 99 0. 25
1 nS. 46 50 0 99 0. 19
1 2 51100 0 99 0. 12
2 1 16 50 1 99 25. 00




w 16100 0 1 2. 0
2 3 16100 2 99 10. 0
3 2 16 50 1 99 5. 0
3 2 51100 1 99 2. 5
3 4 16 50 0 2 0. 05
3 4 16 50 3 5 1. 0
3 4 16 50 6 8 2. 0
3 4 16 50 9 11 4. 0
3 4 16 5012 14 8. 0
n
w 4 16 5015 17 16. 0
3 4 16 5018 99 32. 0
3 4 51100 0 nCm 1. 0
3 4 51100 3 5 2. 0
"3
W 4 51100 6 3 4. 0
3 4 51100 9 11 8. 0
3 4 5110012 14 16. 0
3 4 5110015 99 32. 0
4 5 16100 0 1 0. 0
4 5 16100 2 99 100. 0
5 8 16 30 1 1 10. 0 3
5 8 16 30 «•»Cm 3 4. 0 3
5 8 16 30 4 5 2. 0 3
5 8 31 40 1 1 12. 0 3
5 8 31 40 2 3 5. 0 3
5 8 31 40 4 5 3. 0 3
5 8 41 50 1 1 IS. 0 3
5 8 41 50 Cm 3 8. 0 3
5 8 41 50 4 5 4. 0 3
5 8 51 60 1 1 22. 0 3
5 8 51 60 el 3 12. 0 3
5 8 51 60 4 5 5. 0 3
5 8 61 70 1 1 27. 0 3
C
•»/ 8 61 70 nCm -5w 14. 0 3
5 8 61 70 4 5 6. 0 3
5 oW 71 SO 1 1 41. 0 3
5 8 71 SO -i v3 IS. 0 3
5 8 71 SO 4 5 o. 0 3
5 8 81100 1 1 55. 0 3
5 8 SHOO 2 3 20. 0 3
5 8 81100 4 5 6. 0 3









OBSERVED (E & W) SIMULATED
Pop. (numbers) % start
1961 23,801 100 100
1971 25,067 105.3 105.8
1981 25,474 107.0 105.4
1991 25,764 108.2 106.3
Sources;
GRO : Census 1961 Age, marital conditions and general tables. 1964 HMSO
OPCS : Census 1971 " " " " " 1974 HMSO
OPCS : Population trends vol. 1983 HMSO





BIRTH RATE (FEMALES PER 1000F) DEATH RATE (FEMALES PER 1000F)
OBSERVED SIMULATED OBSERVED SIMULATED
1961 16.5 16.7 11.4 9.6
1962 16.9 16.9 11.3 10.1
1963 17.2 15.6 11.6 10.3
1964 17.5 15.8 10.7 10.7
1965 17.2 16.1 10.9 9.9
1966 16.8 15.5 11.2 10.5
1967 16.3 16.4 10.7 10.8
1968 16.0 15.9 11.4 10.9
1969 15.5 16.4 11.3 11.1
1970 15.2 16.0 11.3 10.9
1971 15.1 11.7 11.1 11.8
1972 13.9 11.0 11.6 12.2
1973 13.0 11.2 11.5 11.4
1974 12.3 11.4 11.5 11.6
1975 11.6 11.1 11.4 11.7
1976 11.3 11.2 11.8 12.2
1977 11.0 11.6 11.4 12.3
1978 11.5 11.2 11.5 12.1
1979 12.3 12.0 11.7 12.0
1980 12.4 11.5 12.8
1981 13.0 11.3 12.9
1982 13.0 12.9
Sources: OPCS Monitors (Births; Mortality)
Population Trends (Population)
TABLE V.3
ESTIMATED PROPORTION OF WOMEN WITH HYSTERECTOMY, BY AGE-GROUP
(ENGLAND 4 WALES)
YEAR
AGE 1963 1968 1973 1978
25-29 0.000 0.001 0.002 0.003
30-34 0.002 0.005 0.009 0.013
35-39 0.013 0.017 0.026 0.033
40-44 0.030 0.045 0.054 0.064
45-49 0.049 0.068 0.089 0.096
50-54 0.056 0.078 0.101 0.122
55-59 0.056 0.069 0.094 0.117
60-64 0.056 0.064 ' 0.077 0.101
65-69 0.058 0.064 0.071 0.084
70-74 0.058 0.066 0.072 0.080
75-79 : 0.055 0.064 0.071 0.078
Source: Parkin et al (1984)
TABLE V.4
COMPARISON OF 3 MATURAL HISTORIES
SCREENING POLICY: EXAMINATIONS AT AGES 35, AC, 45, 5C, 55, 60, 65
ATTENDANCE RATE: 453 AND 303, RANDOM
SENSITIVITY 703, SPECIFICITY 99.53
LOSS TO F.U.: 83 PA DYSPLASIA, 43 PA C.I.S. FOR 3 YEARS
OUTCOME 1961-1990






NEW CASES 57 45 54 40 64 46
DEATHS 53 41 49 41 55 37
LIFE-YEARS 56 42 48 41 56 37
TESTS
TOTAL (Thousands) 193 109 192 109 192 109
3 POSITIVE 1.7 1.8 1.6 1.8 1.3 1.9
- OF WHICH FALSE POS. 29.4 25.5 30.5 25.6 27.8 25.4
3 SAVING PER ICOO TESTS
CASES 0.30 0.41 0.28 0.37 0.33 0.42
DEATHS 0.27 0.38 0.26 0.38 0.29 0.34
LIFE-YEARS 0.29 0.38 0.25 0.38 0.29 0.34
3 SAVING PER 1000 POS. TESTS
CASES 17.6 22.9 17.5 20.1 18.a 22.0
DEATHS 16.4 21.1 15.8 20.7 16.2 17.4
LIFE-YEARS 17.3 21.4 15.5 20.6 16.4 17.6
TABLEV.5
EFFECTOFVARYINGATTENDA ER T S


































































































































































































































































COMPARISON OF SIMPLE SCREENING POLICIES
ATTENDANCE RATE: 80S
SENSITIVITY 70S, SPECIFICITY 99.5%
LOSS TO FOLLOW-UP: 85 PA DYSPLASIA, AS PA C.I.S
NATURAL HISTORY 11 M
OUTCOME 1961-1990
SCREENING POLICY
EXACT AGES 35, 40, 45, 50, 55, 60, 65 ALL WOMEN PREGNANCY
35 - 65 ONLY
FIVE-YEARLY
ALL WOMEN NOT PARA 0 DYSPLASTIC
NOT SINGLE TESTS IGNORED
SAVINGS
CASES 438 354 405 450 128
DEATHS 214 172 180 233 68
LIFE-YEARS 4442 3530 3360 4924 1969
TESTS
TOTAL (Thousands) 193 153 194 194 89
POSITIVE 3230 2790 1871 3138 1444
- OF WHICH FALSE POS. 292 29% 535! 30% 31%
PER 100C TESTS
CASES 2.2 2.3 2.1 2.3 1.4
DEATHS 1.1 1.1 0.9 1.2 0.8
LIFE-YEARS 23.1 23.1 17.3 25.4 22.0
SAVINGS PER POSTIVE TEST
CASES 0.14 0.13 0.22 0.14 0.09
DEATHS 0.07 0.06 0.10 0.07 0.05
LIFE-YEARS 1.39 1.27 1.80 1.57 1.36
TABLE V.9
SCREENING POLICIES FOR ENGLAND AND WALES
1. Ministry of Health (1966)
Women over 35, five yearly intervals (? to 65).
2.
As above, but starting under age 35 after 3rd pregnancy.
3. British Society for Clinical Cytology (1977)
Start : 25 for women attending for contraception, pregnancy or
venereal disease.
30 if sexually active and not already tested.
Intervals : Five yearly.
Stop : 70 (no age limit for first test).
4.
As above, but 3 yearly intervals after age 35.
5. Committee on Gynaecological Cytology (1982)
(i) Early in each pregnancy.
(ii) Age 22 (or next visit): attenders at family planning - if not
previously screened.
(iii) Age 30: attenders at family planning - if no smear in previous
5 years.
(iv) Anyone else age 25-35, sexually active, who requests a test.
(v) At exact ages 35, 40, 45, 50, 55, 60, 65.
(vi) Stop at 65 (if never had positive or doubtful smear).
(also, «diagnostic» tests considered «useful»).
TABLE V.1C
COMPARISON OF POLICIES PROPOSED FOR ENGLAND 4 WALE5
ATTENDANCE RATES: 80S (UNLESS STATED)
SENSITIVITY 70S, SPECIFICITY 99.5$
LOSS TO F.U.: 8% PA DYSPLASIA, 4$ PA C.I.S.
NATURAL HISTORY: II M
OUTCOME 1961-1990
POLICY
1 2 ^ 1 ^ 1 ^ 2
MOH Modified 8SCC BSCC C.G.C.
MOH "Plus"
SAVINGS
CASES 433 463 488 577 478
DEATHS 2C0 221 224 283 227
LIFE-YEARS 4C81 4819 4852 6111 4858
TESTS
TOTAL (THOUSANDS) 193 203 251 351 308
POSITIVE 3205 3366 4232 5210 4747
- OF WHICH FALSE POS. 29% 29$ 30$ 34$ 31%
SAVINGS PER 1000 TESTS
CASES 2.3 2.3 1.9 1.6 1.6
DEATHS 1.0 1.1 0.9 0.8 0.7
LIFE-YEARS 21.2 23.7 19.3 17.4 15.3
SAVINGS PER POSTIVE TEST
CASES 0.14 0.14 G. 12 0.11 0.1C
DEATHS 0.06 0.07 0.C5 0.05 0.C5
LIFE-YEARS 1.27 1.43 1.15 1.17 1.02
^ Between ages 25-29, annual probability of first test = 0.2 (normal), 0.4 (abnormal
2
At 22 or 23 ) 50$ annual probability of receiving first test

























































Incidence of cervical carcinoma Cage-standardised)

























10 20 30 40 50 60 70 80 90 100 110 120
Source of data : USA : SEER (1981)
England and Wales : 0PCS (1981)
Other : Waterhouse et al (1982)
I
Fig. 2.2
AGE-SPECIFIC INCIDENCE OF CARCINOMA OF CERVIX




MORTALITY FP.OM CARCINOMA OF CERVIX, ENGLAND & WALES 1976-1980
Source : Cancer mortality in England & Wales, 1976-1980, OPCS monitor DH1 82/2
Figure 2.4 Cancer of the cervix uteri (ICD 180) Females, England and Wale
Table of deaths per million population with birth cohorts indicated on the diagonals
Age-group
Year of death 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85 and
over
1951-55 0 0 1 10 30 58 93 136 203 254 285 304 315 361 327 315
N \ S N N S N v. N s V. ■S. N. V. s •V.
1956-60 0 - V 0 ^ 0 ^ 1 ^ 9 ^ 37 V 74 119 154 181 197 246 284 313 336 366 ^ 361
N N S \ N \ >» \ s s N \ ^ "V
332 357 1£1961-65 0 - " - - - -1 - 5 ^ 18 % 67 134 180 187 ^ 178 222 232 274 301
1966-70 0
— s N v S
- --^0^2-7"
-v









N N N N. N s \ s N s N >• s sv x.
1971-75 - - ^ v 3 10 " 22 ^ 38 ^ 67 x 130 190 ^ 199 199 v 193 206 247 257 262 16
Vv N V N \ s N N X N N N N. v




















Birth cohort (diagonal) 1956 1951 1946 1941 1936 1931 1926 1921 1916 1911 1906 1901 1896 1f
Graphs drawn from data in the table above to investigate and demonstrate cohort changes in mortality fro
cancer of the cervix
1871 1881 1891 1901 1911 1921 1931 19*1 1951 1961
Year of birth
Death rates presented so as to show changes
within age-groups for varying years of birth
Source : Cancer Statistics : Studies on Medical
and Population Subjects No. 43
100-
Age
Death rates presented so as to show difference
between birth cohorts at varying ages (alternc





















incidence 20- 25- 50- 35-
AGE-GROUP













225 370 393 374 356 324 506 322 296 290 224.
. \ \ \ \ \ \ \ \ \ \
163 313 408 405 370 oOO 304 293 261 243 238.
. \\\\\\\\\\
145 201 296 390 375 335 290 276 269 251 240.
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1891 1901 1911 1921 1931 1941 1951
Year of birth
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Age
70 80
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Total pregnane tes
Source : Sweetnam et al (1981)
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Fig. 2.12
RELATIONSHIP BETWEEN INCIDENT IN SITU CANCER & OUTCOME
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RELATIONSHIP BETWEEN INCIDENCE OF PRECLINICAL DISEASE AND OUTCOME
Data of Kashgarian & Dunn (1970)
Fig 2.15
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National recall scheme - form H.M.R. 101/5 (1977).
Fig 2.16
/iob
Annual incidences of cervical cancer in the Nordic countries in 1943-1978.
Fig 2.17
Ages 40-44
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SIMPLE MODEL OF DISEASE NATURAL HISTORY
NATURALHISTORY:EXAMPLEOFS TESUSEDINM LATION
RELATIVESURVIVAL,CARCINOMAOFX:1971-1973ENGL ND&W ES Years



























































, I. . ■ , , , J
654321 12345678
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% 1991
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%
Female population (England and Wales) by age
L : model predictions








LHS : model predictions
RHS : census data (1961,71,81
projections (1991)
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ig 5,6 Prevalence of cis at different periods of simulation
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Age
Fig 5.7
OBSERVED AND PREDICTED CLINICAL CANCER INCIDENCE
AGE

































































•--- Exact ages, 35,40,45,50,55,60,65
APPENDIX 1
GENMAK
GENMAK is a generalised markov simulation model which is deterministic in
type. It examines events in a cohort of 100,000 individuals as they age from 0
to 85 years. Several versions of this are available, offering various degrees
of refinement in specification of input and output.
GM.FOR is the simplest programme. In this, transfer rates between states
are specified simply by age.
GMT.FOR allows duration or Time in starting state to be specified in
addition.
GMTO.FOR prints a fuller output of data, producing a variety of files




VAX/VMS PARKIN GM i 0 12-OCT—1983 07: 39 LPAO: 12—OCT—1V83 07 39 1-
VAX/VMS PARKIN GMTO 12-0CT-19S3 07: 39 LPAO: 12-OCT-1983 07 39 J",
VAX/VMS PARKIN GMTO 12-OCT-1993 07: 39 LPAO: 12-OCT-1983 07 39 D
pppp AAA RRRR K K iii N N
p P A A R R K K I M M
p P A A R R K K i NN N
pppp A A RRRR KKK I N N N
p AAAAA R R K K i N NN
a
r A A R R K K I N N




































































FF 00 00 RR RR
FF 00 00 RR RR
FF 00 00 RR RR
FF 00 00 RR RR
FFFFFFFF 00 00 RRRRRRRR
FFFFFFFF 00 00 RRRRRRRR
FF 00 00 RR RR
FF 00 00 RR RR
FF 00 00 RR RR
FF 00 00 RR RR
FF 000000 RR RR

















PPPP AAA RRRR K K III N N
P P A A R R K K I N N
P P A A R R K K I NN N
PPPP A A RRRR KKK I N N N
P AAAAA R R K K I N NN
P A A R R K K I N N







GMTO 12—OCT—19B3 07:39 LPAO
GMTO 12—OCT—1983 07: 39 LPAO





c -ft. 4L *l OI 21 —1i Oi *1 jK-I £1
C ^ "iT
c A wENER faL. AGE/ DURATION-BASED MARKOV SIMULATION MODEL
C -ji* •£••£* •£•
WRITTEN EY DMP
"ft"-ft" vr-sr-a
C Input vis channel i
C **Or** Output to channel 6(INTERACTIVE)
'w -S- channel 32 = sojourn distribution of state 2
-ft-"ft" "ft" "J5* c h ann e 1 O'D »» »» '• 'JUU — w~
c h ann e1 92 = age/duration array of state 2(for i. p. to











DIMENSION IASDMAT(S5, 21, 100)
CHARACTER#32 NAME(21)
DATA ISLASH/'/'/,NAME/21#'DEAD OF OTHER CAUSE'/
C
c#####






IF (NUMST. LT. 20. AND. NUMST. GT. 1 ) GOTO 50
WRITE(6,601) NUMST
601 FORMAT(/' *#* INCORRECT NUMEER OF STATES —',14,
1 ' #•■#* ' / )
STOP























READ(1, 504) XFR, ITO
504 FORMAT(213)
IF(IFR. GE. 1. AND. IFR. LT. NUMST. AND.
1 I TO. GE. 1. AND. ITO. LE. NUMST. AND.
2 VALIDTR(IFR, I TO). EG. 0) GOTO SO
WRITE(6, 602) ILINE
602 FORMAT ( / ' #■** INCORRECT TRANSFER DEFINED IN LINE —',14,






90 READ(1, 503) LINE
IF <LINE( 1 ). EG. ISLASH) GOTO 200
ILINE=ILINE+1
BACKSPACE 1
READ(1, 505) IFR; ITO; IFRAGE; ITOAGE; IFRDUR; ITODUR;RAT
IF(IFR. GE. 1. AND. IFR. LT. NUMST. AND.
1 ITO. GE. 1. AND. ITO. LE. NUMST. AND.
2 VALIDTR < IFR; ITO). EG. 1 ) GOTO 140
WRITEC6,603) ILINE
603 FORMAT ( / ' *•** INCORRECT RATE IN LINE'; 14,




RATE < NUMTR) = RAT
IFROM (NUMTR) = IFR







THE SIMULATION PART STARTS HERE
C *■**•*-»■









DO 220 J=l, 100
P0P2(I,U)=POPN<I, J)
CONTINUE
DO 230 1 = 1, LIVST
DO 230 J=l,IYR
P0P2(TOTST,J)=F0P2(TOTST,J)+POFN(I, J)*XMORT(IYR)
P0P2 (I, U) =P0P2 ( I, J) -POPN (I, J) -k-XMORT (I YR )














IF(IYR. LT. IMNAGE< I ) ) GOTO 300
IF-: IYR. GT. IMXAGE< I ) ) GOTO 300
DO 250 J=IMINDUR<I), IMAXDUR(I)
TRANS<J) = <POPN<IFROM<I), J)*RATE<I)> / 100.0










DURST(IFROM(I),J) = DURST(IFROM(I),U) + TRANS(J)
PDP2(IFROM(I), J)=P0P2 <IFROM(I),J)-TRANS(J)




POPPR < I) = 0. 0
DO 320 J=l, IYR
POPN(I, J) = P0P2(I, J)
POPPR <I) = POPPR(I) + POPN <I» J)
CONTINUE
DO 330 I = 1,TOTST
IF (POPPR < I). NE. 0. ) GOTO
TFACT ( I) = 0. 0
GO TO 324
TFACT(I) = 100/P0PPR(I)
CTMAT <I, 1) = POPN <I» 1)
DO 330 J = 2, 100
CTMAT<I, J) = CTMAT(I, J—1) + (POPN(I.J) * TFACT<I))
IASDMAT(IYR,I,J) = IFIX(CTMAT(I,J)+0. 5)
CONTINUE
WRITE(6,606) IYR, <IFIX<POPPR< I)+0. 5), 1 = 1,TOTST)
DO 350 1 = 1, TOTST
DO 340 J=IYR,1,-1
K=J+1
POPN(I, K) = POPN< I, J)
CONTINUE





WRITE OUTPUT FILES HERE
WRITE<82, *) (DURST<2, J), U=l, 75)
WR ITE < S3, *> < DURST ( 3, J), J=l, 75)
DO 460 IYR = 15,85
WRITE < 92, 510)IYR, <IASDMAT<IYR,2, J),J=2, 76)
WRITE < 93, 510)IYR, <IASDMAT<IYR, 3,J),J=2,76)
460 CONTINUE
500 FORMAT</////10X, 'GMT - AGE/DUR MARKOV SIMULATION MODEL'
1 /10X, '====== '///)
505 FORMAT<613, F6. 2)





Derivation of starting prevalence data
The full date file (FILE4.DAT) for distributing the starting population
into different disease states is shown in the input files in Appendix 5. It is
derived from the simple prevalence rates shown in Tables IV. 13 as described
below.
Prevalence of the live abnormal states (2-5) in the starting population
is contained in FICHE4.DAT as prevalence in 5-year age-groups per 10,000
population. Using this as input the program CRESTPRV.FOR produces the full
data set of FILE4.DAT. The relative prevalence of the different states by
marital state and parity as contained in the data-block of CRESTPRV is derived
from Table IV. 15.
The other data used is the age-marital state-parity composition of the






VAX/VMS P ARKIN FI CHfc.4 12—OCT— i 983 07 44 LPAO: 12—OCT—1933 07: *t"
VAX/VMS PARKIN FICHE4 ii_nrt-A CL LJ «W 1 1983 r,~7\j / 44 LPAO: 12—OCT—1933 07: 44
VAX/VMS PARKIN FICHE4 12-0C7— 19S3 07 44 LPAO: 12—OCT-1933 07: 44
PPPP AAA RRRR K K 111 N N
P P A A R R K K I N N
P P A A R R K K I NN N
PPPP m A RRRR KKK T N N M
p A A AAA R R K K 1' N NN
P A A R R K K I N N
P A A R R K K I I I N hi
ffffffffff iiiiii cccccccc hh hh eeeeeeeeee
ffffffffff iiiiii cccccccc hh hh eeeeeeeeee
ff ii cc hh hh ee
ff ii cc hh hh ee
ff ii cc hh hh ee
ff ii cc hh hh ee
ffffffff ii cc hhhhhhhhhh eeeeeeee
ffffffff ii cc hhhhhhhhhh eeeeeeee
ff ii cc hh hh ee
ff ii cc hh hh ee
ff ii cc hh hh ee
ff ii cc hh hh ee
ff iiiiii cccccccc hh hh eeeeeeeeee























































































pppp aaa rrrr k k iii n n
p p a a r r k k i n n
p p a a r r k k i nn n
pppp a a rrrr kkk i n n n
p aaaaa r r k k i n nn
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****** THIS PROGRAM TAKES STARTING PREVALENCE RATES OF STA
****** THESE ARE IN FORMAT OF FI CHE4. DAT READ IN FROM FOR
****** DATA IS: AGE/M.S./PARITY OF STARTING POPULATION IN
****** PREVALENCE RATIOS FOR STATES(SEE DATA IN P
****** NUMBER OF ABNORMAL STATES IN FICHE4.DAT (f
****** OUTPUT IS FULL PREVALENCE FILE FILE4.DAT IN F0R043
DIMENS ION IPOF < 3, 3, 100)
DI MENS I ON IR R ( 3 .• 3, 8 5
DI MENS I ON IP R EV < 20, 8 )
DIMENSION ITOTPOP(100)
DIMENS ION FACT(100, 3)
DIMENSION IWR(100,3)
DIMENSION WT <100,8)















DATA FOR 1ST IS NO. OF ABNORMAL STATES IN FICHE4.DAT
DATA 1ST/4/
DATA BELOW ARE RELATIVE PREVALENCE OF STATES 2. . . 8 (PARA/M. S. )
DATA IRR/084, 088, 094, 090, 095, 101, 145, 158, 167,
1 084, 088, 094, 090, 095, 101, 145, 158, 167,
2 084, 0e8, 094, 090, 095, 101, 145, 158, 167,
3 084, 088, 094, 090, 095, 101, 145, 158, 167,
4 084, 088, 094, 090, 095, 101, 145, 153, 167,
5 084, 088, 094, 090, 095, 101, 145, 158, 167,
6 084, 088, 094, 090, 095, 101, 145, 158, 167,
7 084, 088, 094, 090, 095, 101, 145, 158, 167/
READ(42,100)IPOP
DO 5 N=1, 20
5 READ(41, 101)(IPREV(N, S),S=l, 1ST)
DO 60 S=1,1ST
DO 55 A=l, 100
ITOTPCP(A)=0
WT (A, S)=0. 0
DO 15 M=i, 3
DO 15 P=l, 3
WT(A, S)=WT<A, S) + <IPOP(P, M, A)#IRR(P,M,S))/100
ITOTPOP(A)=ITOTPOP(A)+IPOP(P,M,A)
15 CONTINUE
FACT(A, S)=ITOTPOP < A)/WT(A,S)
L=1
25 M=L+4





DO 40 M-l, 3
DO 40 P = l, 3





DO 90 M=l, 3
A 1 1
DO 90 P = l, 3
I NORMRiP, M, A) = 10000
DO 34 3=1/1ST
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2 + 0 1 2 + 0 1 2 +
0 0 0 0 0 0
o 0 0 o 0 0 0
0 G 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 \J 0
0 0 0 o 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 o
0 0 0 0 0 0 Q
0 0 o o 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 o 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 32 18 0 0 0 0
0 41 45 3 0 0 0
0 78 40 11 0 0 0
0 130 66 8 0 0 0
0 193 130 31 2 1 0
0 277 192 68 0 0 1
0 334 255 131 1 0 0
0 351 284 198 2 1 0
0 319 327 246 1 2 4
0 311 287 310 0 0 nu
0 266 303 416 2 4 1
1 229 331 435 3 5 8
1 193 283 496 5 1 1
1 198 267 551 7 2 4
1 186 296 652 2 5 5
3 173 314 583 3 5 10
0 170 251 613 5 6 6
1 152 243 618 2 2 14
1 154 291 653 3 7 11
0 137 290 710 3 11 9
4 147 289 728 7 12 14
1 153 267 731 4 16 17
n
u 147 290 800 8 10 14
C- 173 317 854 8 12 23
0 182 334 913 7 9 36
1 157 302 834 16 35 36
0 131 243 625 3 9 25
0 148 228 563 6 10 26
0 131 258 627 12 26 26
1 154 265 632 20 23 26
1 181 299 699 17 28 45
—i
c. 190 288 675 15 26 50
1 219 313 622 19 30 56
1 182 233 612 18 26 50
1 244 309 632 24 38 50
1 213 265 569 26 31 57
2 218 280 585 21 45 81
0 214 285 559 26 42 69
1 201 303 518 36 39 87
2 226 242 487 49 43 81
0 238 239 470 48 45 34
0 212 259 461 41 53 101
5 189 232 427 51 60 B8
4 182 230 434 55 57 117

































































































































































































































































































































































































































































































































































































DERIVATION OF TRANSITION RATES
This appendix illustrates the use of GMTO, Vvhich is one of the versions
of the generalised markov simulation model GENMAK, described in Appendix I.
Here it is used to derive transition rates which are consistent with
observations made on human populations.
It should be recalled that GMTO simulates events in a single cohort of
individuals ageing from 0 to 85 years. However most of the data on incidence
and prevalence of preclinical and clinical cancer is cross-sectional in nature
- hence its use in a cohort model such as this is, strictly speaking,
inappropriate ; this is discussed later.
The attached computer printouts illustrate some input data for GMTO/ and
results obtained.
INT1.DAT shows sets of transition rates between the following states :
1 Normal
2 Dysplasia
3 Carcinoma in situ
4 Micro/occult invasive
5 Clinical cancer
As a first stage/ mortality (both cancer and other causes) is ignored/
since we are interested in deriving rates rather than absolute numbers.
Hysterectomy is included/ since this removes 'at risk' subjects and hence
markedly alters the results. Finally as an initial simplification/ the
transition from state 4 to state 5 is set at 100%/ implying that micro/occult
invasive disease lasts exactly 1 year.
The way in which transition rates from 1 to 2 have been derived from
dysplasia incidence data has already been described in the main text.
The principal output file from the simulation is shown as OUT.DAT ; 1.
The figures represent the numbers in each state at each year of age. Since no
deaths are occurring, there are 100,000 at each age, and the figures can be
read directly as prevalence per 100,000. Since the duration of state 4 is only
one year, and all units in this state transfer to state 5 (transition rate 4
to 5 = 100%) , the figures in this column should be the annual incidence of
clinical cancer. The prevalence of carcinoma in situ can be estimated from the
results of screening programmes (see Table IV.13) and column 3 (carcinoma in
situ) should thus approximate these values. Given this prevalence distribution
and the numbers which exit to state 4 every year (ie incidence of clinical
cancer) , an appropriate set of transition rates from state 3 to state 4 can be
derived.
The figures in column 5 now represent cumulative incidence of clinical
cancer. Note that these do not correspond to prevalence of clinical cancer,
estimated in appendix 2, and reproduced in Table IV.13, since death from
clinical cancer is proportional to age, and operates on this group in addition
to normal mortality.
The transition rates which remain to be estimated are as follows :
State 2 to State 3 (transition from dysplasia to CIS)
State 2 to State 1 (regression of dysplasia to normal)
State 3 to State 2 (regression of CIS to dysplasia)
The rates used must be compatible with observed prevalence of the
preclinical states, and also be consonant with such knowledge of natural
history as is available (see II.2).
INT1.DAT represents a set of rates which maintain the prevalence of the
disease states as shown in OUT.DAT. The full set of data is shown as 11M in
Table IV. 16. The choice of transition rates was governed by the wish to keep
the figures for state 3 to state 2 transfers to a minimum, in accordance with
the view that this condition rarely regresses spontaneously. With the low
rates shown (1% per year up to age 50 and 0.5% per year thereafter) , a
transition rate from dysplasia to carcinoma in situ of 5% per year is
sufficient to maintain the prevalence of the latter condition at the level
A 1 7
-3-
shown. This is probably a rather conservative figure judging by the
observations on progression observed in various series (II.2.3). An
alternative formulation would be to increase both of these rates, implying
that carcinoma in situ is a more 'dynamic' condition, of higher incidence and
regression, and hence shorter average duration. A data set with these
specifications is reproduced in Table IV.17 (Data UN).
A third set of data which reproduces the same pattern of prevalence in
the output file is shown in Table IV.18 (Data 110). In this formulation
transition rates from carcinoma in situ (state 3) to invasive disease
(state 4) are made dependent upon the duration of carcinoma in situ. In
practice it proved impossible to find a data set depending only upon duration
which could reproduce a similar prevalence pattern to that of OUT.DAT, thus
duration specific rates for two age-groups (up to year 50, over year 50), have
been used.
The figures for regression of dysplasia (25% under age 50, 12.5% over age
50) are determined by the other rates already estimated and the requirement to
maintain the prevalence of dysplasia shown. These are reasonable estimates in
the light of such data as is available frcm studies in human populations, and
consistent with dysplastic changes in younger women being more transient in
nature.
GMTO produces four other output files in addition to the age-specific
prevalence of the different states shown as OUT.DAT.
Files FOP.092 and FOR093 represent for dysplasia and c.i.s. respectively,
cumulative distributions of duration at each individual year of age. These
files are used in the initial stages of the main simulation (as FILE 92.DAT &
FILE 93.DAT) to assign appropriate durations to the members of the starting
population who are allocated to these two states (see Appendix 5).
Files FOR082 and FOR083 are the sojourn distributions of states 2
(dysplasia) and 3 (cis) - for those lesions which progress or regress in the •
course of simulation. These distributions are shown graphically for the three
natural histories 11M, UN and 110 as figures 4.4 & 4.5.
To complete the set of transfer rates for the model, an appropriate
figure for transition from micro/occult invasive disease to clinical cancer is
required. The duration of this state is not known, but its prevalence, when
studied, has been generally much lower than carcinoma in situ. The solution
adopted in the natural histories of Tables TV.16-18 is to make the duration
fixed at 2 years, so that transfer rates are zero in year 1 and 100% in
year 2. The result of this is a doubling of the prevalence figures for state 4
shown in OUT.DAT. The transfer rates for 5 to 8 transitions shown in the
natural histories are derived from England and Wales survival data as already
described (see Figure 4.3).
The final stage in creating the transition rate data file for the main
model is to incorporate data on relative risk according to marital state and
parity. The relevant data is shown in Table IV.15. Since the relative risk
figures apply to incidence of preclinical disease (and not to transfer between
different stages of preclinical disease), adjustment of crude rates is made
only for transitions from normality (ie in the natural history modelled,
transfer rates 1-2).
However, it is not possible to obtain age-parity-marital state specific
rates directly, by applying the relative risk to the crude 1-2 transition
rates in the data of tables IV.16-18 (FICHE 11.DAT). These rates were based on
population observation, and are hence already weighted by the marital state
and parity distribution in each of the age groups. An unweighted rate must be
calculated, to which the relative risk figures can be applied.
The program CRETRAT uses the relative risk figures (as a data block
within the program), the crude transfer rate data in FICHE 11.DAT and the
population structure by age, marital status and parity (F0R042) to produce the
full set of transition data used by the model (FILE 11.DAT) . This latter
incorporates a set of rates for each decade simulated to allow for changing
transition rates or population structure.
The use of a single set of transition rates over the 30 year period of
the simulation implies that transition rates are the same for all birth
cohorts in the population. In fact, as has been described in section II, there
are quite marked changes in disease risk according to year of birth. This can
be allowed for in the model by reading in new data files for different periods
of simulation; in the program shown a new data set is read for each decade.
The main problem concerns the decision about which transitions should be
changed to correspond to an apparent increase in incidence of invasive cancer
- is this the end result of a rise in probability of the first step in the
natural history (incidence of dysplasia), or are other transitions changed as
well?
If transition rates are made dependent upon individual characteristics
(e.g. marital state and/or parity) a secular change in the distribution of
these variables in the population will give rise to changes in disease rates.
Care must be taken therefore that any ad-hoc increase in transition rates
designed to simulate cohort effects represent residual changes after those
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0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
220 260 300 380
860 900 900 800
280 220 160 156
152 156 160 156
116 108 100 98
84 82 80 80







1 2 15 19 01 99 0. 17
1 2 20 24 01 99 0. 50
1 2 25 29 01 99 0. 45
1 2 30 34 01 99 0. 37
1 2 35 39 01 99 0. 31
1 2 40 44 01 99 0. 25
1 2 45 49 01 99 0. 19
1 2 50 85 01 99 0. 12
2 1 15 49 01 99 25. 0
2 1 50 85 01 99 12. 5
2 3 15 85 01 99 5. 0
3 2 15 49 01 99 1. 0
3 2 50 85 01 99 0. 5
3 4 15 19 01 99 0. 5
3 4 20 24 01 99 1. 0
3 4 25 29 01 99 1. 5
3 4 30 34 01 99 2. 0
3 4 35 39 01 99 3. 0
3 4 40 44 01 99 5. 0
3 4 45 49 01 99 5. 0
3 4 50 59 01 99 7. 0
3 4 60 69 01 99 8. 0
3 4 70 79 01 99 9. 0
ry
•s 4 80 85 01 99 10. 0
4 5 15 85 01 99100. 0
A 21
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 20 40 SO 120 160
460 540 620 680 740 800
700 600 520 460 400 340
152 148 144 140 144 148
152 148 144 140 132 124
96 94 92 90 88 86
80 80 80 80 80 80
80 80 SO 80 80 80
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G M T - AGE/DUR: MARKOV SIMULATION MODEL
1100000 0 0 0 0 0 0 0
2100000 0 0 0 0 0 0 0
3100000 0 0 0 0 0 0 0
4100000 0 0 0 0 0 0 0
5100000 0 0 0 0 0 0 0
6100000 0 0 0 0 0 0 0
7100000 0 0 0 0 0 0 0
8100000 0 0 0 0 0 0 0
9100000 0 0 0 0 0 0 0
10100000 0 0 0 0 0 0 0
11100000 0 0 0 0 0 0 0
12100000 0 0 0 0 0 0 0
13100000 0 0 0 0 0 0 0
14100000 0 0 0 0 0 0 0
15 99830 170 0 0 0 0 0 0
16 99703 289 9 0 0 0 0 0
17 99605 372 23 0 0 0 0 0
18 99529 430 41 0 0 0 0 0
19 99467 470 62 0 0 0 0 0
20 99088 827 84 1 0 0 0 0
21 98799 1075 124 1 1 0 0 0
22 98574 1248 175 1 2 0 0 0
23 98393 1368 234 2 3 0 0 0
24 98243 1452 298 nGL 5 0 0 0
25 98164 1462 363 4 7 0 0 0
26 98068 1468 427 5 12 20 0 0
27 97954 1473 489 6 17 60 0 0
28 97803 1475 550 7 23 140 0 0
29 97615 1477 610 8 31 260 0 0
30 97467 1399 664 12 39 419 0 0
31 97241 1343 713 13 51 638 0 0
32 96964 1304 757 14 64 897 0 0
33 96641 1275 797 15 78 1194 0 0
34 96235 1253 834 16 93 1570 0 0
35 95807 1178 859 25 108 2022 0 0
36 95287 1124 879 26 133 2551 0 0
37 94682 1084 895 26 158 3156 0 0
38 94015 1054 907 27 183 3814 0 0
39 93292 1030 917 27 208 4526 0 0
40 92570 955 906 46 233 5290 0 0
41 91781 901 892 45 277 6104 0 0
42 90951 861 875 44 319 6949 0 0
43 90120 831 858 43 361 7787 0 0
44 89382 809 841 43 401 8524 0 0
45 88789 739 825 42 441 9165 0 0
46 88272 690 808 41 480 9710 0 0
47 87817 655 789 40 519 10179 0 0
48 87410 630 771 39 556 10592 0 0
49 87052 612 753 38 593 10950 0 0
50 86728 611 725 53 630 11253 0 0




































609 676 49 730 11696 0 0
609 654 47 777 11837 0 0
608 635 46 823 11975 0 0
607 617 44 868 12109 0 0
606 600 43 911 12239 0 0
605 584 42 953 12365 0 0
603 570 41 993 12488 0 0
602 556 40 1033 12614 0 0
601 538 44 1071 12743 0 0
599 522 43 1114 12876 0 0
598 507 42 1155 13012 0 0
597 493 40 1195 13151 0 0
595 480 39 1234 13286 0 0
594 468 38 1271 13418 0 0
592 457 37 1307 13546 0 0
591 447 37 1343 13671 0 0
590 438 36 1378 13792 0 0
588 430 35 1412 13905 0 0
587 418 39 1445 14012 0 0
586 407 38 1482 14112 0 0
585 397 37 1518 14205 0 0
584 388 36 1553 14291 0 0
583 380 35 1587 14375 0 0
582 373 34 1620 14457 0 0
581 366 34 1653 14537 0 0
580 360 33 1685 14616 0 0
579 355 32 1717 14693 0 0
578 350 32 1747 14768 0 0
577 341 35 1778 14841 0 0
576 334 34 1811 14913 0 0
575 328 33 1844 14982 0 0
575 322 33 1876 15050 0 0
574 316 32 1907 15118 0 0
573 312 32 1938 15186 0 0
A 2S
VAX/VMS PARKIN F0R082 8-FEB-l984 08:01 LPAO: 8—FEB—'1984 08: 01
VAX/VMS PARKIN F0R082 8—FEB—1984 08:01 LPAO: 8—FEB—1984 08: 01
VAX/VMS PARKIN FDR082 8—FEB-1984 08:01 LPAO: 8—FEB—19S4 08: 01
PPPP AAA RRRR K K III N N
P P A A R R K K I N N
P P A A R R K K I NN N
PPPP A A RRRR KKK I N N N
P AAAAA R R K K I N NN
P A A R R K K I N N
P A A R R K K III N N
FFFFFFFFFF 000000 RRRRRRRR 000000 888888 222222
FFFFFFFFFF 000000 RRRRRRRR 000000 888888 222222
FF 00 00 RR RR 00 00 88 88 22 22
FF 00 00 RR RR 00 00 88 88 22 22
FF 00 00 RR RR 00 0000 88 88 22
FF 00 00 RR RR 00 0000 88 88 22
FFFFFFFF 00 00 RRRRRRRR 00 00 00 888888 22
FFFFFFFF 00 00 RRRRRRRR 00 00 00 888888 22
FF 00 00 RR RR 0000 00 38 88 22
FF 00 00 RR RR 0000 00 88 88 22
FF DO 00 RR RR 00 00 88 88 22
FF 00 00 RR RR 00 00 88 88 22
FF 000000 RR RR 000000 888888 2222222222
FF 000000 RR RR 000000 888888 2222^22222
DDDDDDDD AAAAAA TTTTTTTTTT
DDDDDDDD AAAAAA TTTTTTTTTT
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT
DD DD AAAAAAAAAA TT
DD DD AAAAAAAAAA TT
DD DD AA AA TT
DD DD AA AA TT
DDDDDDDD AA AA TT





















PPPP AAA RRRR K K 111 N N
P P A A R R K K I N N
P P A A R R K K I NN N
PPPP A A RRRR KKK I N N N
P AAAAA R R K K I N NN
P A A R R K K I N N
































































































pppp AAA RRRR K K III N N
p p A A R R K K I N N
p p A A R R K K I NN N
pppp A A RRRR KKK I N N M
p AAAAA R R K K I N NN
p A A R R K K I N N
















FFFFFFFFFF 000000 RRRRRRRR 000000 888888 333333
FFFFFFFFFF 000000 RRRRRRRR 000000 888888 333333
FF 00 00 RR RR 00 00 88 88 33 33
FF 00 00 RR RR 00 00 88 88 33 33
FF 00 00 RR RR 00 0000 88 S8 33
FF 00 00 RR RR 00 0000 83 88 33
FFFFFFFF 00 00 RRRRRRRR 00 00 00 888888 33
FFFFFFFF 00 00 RRRRRRRR 00 00 00 888888 33
FF 00 00 RR RR 0000 00 88 88 33
FF 00 00 RR RR 0000 00 88 88 33
FF 00 00 RR RR 00 00 88 88 33 33
FF 00 00 RR RR 00 00 88 88 33 33
FF 000000 RR RR 000000 88S888 333333
FF 000000 RR RR 000000 888888 333333
DDDDDDDD AAAAAA TTTTTTTTTT 333333
DDDDDDDD AAAAAA TTTTTTTTTT 333333
DD DD AA AA TT 33 33
DD DD AA AA TT 33 33
DD DD AA AA TT 33
DD DD AA AA TT 33
DD DD AA AA TT 33
DD DD AA AA TT 33
DD DD AAAAAAAAAA TT 33
DD DD AAAAAAAAAA TT 33
DD DD AA AA TT 33 33
DD DD AA AA TT 33 33
DDDDDDDD AA AA TT 333333
DDDDDDDD AA AA TT 333333
PPPP AAA RRRR K K III N N
P P A A R R K K I N N
P P A A R R K K I NN N
PPPP A A RRRR KKK I N N N
P AAAAA R R K K I N NN
P A A R R K K I N N



































































































CRETRAT 8-FEB-1984 OS:01 LPAO
CRETRAT S-FEB-1984 OS:01 LPAO





P P A A






R R K K
R R K K
RRRR KKK
R R K K
R R K K








CCCCCCCC RRRRRRRR EEEEEEEEEE TTTTTTTTTT RRRRRRRR AAAAAA TTTTTTTTT
CCCCCCCC RRRRRRRR EEEEEEEEEE TTTTTTTTTT RRRRRRRR AAAAAA TTTTTTTTT
CC RR RR EE TT RR RR AA AA TT
CC RR RR EE TT RR RR AA AA TT
CC RR RR EE TT RR RR AA AA TT
CC RR RR EE TT RR RR AA AA TT
CC RRRRRRRR EEEEEEEE TT RRRRRRRR AA AA TT
CC RRRRRRRR EEEEEEEE TT RRRRRRRR AA AA TT
CC RR RR EE TT RR RR AAAAAAAAAA TT
CC RR RR EE TT RR RR AAAAAAAAAA TT
CC RR RR EE TT RR RR AA AA TT
CC RR RR EE TT RR RR AA AA TT
CCCCCCCC RR RR EEEEEEEEEE TT RR RR AA AA TT
CCCCCCCC RR RR EEEEEEEEEE TT RR RR AA AA TT
FFFFFFFFFF 000000 RRRRRRRR ! > i 1 222222
FFFFFFFFFF 000000 RRRRRRRR i i i 1 222222
FF 00 00 RR RR iii in 22 22
FF 00 00 RR RR i j; in 22 22
FF 00 00 RR RR l 22
FF 00 00 RR RR l 22
FFFFFFFF 00 00 RRRRRRRR / ; l 22
FFFFFFFF 00 00 RRRRRRRR J i l 22
FF 00 00 RR RR > i l 22
FF 00 00 RR RR i t i 22
FF 00 00 RR RR i l 22
FF 00 00 RR RR t l 22
FF 000000 RR RR } in li 2222222222






















K K III N N
K K I N N
K K I NN N
KKK I N N N
K K I N NN
K K I N N




CRETRAT 8—FEB-19S4 08:01 LPAO
CRETRAT S-FEB-1984 08:01 LPAO
CRETRAT 8-FEB-1984 08:01 LPAO








Caaa-a-a* PROGRAM CRETRAT. FOR
C******
Caa*aa*This program generates the transfer rate data block FILE11. DAT in F0R043
Caaaaaa Data is population bg 100 single years of age. for each
Caaaaaa time period for which transfer rates required - in F0R042
Caaaaaa (Check format of F0R042. . . line 1100 914)
Caaaaaa Simple crude transfer rates in FICHE11. DAT read from F0R041
C a-* *a* -a -a*# a- a a aa *aaaa -a a a a a aa**a*aa aa a -a -a -a a -a- -a *aaa -a * -a- -a -a- -a a -a- a a* -a- -a -a- -a -a -a-a aat * a-a- a -a- -a -a * -a a**
INTEGER TIM1. TIM2. M. P, G. A
DIMENSION IP0P(3. 3, 100)
DIMENSION IRR(3,3)
DIMENSION LINE(80)






C DATA BELOW ARE RELATIVE RISK(ALL AGES) OF 1-2 TRANSFER













IF(LINE<1) . EQ. ISLASH) GOTO 900
BACKSPACE 41
READ(41, 1102)IFR, ITO, IAG1, IAG2,TIM1,TIM2, RATE
IF(IFR .NE. 1) GOTO 400
G=G+1
ITOTPOP(G)=0
DO 150 M = 1,3
DO 145 P = 1, 3
IPOPGP(P,M, G)=0
DO 140 A = IAG1,IAG2
140 IPOPGP(P,M,G) = IPOPGP<P,M,G) + IPOP(P,M,A)




WT (G) =0. 0
DO 200 M = 1,3
DO 200 P = 1, 3
WT < G) = WT(G) + (IPOPGP(P,M,G) * IRR(P,M)) / 100
200 CONTINUE
FACT(G) = ITOTPOP(G) / WT(G)
WR < G) = RATE -a FACT (G )
DO 300 M = 1, 3
DO 300 P = 1, 3
FINR <P,M,G) = (WR(G) * IRR(P.M)) / 100
WRITE(43, 1103)IFR, ITO, IAG1, IAG2,P,M,TIM1, TIM2,FINR(P,M,G)
300 CONTINUE
GO TO 50
400 M = O
P = 0






1102 FORMAT(IX, 2(12, IX), 2<13), 2<12, IX),F7. 2)
























C ************************************* *•»•■«■************* ■»•■»• ***********************
C ******************************************************************************
C
C ADTNUM TOTAL NUMBER OF THOSE AGED 15+(IE. IN 16TH OR MORE YEAR)
C ADULT(I> CODED AGE,MS,IP,ISTAT, FOR THE I'TH ADULT
C INFANT(I) NUMBER OF INFANTS AGED I
C INFNUM TOTAL NUMBER OF THOSE IN THEIR 1ST TO 15TH YEARS
C INFTPC NO PER 1000 DEEMED TO BE INFERTILE FROM BIRTH
C IYR CURRENT SIMULATION YEAR
C NUMST TOTAL NUMBER OF STATES INCLUDING +VES, DEAD STATES ETC
C NUMYRS NUMBER OF YEARS IN SIMULATION
C POPSZE TOTAL INITIAL POPLATION SIZE
C STHIS STATE NUMBER OF 'DEAD OF THIS DISEASE'
C STHYST STATE NUMBER OF 'HYSTERECTOMY STATE'
C STOTH STATE NUMBER OF 'DEAD OF OTHER CAUSES'
C STPOS STATE NUMBER OF 'POSTIVE SMEAR STATE'
C TIMES(I) CODED ITIMM AND ICLOCK FOR I'TH ADULT
C
INTEGER POPSZE, STHYST, STPOS,STHIS, STOTH,ADTNUM
INTEGER ADULT,TIMES,DEAD
COMMON POPSZE, NUMST, NUMYRS, STHYST, STPOS, STHIS, STOTH, INFNUM
COMMON ADTNUM,IYR
COMMON INFANT(15), ADULT(109999), TIMES<109999), DEAD(100)
c
C VARIABLES USED BY TRANSF SUBROUTINE:
C ITRATE(I) ... TRANSFER RATE OF I'TH LINE OF TRANSFER DATA
C ITRFR (I) ... FROM STATE FOR I'TH LINE
C ITRTO (I) ... TO STATE FOR I'TH LINE
C IAGMIN(I) ... MIN AGE FOR I'TH LINE
C IAGMAX(I) ... MAX AGE FOR I'TH LINE
C ITRMS (I) ... MARSTAT RATE IT APPLIES TO <0=ALL)
C ITRIP (I) ... PARA GROUP IT APPLIES TO (0=ALL)
C ITRTM1(I) ... TIME IN STATE FROM VALUE IT APPLIES TO
C ITRTM2(I) ... TIME IN STATE TO VALUE IT APLLIES TO
C IOST ORIGINAL STATE - BEFORE ANY TRANSFERS BEGIN
C ISCPOSBK(I, J). RATE OF REVERSION TO ORIGINAL STAYE(I) FROM STPOS
C NUMTR NUMBER OF LINES OF TRANSFER DATA
C
COMMON /TRSVAR/ ITRATE(500),ITRFR (500),ITRTO (500),
1 IAGMIN(500)»IAGMAX(SOO),
2 ITRMS (500),ITRIP (500),ITRTM1(500>,ITRTM2(500)
C
S20 - THE MICRO-SIMULATION PROGRAM (VERSION XIV)
Accepts initial population size of 100,000
Input :from 92 & 93 needed to provide duration of states
2 and 3 in starting population (see ST 1ST)
Outputs 1) F0R008-new cancer deaths
2) F0R009-new cancer cases
3) FOROiO-person-years at each age, each year
4) F0R034-tables,format of which must be specified
in FILE33. DAT
ORIGINAL BY P. HODGSON , MODIFIED BY DMP & MS
A 34
C VARIABLES USED BY SCREEN SUBROUTINE:
C ISCYR (I, J) . (1,1) IS START YR, (1,2) END YR OF I'TH POLICY
C ISCINT (I) . SCREENING INTERVAL FOR I 'TH SCREEN POLICY
C ISCAGE(I,J) . (1,1) IS START AGE, (1,2) END AGE FOR I'TH POL
C ISCMS (I) . MARSTAT OF I'TH POLICY TARGET POP'N (0=ALL)
C ISCIP (I) . PARITY OF I'TH POLICY TARGET POP'N (0=ALL)
C ISC ATT < I, J) . ATT RATE <"/.) OF J'TH STATE IN I'TH POLICY
C ISCPOS(I,J> . POS RATE ('/.) OF U'TH STATE IN I'TH POLICY
C ISCPOSEK(I,J).RATE OF REVERSION TO ORIGINAL STATE<I) FROM STPOS
C ISCTOT NUMBER OF SCREENING TESTS IN YEAR
C ISCNA NUMBER OF ELLIGIBLE NON-ATTENDERS IN YEAR
C ISCGTOT NUMBER OF SCREENING TESTS SINCE YEAR 0
C ISCGNA NUMBER OF ELLIGIBLE NON-ATTENDERS SINCE YEAR 0
C IPOSTGT(I)... NUMBER OF POS. TESTS SINCE TIME 0 IN STATE I
C NUMSCR NUMBER OF POLICIES IN SCREENING CAMPAIGN
C
COMMON /SCRVAR/ ISCYR<20, 2), ISCINT(20) , ISCAGE(20, 2) , ISCMS(20),
1 ISC IP(20) , ISCATT(20, 6), ISCP0S(20, 6), I5CP0SBK(20, 6), IPDSTGT(S),
2 ISCTOT,ISCNA,ISCGTOT,ISCGNA
C
C VARIABLES USED BY AGEING SUBROUTINE:
C ICHILD(I,J,K) ... CHANCE IN 1000 THAT A WOMAN AGED I, MS J, IP K HAS A KID
C IHYST (I) CHANCE OF HAVING HYSTERECTOMY AT AGE I
C IMARRY(I,J,K) ... CHANCE OF MOVING TO MS K GIVEN AGE I AND MS J
C IPOPT (I) TOTAL NUMBER OF WOMEN AGED I
C ISTOT (I) TOTAL NUMBER OF WOMEN IN STATE I
C ITRMAT(I,J) NUMBER TRANSFERRING FROM STATE I TO STATE U IN YEAR
C MORT (I) CHANCE OF DYING IF AGED I
C XPFACT(I,J) CORRECTION FACTOR FOR ICHILD(I,J, 1)
C
COMMON /AGEVAR/ ICHILD(100, 3, 3), IHYST<100),





C VARIABLES ADDED FOR TABULATION PURPOSE
C NXYRTPRT NEXT YEAR FOR WHICH OUTPUT IS REQUIRED
C TABCOUNTS INTEGER ARRAY TO HOLD COUNTS
C LWBNDS LOWER BOUNDS FOR DIMENSIONS
C UPBNDS UPPER BOUNDS FOR DIMENSIONS
C NTABDIMS NUMBER OF DIMENSIONS IN TABULATION





C 5. TIME IN STATE
C 6. CLOCK YEARS
C 7. PREV STATE
C NVARCL NUMBER OF CLASSES FOR VARIABLES
C INDVAL THE 7 VALUES FOR AN INDIVIDUAL
C LWCLVAL LOWER VALUE FOR ONE CLASS







C INIT READS IN INITIAL DATA & PRINTS MAIN HEADINGS
A 35
c ST AGE GENERATES STARTING AGES
C ST MST GETS STARTING MARSTAT FROM AGE
C ST IPS GETS STARTING PARA FROM AGE & MARSTAT
C ST 1ST GETS STARTING STATE FROM PARA, MARSTAT Z< AGE
c
C: :
C THE FOLLOWING SUBROUTINES ARE CALLED ONCE ONLY AT BEGINNING OF SIMULATION
C::::::::::::::::::::::::::::: :::::::::::::::: :
CALL INIT ( IPRTYR)
CALL ST AGE
CALL ST MST
CALL ST IPS <INFTPC >


















20 IF ( IYR. GT. NXYRTPRT ) GOTO 10
IF ( IYR. LT. NXYRTPRT ) GOTO 100
C
C DO THE TABULATION
CALL TAB INI(TABCOUNTS,NTABDIMS,LWBNDS,UPBNDS)
DO IREC=i,ADTNUM






IF ( IVAL. GE. LWCLVAL<IDIM, IVCL) .AND.
1 IVAL. LE. UPCLVAL(IDIM, IVCL) ) GOTO 30
END DO
C AT THAT POINT INDIVIDUAL IREC IS UNCLASSIFIABLE
















DO 1 = 1, 15
INDVAL(1>=I





IF ( IVAL.GE.LWCLVAL<IDIM,IVCL) .AND.
1 IVAL. LE. UPCLVALCIDIM, IVCL) ) GOTO 31
END DO
C AT THAT POINT INDIVIDUAL IREC IS UNCLASSIFIABLE








C OUTPUT RESULT OF TABULATION TO NEWFILE F0R034
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :







IF < IYR. GT. NUMYRS ) STOP
c
C YEAR ON YEAR SUBROUTINES:
C TRANSF PERFORMS THE TRANSFERS BETWEEN STATES
C SCREEN DOES ANY SCREENING CALLED FOR THAT YEAR
C AGEING PRINTS YR SUMMARY, AGES THEM AND ADDS NEW ONES TO END OF LIST
C
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :














C RAND(I,J) PRODUCES RANDOM INTEGER, I, IN RANGE 1-J
C ENCODEd, list) ENCODES I'TH PERSON'S list OF AGE,MS, IP ETC
C ENCTIM(I, ITME, ICL, LST). ENCODES I'TH TIME IN STATE, CLOCK YEARS & PREV STATE
C DECODEd, list) DECODES I'TH PERSON'S list OF AGE,MS, IP ETC
C DECTIMd, ITME, ICL, LST). DECODES I'TH TIME IN STATE, CLOCK YEARS & PREV STATE




C **##■## ■» #■** # **■*■**-a*##***•*#■** *■* *■*■* ■» •» *##■»•»# •#• •»#***•»•»#•»#*## ■» #•»•»•* ■» ****■** -if ## #* •«■ -*
C** ■» «■* *■***•»-a- ■* ■» »•»•**** -a- •»•»**#*•»•**■» -a-* «• *•»*•«• ■» -a- ■» •»** *■•*•»■«• -a- -s#* -* ■# * -a- *■* ■* «•** ■«•■■» -a--* ■»• •«■ -i***#*•» *
C




COMMON POPSZE, NUMST, NUMYRS, STHYST, STPOS,STHIS,STOTH, INFNUM
COMMON ADTNUM,IYR
COMMON INFANT v 15), ADULT<i09999), TIMES<109999),DEAD(100)
COMMON /SCRVAR/ ISCYR(20, 2), ISC INT(20) , ISCAGE(20, 2> , ISCMS<20>,
1 ISC IP(20) , ISCATT(20, 6), ISCP0S(20, 6), ISCP0SBK(20, 6), IP0STGT<6),
2 ISCTOT,ISCNA,ISCGTOT,ISCGNA
C
C ISCTOT TOTAL NUMBER OF PEOPLE SCREENED IN CURRENT YEAR
C
WRITE<6, 600)








C READ IN AND VALIDATE POP'N SIZE, NUMBER OF STATES AND YEARS IN SIMULATION
C: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
READ<1,1101) POPSZE,NUMST
IF (POPSZE. GT. 50. AND. POPSZE. LE. 100001 ) GOTO 20
WRITE(6,601) POPSZE
STOP
20 IF(NUMST. GT. 4 . AND. NUMST . LE. 10 ) GOTO 30
WRITE(6,602) NUMST
STOP




READ<1, 1101, END=40) NUMYRS










600 FORMAT(//20X, 'THE I.A. R.C. CERVICAL CYTOLOGY SCREENING MODEL'
1 /20X, ' '
2 ////)
601 FORMAT(' ** ERR IN FILE1 — POPSZE', 13, ' INCORRECT **')
602 FORMAT ( ' ** ERR IN FILE1 — NUMBER', 13, ' OF STATES **' )
603 FORMAT(' ** ERR IN FILE1 -- NUMYRS INCORRECT **')





C &&&&•& -Jt- -tt- -ji- -Ji-
C *-it ■»■»■»■»■»#*#■ •** •* •* -M- •*•*#■»■•»••«••«■■»•** •&#-£•)(■■«• ■«•*■«■ ■«■•»•■«• «•■*■*■ -a- ■*■#* •#■■«■ •*■*■*■!«• ■«•#**■»* •*■«■* *<*<**•*<** *##■»■##■#••»••»•*## *
SUBROUTINE ST AGE
C -a-***#
C # •» **•***•»**•»*#■***#**■**•»** #*** •£**#****■»* *■* -ft ■$•*■*•»*■*•*•#■■**■«■-*■*■*■**■&•«•*
C #**•»■** •**# -a- •«•**■** •* *#■*•*■«■•«•**** ■«••** •»*■» **■#•**» -H- #■* ■»#* ■&•*■*•«••*■****•»***# •» •# *•# *#■» ■*•&•& -a-
INTEGER POPSZE, STHYST, STPOS,STHIS, STOTH,ADTNUM
INTEGER ADULT,TIMES,DEAD
COMMON POPSZE, NUMST, NUMYRS,STHYST,STPOS,STHIS,STOTH, INFNUM
COMMON ADTNUM,IYR
COMMON INFANT(15), ADULT<109999), TIME5<109999),DEAD<100)
COMMON /SUMVAR/ ISTOT(10),ITRMAT(10,10)
c
C ICUMUL <I) NUMBER OF PEOPLE IN TARGET POP'N WITH AGE LE I
C IPOP (I) NUMBER OF PEOPLE IN TARGET POP'N WITH AGE EQ I






C CALCULATE THE AGE CUMULATIVE POPULATION TOTALS AS WELL AS TOTAL POPULATION
C:::::::::::::::::::::::::::::::::::::::::::::: r :::::::::::::::::::::::::::::: :
DO 50 1 = 1, 100
ICUMUL<I) = 0
ICUMUL<I) = ITOT + IPOP(I)









DO 70 K=l, 100






IF < K. EQ. 100) K=100
IF<K. GT. 15) GOTO 90
FOR AN INFANT SIMPLY INCREMENT THE CORRECT VALUE IN ARRAY INFANT
INFNUM =INFNUM +1
INFANT <K)=INFANT(K) + l
GOTO 100


















C aa **■********aaaa******aaaaaaaaa*aaaaaaaaaaaaaaaaaaaaaaaa -if- aaaaaaa if aaaaaaaaaaaa*
c aa aaaaaa aaaa****a a*aaaa *aa**a aaa aaaaaa***** -a- ******aaa a**aa*aaaaaaaaa aa** 44- aa*■a a
INTEGER POPSZE,STHYST. STPOS,STHIS,STOTH,ADTNUM
INTEGER ADULT,TIMES,DEAD
COMMON POPSZE, NUMST, NUMYRS, STHYST,STPOS,STHIS,STOTH, INFNUM
COMMON ADTNUM,IYR
COMMON INFANT(15), ADULT(109999 >, TIMES(109999), DEAD(100)
C
C IMAR(I, J> NUMBER OF PEOPLE (PER 1000) IN TARGET POP'N
C AGED I WHO HAVE MARSTAT J
c
DIMENSION IMAR(100,3)
READ (2,1201) ( ( IMAR( I, J), J=l, 3), 1 = 1, 100)
C: :::::::::: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C CONVERT THE INPUT PROBABILITY DISTRIBUTION INTO CUMULATIVE PROBABILITIES
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
DO 50 1=1,100
IMAR (1,2) = IMAR (1,2) + IMAR(I,1)
IMAR (1,3) = IMAR (1,3)- + IMAR(I,2)





C FOR EACH ADULT GENERATE STARTING MARSTAT WITH REGARD TO AGE
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
DO 100 1 = 1, ADTNUM
CALL DECODE(I, IAG,MS, IP, 1ST)
CALL RAND(J,1000)
DO 70 K=1, 3




SO CALL ENCODE(I, IAG, K, 1, 1 )
100 CONTINUE
RETURN
601 FORMAT( ' ** ERR IN LINE', 14, ' IN INIT MAR DIST')





C «• #*•*********** *#■»■*■» •»■ •* * **#* ■«• ** **■»•*** «■* *■ •» *##*****■»-a-****■»##*#*■»«■* -a- -a- ***# -a-*****-a
C -iJ- -ii- -54--i4* -J5* -ii--5i**Jt- -ii- -JS* "W- ^ -t5- -44- -ii- -ti--54- -ii- -Ji--Ji- *34- "54--^ -J5- -J4--54- ^4- -J4- -Jt- -*4- -Jt* -K- -ii* -W--Jt--iS--iS- -5^- -a-a-a-a a-aa-a-aaa-a-a-a-a-a-a-a-a-a-aaaaaaaaaaa
c****»
SUBROUTINE ST IPS (INFTPC)
Caaaaa
C aaaaaaaaaaaaaa*aaaaaaaaaaaaaaaaaaaaaaaaaaa*aaaaaaaaaaaaaaaaaaaaa* *aaaaaaaaaaa*
C ***#aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa************aaaaa** •** 45- aaa -a-a wa# a
INTEGER POPSZE,STHYST, STPOS, STHIS, STOTH,ADTNUM
INTEGER ADULT,TIMES,DEAD
COMMON POPSZE, NUMST, NUMYRS, STHYST, STPOS, STHIS, STOTH, INFNUM
COMMON ADTNUM,IYR
COMMON INFANT(15), ADULT<109999), TIMES(109999), DEAD(100)
COMMON /AGEVAR/ ICHILD(100,3, 3), IHYST(100),
1 IMARRY<100, 3, 3), MORT (100),
1 XPFACT(100, 3)
c
C IPAR(I, J, K ) NUMBER OF PEOPLE (PER 1000) IN TARGET POP'N AGED I AND
C MARSTAT J WHO HAVE PARA K
C
DIMENSION IPAR(100,3,3)
DIMENSION XIPAR(100, 3, 1)
READ(3,1301> INFTPC
READ(3, 1301) (((IPAR(I,U,K),K=1,3),J=1,3), 1 = 1, 100)
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C CALCULATE FACTOR(XPFACT) THAT WILL BE USED IN AGEING SUBROUTINE TO CORRECT




DO 10 J=l, 3
XIPAR(I,J,1)=FLOAT(IPAR(I,J,1))
IF( XINFTPC. LT. XIPAR (I, J, 1) ) GOTO 5
WRITE(6, 600)
STOP
5 XPFACT(I,J) = 1.0 - (XINFTPC / XIPAR(I,J,1))
10 CONTINUE
C: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C CORRECT THE PARITY PROPORTIONS TO ALLOW FOR INFERTILE WOMEN (PARA 0) &
C CONVERT THE INPUT PROBABILITY DISTRIBUTION INTO CUMULATIVE PROBABILITIES
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
DO 50 1 = 1, 100
DO 40 J=i, 3
IPAR(I,J,3) = IFIX (FLOAT(IPAR(I, J, 3))/(<1000-INFTPC >/1000. ))
IPAR(I,J,2) = IFIX (FLOAT(IPAR(I, J, 2))/((1000—INFTPC)/1000. ))
IPAR (I, J, 1) = 1000 - IPAR (I, U, 2) - IPAR(I,J,3)
IPAR (I, J, 2) = IPAR ( I, J, 2) + IPAR ( I, J, 1 )
IPAR(I,J,3) = IPAR(I,J,3) + IPAR(I,J,2)






C FOR EACH ADULT GENERATE PARA ACCORDING TO AGE AND MARITAL STATUS
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
DO 100 1=1,ADTNUM
CALL DECODEd, IAG, MS, IP, 1ST)
60 CALL RAND(J,1000)
A 41
DO 70 IP = 1,3










600 FORMAT(' PROPORTION INFERTILE IN DATA FILE3 IMPOSSIBLY LARGE')
601 FORMAT(' ** ERR IN LINE',14,' OF INIT PAR DIST')









C **********************a* -a- aaaaaaaaaaaaaaaaaaaaaaaaaaa*aaaaaaaaaa*aaaa -if- *aaaaaaa a
Caaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa














STCUfK I, J, K, L)
IADMAT2<I, J). . .
IADMAT3(I, J). . .
NUMBER OF 'ORDINARY' DISEASE STATES (USUALLY 4?)
NUMBER (PER 100,000) OF TARGET POP'N AGED I WITH HYSTERECTY
TOTAL NUMBER IN STATE I AT BEGINNING OF SIMULATION
CUMUL. PROB OF BEING AGED I, MS J, IP K AND IN STATE L
CUMULATIVE PROBABILITY OF DURATION(J) IN ST 2 AT AGE I
CUMULATIVE PROBABILITY OF DURATION(J) IN ST 3 AT AGE I
INTEGER STCUM, HYST
DIMENSION HYST(100),STCUM(100,3,3, 8), ISTOT(10)
DIMENSION IADMAT2<70,75), IADMAT3<70,75)




C READ IN PROB. DIST. OF OTHER STATES AND, WITH HYST DATA, MAKE CUM. PROBS
C::::::::::::::::::::::::::::::::::: :::::::::::::::::::::::::::::::::::::: :
DO 40 1=1,100
DO 30 J=i, 3





READ(4, 1401 ) (STCUM( I, J, K, L), L=l, DIST)
STCUM(I,J, K, STHYST)=HYST(I)
STCUM ( I, J, K, 1 ) =STCUM (I, J, K, 1 ) -HYST ( I)
STCUM(I,J,K,STPOS )=0
DO 10 L=2,STHYST
STCUM(I, J, K, L)=STCUM( I, J, K, L )
+STCUM(I, J, K, L-i )
CONTINUE
IF(STCUM< I, U, K, STHYST). EG. 10000) GOTO 20





C READ IN AGE/DURATION MATRICES FOR STATES 2 , 3 FROM CHANNELS 92 , 93










IF (IPT. EG. 0) IPT = 1
CALL RAND<J, 10000)
DO 70 K=1,STHYST





C IF STATE=1 THEN TIME IN STATE IS AGE
C OTHERWISE READ FROM CHANNELS 92,93.... AS IADMATx(age, dur) MATRIX
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
SO IF (K. NE. 1 ) GOTO 82
ITIMM = IAG
GOTO 95
82 IF<K. NE. 2) GOTO 84
CALL RAND(L,100)
M = IAG - 15
IF(M. GT. 70) M=70
DO 83 N = 1, 75
ITIMM = N
IF(L. LE. IADMAT2CM, N) ) GO TO 95
83 CONTINUE
GOTO 95
84 IF(K. NE. 3) GOTO 86
CALL RANDIL, 100)
M = IAG - 15
IFCM. GT. 70) M=70
DO 85 N = 1, 75
ITIMM = N
IF(L. LE. IADMAT3(M, N) ) GO TO 95
85 CONTINUE
GOTO 95
86 IF I K. NE. 4) GOTO 88
CALL RAND(L,100)
ITIMM = L/50 + 1
GOTO 95
88 IF (K. NE. 5) GOTO 90
CALL RAND(L, 100)
ITIMM = 1
IF (L. LT. 70) ITIMM=2
IF<L. LT. 65)ITIMM=3
IF (L. LT. 50) ITIMM=4
IF <L. LT. 40)ITIMM=5
GOTO 95





C PRINT THE STARTING POPULATION'S DISTRIBUTION AMONGST STATES AND POPN SIZE
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :




IST0T<1) = ISTOT(l) + INFANT(I>
160 CONTINUE
DO 180 1=1,ADTNUM
CALL DECODE<I, IAG,MS, IP, 1ST)















DO 200 1 = 1,NUMST





FORMAT! ' »# ERR IN STATE DATA . . AGE, MS, IP. . ',314)
FORMAT(' ** ERR IN PROG IN ST 1ST SR')
FORMAT(20X, 'YEAR 0'/20X, ' '/)
FORMAT ! ' NUMBER IN STATE ',12,' ... ',19)
FORMAT!/' TOTAL POPULATION ',18///)
FORMAT(813)





C ## ir -a-a.##*# -a- -a- -jj. #■«■#•»■■«■■>{■■» •* ■«•■«■ ■» #* is- -a- -a- #■ -h-*##**«■* «• **■»■***■»#•» -a- * •» «■ *•# ■» *# •» # # «■*•«■ * #■ # ■«• **•»•***#* -s-





INTEGER POPSZE,STHYST, STPOS,STHIS,STOTH, ADTNUM
INTEGER ADULT,TIMES, DEAD
COMMON POPSZE, NUMST, NUMYRS,STHYST,STPOS, STHIS,STOTH, INFNUM
ADTNUM,IYR
INFANT <15),ADULT(109999), TIMES(109999), DEAD(IOO)
/SUMVAR/ ISTOT(10), ITRMAT <10, 10)
ITRATE(500>,ITRFR <500>,ITRT0 (500),
IAGMIN(500), IAGMAX < 500),
ITRMS (500),ITRIP (500),ITRTM1<500),ITRTM2(500)
ISCYR(20,2), ISCINT(20) , ISCAGE(20,2> ,ISCMS(20),






























FROM AGE TO AGE (AS YEAR OF LIFE) READ IN FROM FILE
FROM STATE READ IN FROM FILE
'/' MARKS END OF TRANSFER RATE DATA
TO STATE READ IN FROM FILE
INPUT LINE ARRAY USED TO SEARCH FOR '/' WHICH MARKS END OF FILE
NUMBER OF LINES OF TRANSFER RATE DATA
TRANSFER RATE READ IN FROM FILE
FROM 'TIME IN STATE' READ IN FROM FILE
TO 'TIME IN STATE' READ IN FROM FILE
PERCENT REVERTING TO ORIGINAL STATE FROM STPOS
(ONLY POSSIBLE AFTER YEAR 1)
DATA ISLASH/1H//
IF YEAR IS 1 OR 11 OR 21 THEN READ IN A TRANSFER RATE DECLARATION FILE
IF( IYR. NE. 1. AND. IYR. NE. 11. AND. IYR. NE. 21 ) GOTO 100
NUMTR=1
50 READ(11, 1101,END=90) LINE
IF THE INPUT LINE WAS NOT '//' THEN READ IT AGAIN AS A LINE OF TRANSFER DATA
IF(LINE(1). EQ. ISLASH) GOTO 90
BACKSPACE 11
READ(11, 1102) IFR, ITO, IAG1, IAG2,MS, IP, TIM1,TIM2,RATE
IF ANY OF ITEMS IN TRANSFER FILE IS OUT OF RANGE THEN PRINT MESSAGE AND STOP
IF(IFR . LT .1. OR. IFR . GT. STPOS) GOTO SO
IF(ITO . LT .1. OR. ITO .GT. STHIS) GOTO SO
IF( IAG1. LT. 16. OR. IAG1. GT. 100 ) GOTO SO
IF(IAG2. LT. 16. OR. IAG2. GT. 100 ) GOTO SO
IF(MS . LT. 0. OR. MS . GT. 3 ) GOTO 80
IF( IP . LT. 0. OR. IP . GT. 3 ) GOTO 80
IF(TIM1. LT. 0. OR. TIM1. GT. 100 ) GOTO SO
IF(TIM2. LT. 1. OR. TIM2. GT. 100 ) GOTO 80
IF(RATE. LT. 0. OR. RATE. GT. 100. 0) GOTO SO
C PUT VALIDATED ITEMS INTO TRANSFER ARRAYS AND INCREMENT NUMBER OF LINES USED
A 46
ITRATE(NUMTR) = IFIX <RATE * 1 000 000.0)
ITRFR (NUMTR) = IFR
ITRTO (NUMTR) = ITO
IAGMIN(NUMTR) = IAG1
IAGMAX(NUMTR) = IAG2
ITRMS (NUMTR) = MS







90 NUMTR = NUMTR-1
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C SET ALL ELEMENTS OF STATE TRANSITION MATRIX THAT WILL BE USED TO ZERO





C: r :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: : :
C INCREMENT MATRIX FOR INFANTS WHO MUST DO A STATE 1 TO STATE 1 TRANSITION
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
DO 130 1 = 1, 15
ITRMAT(1,1) = ITRMAT(1,1) + INFANT(I)
130 CONTINUE
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C INCREMENT MATRIX FOR ADULTS ON BASIS OF THEIR STATE AT START OF YEAR
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
DO 500 1=1,ADTNUM
CALL DECODE*I, IAG, MS, IP, 1ST)
CALL DECTIM(I, ITIMM, ICLOCK, LSTAT)
IPT = IP
IF( IPT. EQ. 0) IPT = 1
ITRMAT(1ST,1ST) = ITRMAT(1ST,1ST) + l
C: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C FIRST, FOR ALL EXCEPT YEAR 1, (AT THE EEGINNING OF WHICH NO ONE IS IN STPOS)
C RETURN WOMEN IN STPOS TO THEIR ORIGINAL PRESCREEN STATE
C ACCORDING TO RATES SPECIFIED IN LINE 3 OF FILE 12
C <N. B. OPERATES FOR FIRST 3 YEARS AFTER DETECTION ONLY)
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
140 IOST = 1ST
IF(IYR . EQ. 1) GO TO 155
IF(1ST .NE. STPOS) GO TO 155
IF(ITIMM.GT. 3) GO TO 155
CALL RAND(K,100)





C THE MAIN LOOP FOR EXAMINING WOMEN FOR TRANSFERS BETWEEN STATES BEGINS HERE
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
155 IFACT = 1
160 DO 200 J=l,NUMTR
IF (1ST . NE. ITRFR (J)) GOTO 200
IF (IAG . LT. IAGMIN< J)) GOTO 200
IF (IAG . GT. IAGMAX(J)) GOTO 200
A 47
IF (MS . NE. ITRMS <J). AND. ITRMS(J).NE. 0) GOTO 200
IF (IPT . NE. ITRIP (J). AND. ITRIP(J). NE. 0) GOTO 200
IF (ITIMM . LT. ITRTM1<J)) GOTO 200
IF (ITIMM . GT. ITRTM2(J)) GOTO 200
C: :::::::::::::::::::::::::::::::::::::::::::::::::: :::::::::::::::::::::::::: :
C IF THIS TRANSFER IS A POSSIBLE ONE THEN GET RANDOM NUMBER TO SEE IF IT OCCURS
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
CALL RAND(K,100 000 000)





C AFTER A TRANSFER HAS OCCURED, GO BACK FOR ANOTHER (BUT WITH REDUCED PROB)
C:::::::::::::: ::::::::::::::::::::::::::::::::: :::::::::::::::::::::::::::::: :




C INCREMENT THE TRANSITION MATRIX IF CHANGE OF STATE HAS TAKEN PLACE
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
300 IF<ITIMM . NE. 0 .OR. 1ST . EQ. IOST) GO TO 400
ITRMAT(IOST, 1ST ) = ITRMAT(IOST, 1ST ) + 1
ITRMAT<IOST,IOST) = ITRMAT(IOST,IOST) - 1
400 CALL ENCODE(I,IAG,MS,IP,1ST)
CALL ENCTIM(I, ITIMM, ICLOCK, LSTAT)
500 CONTINUE
RETURN
601 FORMAT<' ** ERR IN LINE',14, ' OF TRANSF RATE DATA')
1101 FORMAT(80A1)




C *■■»* -a- # ■* •* »» i? -if- # •«• *■#•£■«••«■■!«•■«•■*■*• # **■*•**•»*•»■ -a- •* *■**»* -M- -if- # -H- * **•»■«■# -a- ■«••*-»■■*■»-»•■»•«• -H- #«#<**** *#«••»* -K- * -K-
C##-**##'***'*####***##*##*#*#*#*•»■**##*#*■*■«■**■*####*#*#**•#*** **#**#*#* ■#■»#**•»*■»■*■* •»■*■»■
SUBROUTINE SCREEN
C *****
C **«■***•»•■«•***«■**■»•***##«•***# *■* ■«• * *■* *• ■»••* **•*#*•■«•■!*•*•*••»•■* * •* *■**■**•«• •* -K- # $■ -a-#* ***■»*#***
C #•»«•#**■**•»■**** -a- »-a- *■ ■«■ •«•■«■* •*■**••«• * *■»* #•»•■«•■»•■h-h-***##**-)*#*- -a- a-
INTEGER POPSZE,STHYST,STPOS,STHIS, STOTH, ADTNUM
INTEGER ADULT,TIMES,DEAD
COMMON POPSZE,NUMST,NUMYRS,STHYST, STPOS, STHIS, STOTH, INFNUM
COMMON ADTNUM,IYR
COMMON INFANT <15),ADULT<109999), TIMES<109999), DEAD(100)
COMMON /SUMVAR/ ISTOT(10),ITRMATC10,10)
COMMON /SCRVAR/ ISCYR<20,2),ISCINT(20) ,ISCAGE(20,2) ,ISCMS(2C),




C DIST NUMBER OF DISEASE STATES BEFORE '+VE SMEAR'
C I ATT < I) TEMP ARRAY FOR I'TH POLICY ATT DATA
C IPOS(I) TEMP ARRAY FOR I'TH POLICY +VE DATA
C IPOSBK< I ) TEMP ARRAY FOR PCT REVERTING TO ORIG STATE
C ISLASH '/' MARKS END OF SCREENING DATA FILE
C LINE INPUT LINE ARRAY USED TO SEARCH FOR '/'










50 READ<12, 1201,END=90) LINE
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C IF INPUT LINE WAS NOT END OF FILE THEN READ THREE LINES OF SCREENING DATA
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :





IF< I YR 1. LT. 1961. OR. IYR1. GT. 1990) GOTO 80
IF< IYR2. LT. 1961. OR. IYR2. GT. 1990) GOTO 80
IF (INT . LT. 1 . OR. INT . GT. 25 ) GOTO 80
IF< IAG1. LT. 16 . OR. IAG1. GT. 100 ) GOTO 80
IF(IAG2. LT. 16 . OR. IAG2. GT, 100 ) GOTO 80
IF<MS . LT. 0 . OR. MS . GT. 3 ) GOTO 80
IF(IP . LT. 0 . OR. IP . GT. 3 > GOTO 80
DO 60 1=1,DIST
IF(IATT<I>. LT. 0. OR. IATT<I). GT. 100) GOTO 80
ISCATT (NUMSCR,I) = IATT(I)
IF (IPOS (I ). LT. 0. OR. IPOS(I). GT. 999) GOTO 80
IF(IPOS(I).EQ. 999) IP0S(I> = 1000
ISCPOS (NUMSCR,I) = IPOS(I)
IF(IPOSBK(I). LT. 0. OR. IPOSBK(I). GT. 100) GOTO 80
ISCPOSBK(NUMSCR< I) = IPOSBK(I)
60 CONTINUE
C IF ALL ITEMS OK THEN PUT THEN IN SCREEN ARRAYS & INCREMENT NO. OF LINES USED
A 49
C I::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::;: ;
ISCYR (NUMSCR, 1) = IYR1-1960
ISCYR (NUMSCR, 2) = IYR2-1960
ISC INT(NUMSCR) = INT
ISCAGE(NUMSCR,1) = IAG1
ISCAGE(NUMSCRi2) = IAG2
ISCMS <NUMSCR) = MS





90 NUMSCR = NUMSCR-1
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C FIRST CHECK TO SEE IF ANY SCREENING IS TO BE DONE IN THIS YEAR
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
100 DO 120 1=1,NUMSCR




C IF SCREENING IS TO BE DONE EXAMINE EACH ADULT TO SEE IF THEY ARE ELLIGIBLE
C: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
125 DO 500 1 = 1, ADTNUM
CALL DECTIM(I,ITIMM,ICLOCK,LSTAT)
IF<ICLOCK. GT. 0 ) GOTO 500
CALL DECODE(I,IAG,MS,IP,1ST)
IPT = IP
IF < IPT. EQ. 0) IPT = 1
IF(1ST . GE. 5 ) GOTO 500
DO 150 J=i,NUMSCR
IPOL = J
IF(IAG . LT. ISCAGE<J, 1) ) GOTO 150
IF<IAG . GT. ISCAGECJ,2) > GOTO 150
IF<ISCMSCJ). EQ. O ) GOTO 130
IF < MS .NE. ISCMS(J) ) GOTO 150
130 IF(ISCIP(J).EQ. 0 ) GOTO 140





C IF SHE IS ELLIGIBLE GENERATE A RANDOM NUMBER TO SEE IF SHE ATTENDED
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
140 CALL RAND (K,100)
IF(K . GT. ISCATT(IPOL, 1ST)) GOTO 400
ISCTOT = ISCTOT + 1
ICLOCK = ISC INT(IPOL)
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C IF SHE ATTENDED GENERATE A RANDOM NUMBER TO SEE IF SHE WAS FOUND TO BE +VE
C: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
CALL RAND (K,1000)
IF(K . GT. ISCPOS(IPOL, 1ST)) GOTO 300
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C IF TEST IS POSITIVE , UPDATE HER VARIABLES AND






ITRMAT(LSTAT,1ST ) = ITRMAT(LSTAT,1ST ) + 1
ITRMAT(LSTAT, LSTAT) = ITRMAT(LSTAT,LSTAT) - 1
300 CALL ENCTIM (I, ITIMM, ICLOCK,LSTAT)
GO TO 500
C::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C DEAL WITH NON-ATTENDERS AT SCREENING
C::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
400 ISCNA = ISCNA + 1
ICLOCK = ISC INT(IPOL)
C (Non attenders not offered test until next is due)
CALL ENCTIM <I, ITIMM, ICLOCK,LSTAT)
500 CONTINUE
601 FORMAT( ' ** ERR IN POLICY', 13, ' OF SCREEN DATA **')
1201 FORMAT(S0A1)
1202 FORMAT <2( IX, I4),3(1X,I2),2(1X,I1),6<1X, 13))










C ****-a******** -a**************************-a*** -a-*********************************
C -a**a- -a-********** -a-*******************-a-************ -a-*****************************
INTEGER POPSZE/STHYST,STPOS,STHIS,STOTH,ADTNUM
INTEGER ADULT,TIMES,DEAD
COMMON POPSZE,NUMST,NUMYRS,STHYST,STPOS, STHIS, STOTH, INFNUM
COMMON ADTNUM,IYR
COMMON INFANT(15), ADULT<109999), TIMES(109999),DEAD<100)
COMMON /AGEVAR/ ICHILD<100,3,3),IHYST<100),
1 IMARRY<100, 3,3),MORT (100),
1 -XPFACT<100,3)
COMMON /SUMVAR/ ISTOT<10),ITRMAT<10,10)
COMMON /SCRVAR/ ISCYR<20,2), ISC INT<20) , ISCAGE<20,2) ,ISCMS<20),
1 ISC IP(20) , ISCATT < 20,6), ISCP0S<20,6), ISCP0SBK<20,6), IP0STGT<6),
2 ISCTOT,ISCNA,ISCGTOT,ISCGNA
C
C IFILE CHANNEL NUMBER OF FILE BEING READ
C IKIDZ NUMBER OF FEMALE BIRTHS IN YR THAT WILL BE ADDED TO INFNUM
C INEW POS'N IN NEW ADULT ARRAY, USUALLY LOWER DOWN DUE TO DEATHS
C IPEOPS<I) PERSONS AT EACH AGE AT START OF YEAR
C IPEOPE(I) PERSONS AT EACH AGE AT END OF YEAR
C PYS(I) PERSON YEARS LIVED AT AGE I DURING THE YEAR












C IF YR 1 OR YR 11 OR 21 THEN READ IN NEW TRANSITION DATA FOR PARA, MARSTAT ETC
C: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
IF (IYR. NE. 1. AND. I YR. NE. 11. AND. I YR. NE. 21) GOTO 100
IFILE=13
READ<13, 1301,END=80) < < < ICHILD(I, J, K), 1 = 1, 100),K=l, 3), J=l, 3)
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C CONVERT INCIDENCE FIGURES IN ICHILD TO TRUE PROBABILITIES
C AND
C CORRECT PROBABILITIES OF FIRST BIRTH TO ALLOW FOR INFERTILES
C: :::::: r ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
DO 55 1=1,100
DO 50 J=l, 3
K=1
ICHILD< I, J, K) = <2000 * ICHILD<I,J,K))
C
1 / <2000 + ICHILD<I,J,K))
ICHILD<I,J,K) = IFIX(ICHILD<I,U,K) * (1.O/XPFACT<I,J)))
DO 45 K=2, 3
ICHILD <I,U,K) = <2000 * ICHILD<I,J,K))
C






C READ IN MARITAL STATUS TRANSITION PROBABILITY DISTRIBUTION FROM F0R014
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
IFILE=14
READ < 14, 1401, END=SO> < I MARRY (I, 1,2), 1 = 1, 100),
1 <IMARRY<I<2,3), 1 = 1, 100),
2 < IMARRY< I, 3, 2), 1 = 1, 100)
C: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C CONVERT MARITAL PROBABILITY DISTRIBUTION INTO CUMULATIVE TRANSITION MATRIX
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
DO 60 1 = 1, 100
I MARRY < I, 1, 1 ) = 1000 - I MARRY (I, 1,2)
IMARRY <1, 1,2) = 1000
IMARRY <1, 1,3) = 1000
IMARRY <1, 2, 1) =0
IHARRY ( I, 2, 2) = 1000 - I MARRY < 1,2, 3)
IMARRY<1, 2, 3) = 1000
IMARRY< I, 3, 1 ) =0
IMARRY<1, 3, 3) = 1000
60 CONTINUE
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C READ IN PROBABLITY OF DYING AND OF HAVING HYSTERECTOMY AT EACH AGE YEAR
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
IFILE=15
READ<15, 1501, END=80) MORT, IHYST
GOTO 100
C: ::::::::::: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :






C SET TOTALS FOR EACH DISEASE STATE TO ZERO PRIOR TO COUNTING
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
DO 135 1=1,10
ISTOT <I) = 0
135 CONTINUE
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
C EXAMINE EACH ADULT FOR CHANGE IN CHARACTERISTICS AND UPDATE MATRIX IF NEEDED
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
INEW = 0
DO 500 1 = 1, ADTNUM
CALL DECODE(I, IAG, MS, IP, 1ST)
CALL DECTIM(I, ITIMM, ICLOCK, LSTAT)
C: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C CHECK FOR CANCER DEATHS THIS YEAR
C: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
140 IF<IST. NE. STHIS) GOTO 150
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C WRITE NEW CANCER DEATHS TO F0R008 AND UPDATE IPEOPSII)
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
IF < ITIMM. NE. 0) GO TO 4S0
WRITE(8,801)IYR, IAG,MS, IP, 1ST, ITIMM, ICLOCK, LSTAT
IPEOPS <IAG) = IPEOPS <IAG) + 1
GO TO 480
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C CHECK THAT NO OTHER DEATHS CARRIED OVER FROM LAST YEAR
C::::::::::::::::::::::::::: :::::::::::::::::::::::::::::::::::::::::::::::::: :





C WRITE NEW CANCER CASES TO F0R009
C: ::::::::::::::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::::::::: :
160 ISTCA = NUMST - 4




C UPDATE IPEOPS(I) FOR LIVE ADULTS
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
170 IPEOPS?IAG) = IPEOPS?IAG) + 1
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C TEST TO SEE IF HER MARITAL STATUS CHANGES, THIS SECTION MISSED IF SHE IS DEAD
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
ISO CALL RAND?K,1000)
DO 200 J=l, 3





C IF SHE IS NOT DEAD .CHECK THAT NOT INFERTILE,OR HAD HYSTERECTOMY;
C IF NEITHER,THEN CHECK TO SEE IF BIRTH OCCURS
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
220 IF?IP . EQ. 0 ) GOTO 300
IF?1ST .EQ. STHYST) GOTO 400
CALL RAND ? K, 1000)
IF?K. GT. ICHILD? IAG, MS, IP) ) GOTO 300
C:::::::::::::::::::::::::::: ::::::::::::::::::::::::::::::::::::::::::::::::: :
C IF SHE HAD ONE THEN TEST TO SEE IF IT WAS FEMALE, INCREMENT IKIDZ IF IT WAS
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
CALL RAND ? K, 1000)
IF? IP. EQ. 1. AND. K. GT. 483) GOTO 240
IF? IP. EQ. 2. AND. K. GT. 485) GOTO 240
IF? IP. EQ. 3. AND. K. GT. 488) GOTO 240
IKIDZ = IKIDZ+1
240 IF(IP. LT.3) IP=IP + 1
:
C NOW CHECK TO SEE IF SHE HAS A HYSTERECTOMY, IF SO CHANGE 1ST, RESET ITIMM,
C AND INCREMENT THE TRANSITION MATRIX TO TAKE ACCOUNT OF CHANGE OF STATE
C ?N. B. THIS SECTION SKIPPED IF ALREADY HAS HAD HYSTERECTOMY, OR DEAD)
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
300 CALL RAND ? K, 100 000)




ITRMAT?LSTAT, 1ST ) = ITRMAT ? LSTAT, IST ) + 1
ITRMAT?LSTAT,LSTAT) = ITRMAT?LSTAT, LSTAT) - 1
C:::::::::::::::::::::::::::::::::::I;;::;:::::::::::::::::::::::;:::::::::::: :
C NOW CHECK TO SEE IF SHE HAS DIED OF OTHER CAUSES,IF SO CHANGE 1ST, RESET
C ITIMM, AND INCREMENT THE TRANSITION MATRIX TO TAKE ACCOUNT OF CHANGE
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
400 CALL RAND ?K, 100 000)




ITRMAT?LSTAT, 1ST ) = ITRMAT(LSTAT, IST ) + 1
A 5 4
ITRMAT(LSTAT,LSTAT) = ITRMAT(LSTAT, LSTAT) - 1
GO TO 500
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: r ::::::::::::::: :
C UPDATE ARRAY IPEOPE(I) FOR LIVE ADULTS
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
450 IPEOPE(IAG) = IPEOPE(IAG) + 1
C: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C AGE HER AND UPDATE ICLOCK
C::::::::::::::::::::::::::::::::::::::::: t :::::::::::::::::::::::::::::::::: :
470 IF < IAG. LT. 100 ) IAG = IAG + 1
IFCICLOCK. GT. O ) ICLOCK = ICLOCK - 1
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C IF SHE DID NOT DIE OF OTHER CAUSES PUT HER BACK IN THE 'INEW POS'N IN ARRAY
C AND INCREMENT ITIMM READY FOR NEXT YEAR
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
490 INEW = INEW + 1
ITIMM = ITIMM + 1
CALL ENCODE<INEW, IAG,MS, IP, 1ST)
CALL ENCTIM<INEW,ITIMM,ICLOCK,LSTAT)
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C GO BACK AND LOOK AT NEXT WOMAN
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
500 CONTINUE
C:::::::::::::::::::::::::::::::::::::::::::::::::::::: r ::::::::::::::::::::: :











IF(INFANT(15). EG. 0) GOTO 700
DO 520 J=1iINFANT(15)
IST=1
CALL RAND(K, 100 000)
IF(K. GT. MORT(15)) GOTO 520
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C FOR EACH DEATH(15TH YR) INCREMENT THE COUNTERS AND ADJUST THE TRANS. MATRIX
C CALCULATE IPE0PE(15)- IE 15 YEAR OLDS WHO SURVIVE THE YEAR
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
NUMDED = NUMDED + 1
INFMRT = INFMRT + 1
ITRMAT(1,1) = ITRMAT(1,1) - 1
ITRMAT(1,STOTH) = ITRMAT<1,STOTH) + 1
520 CONTINUE
IPEOPE(15) = INFANT(15) - NUMDED
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C ADD LIVE INFANTS IN 15TH YEAR TO ADULTS
C: I:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::;::::::::: :
NEWADT=INFANT(15)-NUMDED
IF(NEWADT. EQ. 0) GOTO 600





C CHECK EACH LIVE 15TH YR INDIVL. TO SEE IF SHE IS GOING TO BE FERTILE
A 55
IP = 0
CALL RAND < K, 1000)
IF<K.LE. INFTPC) GOTO 570
IP = 1
570 IAG = 16
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C ENTER LIVE 15TH YEAR INDIVIDUALS AS NEW ADULTS IN 16TH YEAR
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
580 CALL ENCODE*I, IAG,MS, IP, 1ST)
CALL ENCTIMII, IAG, ICLOCK,LSTAT)
590 CONTINUE
600 INFANT<15) = 0
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C LOOK AT REST OF INFANTS (IE IN 1ST TO 14TH YEARS)
C FIRST CHECK WITHIN EACH INFANT YEAR AGE GROUP FOR DEATHS
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
700 DO 715 1=1,14
IPEOPS(I) = INFANT(I)
NUMDED=0
IF(INFANT(I). EG. 0) GOTO 715
DO 710 J=l, INFANT(I)
1ST = 1
IP = 0
CALL RAND < K, 100 000)
IF< K. GT. MORT < I) ) GOTO 710
C:::::: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C FOR EACH DEATH INCREMENT THE COUNTERS AND ADJUST THE TRANSITION MATRIX
C CALCULATE PEOPE<I)-IE NUMBER SURVIVING THE YEAR AT EACH AGE
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
NUMDED = NUMDED + 1
INFMRT = INFMRT + 1
ITRMAT <1,1) = ITRMAT(1,1) - 1




IPEOPE <I) = INFANT(I)
715 CONTINUE
IST0T<1) = ISTOT<1) + INFNUM + NEWADT - INFMRT
ISTOT < STOTH) = ISTOT(STOTH) + INFMRT
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C CALCULATE STATE TOTALS FROM TRANSITION MATRIX
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
DO 718 J = 1,NUMST
ISTOT <J) = O
DO 718 I = 1, NUMST
ISTOT < J) = ISTOT<J) + ITRMAT <I,J)
718 CONTINUE
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C WRITE OUT THE TRANSITION MATRIX, STATE TOTALS AND TOTAL POPULATION FIGURES
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
WRITE<6,602) IYR, <I, 1 = 1,NUMST)
WRITE < 6,603)
DO 720 1=1,NUMST
WRITE(6,604) I, <ITRMAT<I,J),J=l, NUMST)
720 CONTINUE
ISCGTOT = ISCGTOT + ISCTOT
ISCGNA = ISCGNA + ISCNA
IOFFERS = ISCTOT + ISCNA
IGOFFERS= ISCGTOT + ISCGNA
A 56
DO 721 1 = 1,6





722 IATT = <ISCTOT » 100)/I0FFERS
WRITE<6,605) ISCTOT,IATT
723 IF(IGOFFERS. GT. 0) GOTO 724
WRITE<6,616) ISCGTOT
GO TO 725







DO 740 1=1, K
ITTPOP = ITTPOP + ISTOT(I)
IF(I .NE. 1) GOTO 730
ISTOT(I) = ISTOT <I) + IKIDZ
730 WRITE<6, 607)I, ISTOT*I)
740 CONTINUE








C AGE THE LIVE INFANTS*1-14YRS) BY MOVING THEM UP INTO THE NEXT AGE GROUP
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :





INFNUM = INFNUM + INFANT*ITO)
800 CONTINUE
C: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C THE NUMBER OF BIRTHS THIS YEAR IS PUT INTO THE FIRST YEAR INFANT AGE GROUP
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
INFANT*1) = IKIDZ
INFNUM = INFNUM + IKIDZ
C: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :




Y = FLOAT(IPEOPE * I))
PYS(I) = ( X+Y ) /2
850 CONTINUE
WRITE*10, 1601) IYR, (PYS*I), 1 = 1, 10)
DO 860 J=l, 9
JL=<J*10)+l
JU=UL+9
WRITE*10, 1602) * PYS*I), I=JL,JU)
860 CONTINUE
A 57























































IN AGEING SECTION, FILE', 13'
12/20X, ' '///






13, '*/. ELLIGIBLE ) ' )







' NUMBER IN STATE
/' TOTAL POPULATION ',18)
/' NUMBER OF BIRTHS ',18///)
/' DEAD SUBJECT IN AGEING SUBROUTINE,LINE 140')
/'ERROR IN IPEOPE<16),AGEING SUBROUTINE,LINE 470')
' TOTAL SCREENED TO DATE ',18, '(',13, "/. ELLIGIBLE)
30X,6(IX,14))
' TOTAL POSITIVE TESTS TO DATE',IX,515)
/' TOTAL SCREENED THIS YEAR ',18)






IX, 12, IX, 10 (F6. 1 ) )
4X, 10<F6. 1) )
A 58
C -s- ####■*# -S- -K- ft#*##*****####*-a- -55- it- •»•■& S *■»■* •» ■»*** -S-*# •»■ * -M- ■»*** ■»• #*#***** *■»■•*•#■■«••» ft -a-H-i* * ■»■■»■•«•**




C * aaaaaaaaaaaaaaaaaaaaaa*aaaaa aaaaaaaaaaaaaaaaaaa-a- a aa a aaaaaaaaaaaaaaaaaaa-a-aaaaa
C aaaaaaa*aaaaaaaaaaaaaaaaaaaaaaaaaaaaaa aa*aaaaaaaaaaaa*a -a- * -a- -a- aa aaaaaaaaaaaaaaaaa
INTEGER POPS2E,STHYST,STPOS,STHIS,STOTH, ADTNUM
INTEGER ADULT,TIMES,DEAD
COMMON POPSZE,NUMST,NUMYRS,STHYST,STPOS, STHIS, STOTH, INFNUM
COMMON ADTNUM, IYR
COMMON INFANT(15),ADULT(109999),TIMES(109999), DEAD(100)
C THIS IS ROUTINE FOR GENERATING RANDOM NUMBERS IN A GIVEN RANGE
INTEGER*-4 IR1, IR2
LOGICALal CALL1 /. TRUE. /
REAL*4 RLIST(0:99)
IF < CALL1 ) THEN
CALL1 =. FALSE.













C ^ "if-## ■ft###
C ** ■* *•*•* •* -* # •* * -a- -a- •* # •*•** -* *# •«■ *# -a- ■* #-a--a- # •«• #■ ■»• •«• •* *• ■* -a- -a- -a- -a- -a- -a- -a- ■**#■* -a- ■##■*■* a-#-a-#-a### -a- -a-#*-*■«•-a-*•«•*# -a-■«■** -a- #
C "»■ *55"^ "»• #
SUBROUTINE ENCODE (IREC,IAG,MS,IP,1ST)
C
C **** -if ■*•*■»-*■*■* *•£■**•*■**-a-* *■* ■Jf--K--a-^t--S«-*-K-^r*■&■ *-a-■*-«•-» ■*■«•■!«• ■*■«•■* *•»■■«■•*# ■«■■** •*•*•«■'«••* ■*■*•«■•*■* #-*•»■* •*•»■■*•«•■«• ■»■*■«•■«■ ■**•«•■#
INTEGER POPSZE,STHYST, STPOS, STHIS, STOTH, ADTNUM
INTEGER ADULT,TIMES, DEAD




C PRINT ERROR MESSAGE AND STOP PROGRAM IF WE ARE TRYING TO GO OUTSIDE ARRAY
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :




601 FORMAT< ' ** POPN ARRAY OVERFLOW, RECOMPILE WITH'
1 ' LARGER ARRAY IF REQUIRED **')
RETURN
END
C *•■**•*•»■*•» ##*■■**••**•■*■#•£#*#•*-a*#-*###*■*•*■**•* •* ■*#**-«•■*a********aaaa-a- aaaaaaaaaaaaaaaaaaaaaaa




C aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa -a- aaaaaaaaaaaaaaaaaaaaaaaaaaaaaa aaaaaa a
Caaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
INTEGER POPSZE,STHYST,STPOS,STHIS, STOTH, ADTNUM
INTEGER ADULT, TIMES, DEAD




C IREC INDEX NUMBER OF THE PERSON WHOSE VARIBLES WE WANT
C IVAL THE STORED VALUE IN ADULT(IREC) CONTAINING THE VARIABLES
C
C:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :





1ST = IVAL/IS +1
IVAL = IVAL-(IST-1)*1S









SUBROUTINE ENCTIM (IREC,ITIMM,ICLOCK, LSTAT)





COMMON POPSZE,NUMST,NUMYRS, STHYST, STPOS, STHIS, STOTH, INFNUM
COMMON ADTNUM,IYR
COMMON INFANT<15), ADULT(109999), TIMES<109999), DEAD<100)
C I:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C ENCODE THE DESIRED WOMAN'S TIME IN STATE, SCREENING CLOCK AND STATE LAST YEAR
C::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :










INTEGER POPSZE, STHYST, STPOS,STHIS, STOTH,ADTNUM
INTEGER ADULT, TIMES, DEAD






















SUBROUTINE TAB INI<TABLE,NDIM,LBND, UBND)
C*****
C******************************************************************************
INTEGER TABLE(1),NDIM, LBND <1), UBND<1)
C
TABLE <1) = 0
IF < NDIM. LT. 1 ) GOTO 901
C
TABLE < 2) = 1
C





IF ( ISIZ. LT. 1 ) GOTO 902
TABLE < 2) = TABLE < 2) ■* IS IZ
T ABLE(2*IDIM+1) = LBND(IDIM)
TABLE < 2*IDIM+2 > = ISIZ
END DO
TABLE(1) = NDIM






901 PAUSE 'NUMBER OF DIMENSION < 1 IN TAB INI '
RETURN
C

















DO IDIM = 1,NDIM
IND1 = INDEX (IDIM) -TABLE (2-a-IDIM+l)
IF ( IND1.LT. 0 .OR. IND1. GE. TABLE (2*IDIM+2) ) GOTO 902
IOFF = IOFF+1MUL#IND1






901 PAUSE 'NUMBER OF DIMENSION <1 IN TABVAL'
RETURN
C

















DO IDIM = 1,NDIM
IND1 = INDEX(IDIM)—TABLE(2#IDIM+l)





TABLE(2#NDIM+3+I0FF) = TABLE(2*NDIM+3+IOFF) + IVAL
RETURN
C
901 PAUSE 'NUMBER OF DIMENSION <1 IN TABADD'
RETURN
C




C -a- ■*•*** ■* ■«■*•»• ■»**•»■» -a- ***•*■«■•«••»■•&•&■!<■ #■**■&*••«•#•*■«••«■ •*•*•*■»■*■*■*$■# -s- ■* #•»* -a- #
C
SUBROUTINE TABOUT<TABLE, UNIT)




CHARACTER LEAD*100, F0RM*100, BUF*20
C
NDIM = TABLE <1)
IF ( NDIM. LT. 1 ) GOTO 901
C
FORM = ' <2H(*'
LFOR = 5
LLEA = 2
DO IDIM = 2,NDIM
INDEX(IDIM) = TABLE(2*IDIM+1)
WRITE <BUF, '(IS)') INDEX(IDIM)
CALL TRIM(BUF, II, 12, NO
WRITE (BUF, '(18)') INDEX(IDIM)+TABLE<2*IDIM+2)-1
CALL TRIM(BUF, II, 12, 13)
NC = MAX(NC,13)
13 = 1 + 1NT < LOG10 < REAL(NC)))
WRITE (F0RM(LF0R+1: ), 101) ',1H, ,I',NC










10 WRITE (LEAD,FORM) (INDEX<IDIM),IDIM=2,NDIM)
C
IF ( TABLE(4). LE. 10 ) THEN




WRITE (UNIT, 103) (TABLE(I), 1 = I0FF+11, 10FF+TA3LE(4))
END IF
102 FORMAT <1H0,A<LLEA>, X, 10110)
103 FORMAT (1H ,<LLEA>X,X,10110)
C
IOFF = IOFF+TADLE < 4)
IDIM = 1
20 IDIM = IDIM+1
IF ( IDIM. GT. NDIM ) RETURN
INDEX(IDIM) = INDEX(IDIM)+1








C: : : : : ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C TO SKIP LEADING AND TRAILING BLANKS IN A STRING
C: ::::::::::::: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :
C
C #***********■«■*** **■*■*•** •**■**■*-a*#* aaaaaaaaaaaaaaaaaa*
Caaaaa








DO WHILE ( STR ING (BEG_P: EEG_P ). EQ. ' ' .AND. BEG_P. LE. END_P )
BEG_P=EEG_P+1
END DO

























D I SK$D I 9
DISKI 6
DISK$DIE
PPPP AAA RRRR K K III N N
P p A A R R K K I N N
P F A A R R K K I NN N
PPPP A M RRRR KKK TJ. N N N
P AAAnA R R K K I N NN
P A A R R K K I N N
P A A R R K K 111 N N
'FFFFFFFFF IIIIII LL EEEEEEEEEE 11
'FFFFFFFFF 111111 LL EEEEEEEEEE 11
"F II LL EE 1111
F II LL EE 1111
"F II LL EE 11
F II LL EE 11
'FFFFFFF II LL EEEEEEEE 11
FFFFFFF II LL EEEEEEE Z. 11
c
i II LL EE 11
F II LL EE 11
tT
t 11 LL EE 11
C
r II LL EE 11
F IIIIII LLLLLLLLLL EEEEEEE EEE 111111
r
r IIIIII LLLLLLLLLL EEEE EEEEEE 111111
DDDDDDD AAAAAA
j
TTTTTTTTTT i i 11 333333 555555
DDDDDDD AAAAAA TTTTTTTTTT i i 11 333333 555555
-D DD AA AA TT > » 1111 33 33 55
-D DD AA AA TT i > 1111 33 33 55
D DD AA AA TT 11 33 555555
-D DD AA AA TT 11 33 555555
-D DD AA AA TT > i 11 33
-D DD AA AA TT > i 11 33
-D DD AAAAAAAAAA TT i i 11 33
-D DD AAAAAAAAAA TT i i 11 33
-D DD AA AA TT i 11 33 33 55
=D DD AA AA TT i 11 33 33 55
-DDDDDDD AA AA TT t 111111 333333 5555
DDDDDDD AA AA TT > 111111 333333 5555
PPPP AAA RRRR K K III N N
P P A A R R K K I N N
P P A A R R K K I NN M
PPPP A A RRRR KKK I N N N
P AAAAA R R K K I N NN
P A A R R K K I N N
P A A R . R K K III N N
PARKIN
PAR KIN







44 LPAO: 12— OCT—1983 07 : 44
44 LPAO: 12— U!-_/ r-i S'rj3 07: 44




FILE1 12—OCT—1983 07:44 LPAO
FILE1 12—0CT-19S3 07:44 LPAO








Size of starting population
Number of states
Years of simulation
t / 3583 3542 3457 3313 3200 3144 3223 3164 31 66
242 3387 3530 3897 4111 u 161 3342 3247 3163 2863
/ "DZ3 2940 2950 2926 nc-i. n"_/C. 2838 2788 ci / el 3 2794 2860
V-C-U 2814 2948 2900 3037 3145 3115 3176 3288 3522
>808
■H i a
xJ '4 / W
320 i
liTO






uj \J •—} e.
3 i 0 i
/ ■-/
3119




vJ sJ c£ UJ <c_ • I _> V >
:0G9 GL / tzlChtzlcl 2556 2506 / cl 2311 2 12 6
il 14 1877 1919 1313 1O7£) 1598 1508 1327 1 / 1121
067 879 783 679 595 488 407 309 185
145 101 75 53 38 26 18 10 8 5
O 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 ez. 4 6 8 10
12 14 15 28 42 63 80 100 125 165(T4620183 216 250 283 317 354 390 420 445
478 495 505 514 518 521 523 525 526 527
528 529 530 534 538 542 546 550 560 570
580 580 590 600 610 620 630 640 650 660
670 680 690 700 700 700 700 700 700 700






























pppp AAA RRRR K K III N M
p p A A R R K K I N N
p p A- A R R K K I NN N
pppp A A RRRR KKK 1 N N N
p f-\ A i' /M A R R K K I N NN
p h> R R K K I N iM
p A A R R K K 11 I N N
ffffffffff iiiiii ll eeeeeeeeee 222222
ffffffffff iiiiii ll eeeeeeeeee 222222
ff ii ll ee 22 22
ff ii ll ee 22 22
ff ii ll ee 22
ff ii ll ee 22
ffffffff ii ll eeeeeeee C.C.
ffffffff 11 ll eeeeeeee nnC.C-
ff ii ll ee 22
ff ii ll ee 22
ff ii ll ee 22
ff ii ll ee 22
ff iiiiii llllllllll eeeeeeeeee 22d22=:222c:
ff iiiiii llllllllll eeeeeeeeee 2=:22c:222<=:2
DDDDDDDD AAAAAA TTTTTTTTTT i i 1 000000
DDDDDDDD AAAAAA TTTTTTTTTT i } 1 000000
DD DD AA AA TT i i 111 00 00
DD DD AA AA TT i J 111 00 00
DD DD AA AA TT 1 00 0000
DD DD AA AA TT 1 00 0000
DD DD AA AA TT i i 1 00 00 00
DD DD AA AA TT i } 1 00 00 00
DD DD AAAAAAAAAA TT i > 1 0000 00
DD DD AAAAAAAAAA TT i / 1 0000 00
DD DD AA AA TT 1 00 00
DD DD AA AA TT 1 00 00
DDDDDDDD AA AA TT i > 111 11 000000
DDDDDDDD AA AA TT t } 111 11 000000
PPPP AAA RRRR K K 11 I N N
P P A A R R K K N N
P P A A R R K K NN N
PPPP A A RRRR KKK N N N
P AAAAA R R K K N NN
P A A R R K K N N
P A A R R K K III N N
VAX/VMS PARKIN FILE2 12 —OCT—1983 07: 44 LP AO: 12-OCT- 1983 07: 44
VAX/VMS PARKIN FILE2 12 -OCT—1983 07: 44 LP AO: 12 -OCT- 1983 07: 44
VAX/VMS PARKIN FILE2 12 -OCT—1983 07: 44 LP AO: 12 -OCT- 1983 07: 44
s M EM
1 GOO 000 000
1 GOO 000 000
1OOO 000 000
i 000 000 000
1000 000 000
1000 000 000



























































































































































PPPP AAA RRRR K K III N N
P P A A R R K K. J. N N
P P rn A R R K K I NN N
pppp A A RRRR KKK 7 N N N
P rr M f*. fi A R R K K I N NN
P A A R R K K i N N
P A A R R K K 111 N N
ffffffffff iiiiii ll eeeeeeeeee 333333
ffffffffff 111111 ll eeeeeeeeee 333333
ff ii ll ee 33 33
ff ii ll ee 33 33
ff ii ll ee 33
ff ii ll ee 33
ffffffff ii ll eeeeeeee 33
ffffffff ii ll eeeeeeee 33
ff ii ll ee 33
ff ii ll ee 33
ff ii ll ee 33 33
ff ii ll ee 33 33
ff iiiiii llllllllll eeeeeeeeee 333333
ff iiiiii llllllllll eeeeeeeeee 333333
DDDDDDDD AAAAAA TTTTTTTTTT 11
DDDDDDDD AAAAAA TTTTTTTTTT 11
DD DD AA AA TT nil
DD DD AA AA TT 1111
DD DD AA AA TT n
DD DD AA AA TT 11
DD DD AA AA TT 11
DD DD AA AA TT 11
DD DD AAAAAAAAAA TT 11
DD DD AAAAAAAAAA TT 11
DD DD AA AA TT 11
DD DD AA AA TT n
DDDDDDDD AA AA TT i llllll
DDDDDDDD AA AA TT i mill
pppp AAA RRRR K K 111 N N
P P A A R R K K I N N
p P A A R R K K I NN N
pppp A A RRRR KKK I N N N
p AAAAA R R K K I N NN
p A A R R K K I N N
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GE Single Married Married
60 NUMBER IN 1000 iHAT A + E Ii" iFLR
i 1000 0 01000 0 0 1000 0 0
n 1000 0 01000 0 01000 0 0
•Jj 1 000 0 01000 0 01000 0 0
4 1000 0 01000 0 01000 0 0
5 1000 0 01000 0 01000 0 0
6 1000 0 01000 0 01000 0 0
7 1000 0 01000 0 01000 0 0
0 1000 0 01000 0 01000 0 0
9 1 000 0 01000 0 01000 0 0
10 1000 0 01000 0 01000 0 0
1 i 1000 0 01000 0 01000 0 0
12 1000 0 01000 0 01000 0 0
13 1000 0 01000 0 01000 0 0
14 1000 0 01000 0 01000 0 0
15 1000 0 01000 0 01000 0 0
16 990 10 01000 0 01000 0 0
17 990 10 0 667 333 01000 0 0
18 990 10 0 571 410 191000 0 0
19 980 20 0 564 396 401000 0 0
20 970 30 0 560 370 701000 0 0
21 970 30 0 538 356 106 500 500 0
nn
C.C. 970 30 0 514 347 139 333 333 334
23 970 30 0 462 356 182 400 400 200
24 970 30 0 408 359 233 250 500 250
25 960 40 0 358 354 288 333 417 250
26 950 50 0 309 343 348 344 375 281
27 920 70 10 266 329 405 316 363 316
23 920 70 10 239 326 435 273 364 363
29 920 70 10 204 297 499 269 346 385
30 910 SO 10 184 281 535 276 345 379
31 920 70 10 167 267 566 250 333 417
32 910 SO 10 155 257 588 237 329 434
33 900 90 10 146 249 605 238 333 429
34 890 100 10 142 243 615 234 319 447
35 890 100 10 138 242 620 226 321 453
36 890 100 10 133 241 626 222 317 461
37 890 100 10 131 240 629 200 343 457
38 890 100 10 128 241 631 213 312 475
39 890 100 10 127 243 630 213 319 4 68
40 890 100 10 125 244 631 196 330 474
41 890 100 10 126 248 626 199 331 470
42 890 100 10 125 247 628 191 324 485
43 890 100 10 128 247 625 197 308 495
44 890 100 10 132 250 618 185 311 504
45 890 100 10 139 255 606 196 304 500
46 890 100 10 143 254 603 192 299 509
47 890 100 10 145 255 600 182 291 527
48 890 100 10 155 259 586 186 288 526
49 890 100 10 162 263 575 198 289 513
50 890 100 10 169 264 567 192 282 526
51 890 100 10 196 271 533 203 273 524
52 890 100 10 196 271 533 203 273 524
53 890 100 10 196 271 533 203 273 524
54 890 100 10 196 271 533 203 273 524
55 890 100 10 196 271 533 203 273 524
56 890 100 10 229 266 505 215 258 527
57 890 100 10 229 266 505 215 258 527
58 890 100 10 229 266 505 215 258 527
59 890 100 10 229 266 505 215 258 527
60 890 100 10 229 266 505 215 258 527
For each M.S. column












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PPPP AAA RRRR K K 111 N N
p P A A R R K K I ■ N hi
p p A A R R K K .T NN N
PPPP A A RRRR KKK I N N M
p Hi A rn Hi A R R K K j N MM
□ A A R R K K T-L M M













































































































































11 00 00 00







PPPP AAA RRRR K K III N N
p p A A R R K K I N N
p p A A R R K K I NN N
PPPP A A RRRR KKK I N N N
p AAAAA R R K K I N NN
p A A R R K K I N N
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1 2 3 4 5
10000 0 o 0 0
10000 0 0 0
10000 0 o 0 0 PARA MS AGE
10000 0 f. o 0
10000 0 Q 0 0
10000 0 0 0 0
10000 0 0 0 0
10000 0 o 0 0
10000 0 0 0 0 15
10000 0 0 0 0
10000 0 0 0 0
i oooo 0 0 0 0
10000 0 0 0 0
9959 39 oCm 0 0
9957 41 nCm 0 0
9954 44 Cm 0 0
9956 42 2 0 0
■1 /-
9954 44 nCm 0 0 16
9950 47 3 0 0
9928 68 4 0 0
9922 74 4 0 0
9917 78 5 0 0
9959 39 2 0 0 0
9957 41 2 0 0 1 c
9954 44 e- 0 0 2 +
9956 42 Oe. 0 0 n 17
9954 44 Cm 0 0 1 M
9950 47 3 0 0 2 +
9928 68 4 0 0 0
9922 74 4 0 0 1 FM
9917 78 5 0 0 2 +
9959 39 2 0 0
9957 41 2 0 0
9954 44 2 0 0
9956 42 O£. 0 0
189954 44 2 0 0
9950 47 3 0 0
9928 68 4 0 0
9922 74 4 0 0
9917 78 5 0 0
9959 39 Cm 0 0
9957 41 2 0 0
9954 44 2 0 0
199956 42 2 0 0
9954 44 n<2. 0 0
9950 47 3 0 0
9928 68 4 0 0
9922 74 4 0 0
9917 78 5 0 0
9960 38 2 0 0
9958 40 nc. 0 0
9955 43 2 0 0
9957 41 2 0 0
9955 43 2 0 0 20
9951 46 3 0 0
9930 66 4 0 0
9924 72 4 0 0
9919 76 5 0 0
9869 115 16 0 0
9862 121 17 0 0














































































































































































































































































































































































































































































































































































VAX /VMS P AR KIN F ILEUM 12-QCT-1983 07: 46 LPAG: 1 cL 00 i 1983 07: 49
v'Aa /VMS PARKIN FILE11M 12—OCT-19S3 07: 46 LPAO: 1 2—OCT— 1983 07: a aj
; a v
YHA /VMS PARKIN FILE11M 12—OCT-19S3 07: 46 LPAO: 1 2-GCT- 1983 07: 49
pppp aaa RRRR K K III M N
p p a a R R K K I N N
p p A a R R K K I NN N
pppp A a RRRR KKK I N N N
P hAAhiA R R K K I M MM
p A A R R K K I N M
p A A R R K K 111 N N
ffffffffff iiiiii ll eeeeeeeeee
ffffffffff iiiiii ll eeeeeeeeee
ff ii ll ee 111 11
ff ii ll ee 111 11
ff ii ll ee
ff ii ll ee
ffffffff ii ll eeeeeeee
ffffffff ii ll eeeeeeee
ff ii ll ee
ff ii ll ee
ff ii ll ee
ff ii ll ee
ff iiiiii llllllllll eeeeeeeeee 111 111 11
ff iiiiii llllllllll eeeeeeeeee 111 111 11
dddddddd aaaaaa tttttttttt } 222222
dddddddd aaaaaa tttttttttt i 222222
dd dd aa aa tt i 22 22
dd dd aa aa tt } 22 22
dd dd aa aa tt 22
dd dd aa aa tt 22
dd dd aa aa tt i 22
dd dd aa aa tt } 22
dd dd aaaaaaaaaa tt } 22
dd dd aaaaaaaaaa tt ) 22
dd dd aa aa tt 22
dd dd aa aa tt 22
dddddddd aa aa tt } i 2222222222
dddddddd aa aa tt » 2222222222
pppp aaa rrrr k k iii n n
p p a a r r k k i n n
p p a a r r k k i nn n
pppp a a rrrr kkk i n n n
p aaaaa r r k k i n nn
p a a r r k k i n n
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SSSS CCCC RRRR AAA TTTTT CCCC H I.II !
CO
■—} c R R A A 7 c H H
s c R R A A 7 c ! i H
'
W v-« c RRRR A A 7 c HH HHH
c R R r inr'V -»r-» 7 \ • H H
LJ R R ri ft 7 c i"1 H
Cj S —' iU cccc R R ri fn ~r c c cc H H
ffffffffff 111111 ll eeeeeeeeee 222222
ffffffffff 111111 ll eeeeeeeeee 222222
ff ii ll ee 111 ri/~> nnCUC-. C./'.
ff ii ll ee 111 22 22
ff ii ll ee 22
ff ii ll ee 22
ffffffff ii ll eeeeeeee 22
ffffffff ii ll eeeeeeee nnCCi
ff ii ll ee 22
ff ii ll ee 22
ff ii ll ee 22
ff ii ll ee 22
ff iiiiii llllllllll eeeeeeeeee 111 111 2222222222



































































RRRR AAA TTTTT CCCC H H
R R A A T c hi H
R R A A T c H H
RRRR A A T c HHHHH
R R AAAAA T c H H
R R A A T c H H


















1961 1990 01 6;
.1961 1990. 01k *
/ /
STATE
1 2 5 4
60 60 60 60
c; 700 700 7 00
100 a 4 00
55 55 55 55
5 700 700 700
100 a 4 00
50 50 50 50
5 700 700 700
100 0 4 00
45 45 43 45
5 700 700 700
100 S 4 00
40 40 40 40
5 700 700 700
100 8 4 00
35 35 35 35
5 700 700 700
100 8 4 00
30 30 30 30
5 700 700 700
100 8 4 00
<- % in each state who attend
No per 1000 found positive (move
STPOS)
who return from STPOS
to
L Parity eligible )
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PPPP AAA RRRR K K 111 N N
p p A A R R K K I N N
p p A A R R K K I NN N
PPPP A A RRRR KKK I N N N
p AAAaa R R K K I N NN
p A A R R K K I N N
p A A R R K K III N N
FFFFFFFFFF 111111 LL EEEEEEEEEE 11 333333
FFFFFFFFFF 111111 LL EEEEEEEEEE 11 333333
FF II LL EE 1111 33 33
FF II LL EE 1111 33 33
FF II LL EE 11 33
FF II LL EE 11 33
FFFFFFFF II LL EEEEEEEE 11 33
FFFFFFFF II LL EEEEEEEE 11 33
FF II LL EE 11 33
FF II LL EE 11 33
FF II LL EE 11 33 33
FF II LL EE 11 33 33
FF 111111 LLLLLLLLLL EEEEEEEEEE 111111 333333
FF 111111 LLLLLLLLLL EEEEEEEEEE 111111 333333
DDDDDDDD AAAAAA TTTTTTTTTT
DDDDDDDD AAAAAA TTTTTTTTTT
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT
DD DD AAAAAAAAAA TT
DD DD AAAAAAAAAA TT
DD DD AA AA TT
DD DD AA AA TT
DDDDDDDD AA AA TT

















PPPP AAA RRRR K K III N N
P P A A R R K K I N N
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9
9 999tPi 999®, 999, 't9999 999r"ffi999ffi



























PPPP AAA RRRR K K 111 N N
p p A A R R K K I N N
p p A A R R K K I NN N
pppp A A RRRR kkk I N N M
p ri A rn M R R k k I N NN
p A A R R k k I N N
p A A R R K K 111 N N
ffffffffff iiiiii ll eeeeeeeeee 11 44 44
ffffffffff iiiiii ll eeeeeeeeee 11 44 44
ff ii ll ee 1111 44 44
ff ii ll ee 1111 44 44
ff ii ll ee 11 44 44
ff ii ll ee 11 44 44
ffffffff ii ll eeeeeeee 11 44444444-
ffffffff ii ll eeeeeeee 11 44444444-
ff ii ll ee 11 44
ff ii ll ee 11 44
ff ii ll ee 11 44
ff ii ll ee 11 44
ff iiiiii llllllllll eeeeeeeeee 111111 44





























































pppp aaa rrrr k k iii n n
p p a a r r k k i n n
p p a a r r k k i nn n
pppp a a rrrr kkk i n n n
p aaaaa r r k k i n nn
p a a r r k k i n n




file14 12—oct—1983 07:47 lpao
file14 12—gct-1983 07:47 lpao





















































000 000 000 000 000 000 000 000 COO 000 000 000 000 020 050 104 169
266 234 203 173 149 129 112 094 081 073 062 055 049 043 038 033 029
019 017 016 01 5 014 013 012 Oil 010 009 008 007 006 005 005 005 004
|v
001002 002 002 002 002 002 002 002 002 002 002 001 001 001 001 001
001 001 001 001 000 000 000 000 000 000 000 000 000 000 000 000 000
000 000 000 000 000 000 000 000 000 000 000 000 000 000 001 002 003
006 006 007 007 008 008 008 007 007 007 007 007 007 007 007 007 007v
008 009 009 010 010 Oil 011 012 013 014 015 016 017 019 021 023 025
035 038 041 0-14 047 050 054 058 062 066 070 074 079 084 090 096 103
131 136 141 146 150 154 158 162 166 170 174 178 182 186 190 194 198
000 000 000 000 000 000 000 000 000 000 000 000 000 580 559 539 519
438 418 397 377 357 327 298 270 242 214 187 165 148 132 120 108 098 .
066 058 051 045 040 036 033 031 029 027 025 023 021 019 017 015 014 1
010 009 008 007 006 005 005 004 004 004 003 003 003 003 002 002 002
001 001 001 001 001 000 000 000 000 000 000 000 000 000 000 000 000
000 000 000 000 000 000 000 000 000 000 000 000 000 014 043 106 149
215 198 170 162 147 131 117 106 094 084 076 065 058 050 042 038 034
021 020 018 017 015 014 013 012 Oil 010 009 009 008 008 007 007 006
OOO1004 004 003 003 002 002 001 001 001 001 001 000 000 000 000 000
000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000
000 000 000 000 000 000 000 000 000 000 000 000 000 001 002 004 007
018 019 020 021 021 020 020 019 019 018 018 017 017 016 015 015 015
026^014 014 014 014 014 014 014 014 015 016 017 018 019 021 023 024
033 035 038 041 045 048 052 056 061 066 071 076 081 087 093 098 103
128 136 145 155 165 175 195 215 225 255 295 335 385 445 515 595 700
000 000 000 000 000 000 000 000 000 000 000 000 000 770 720 680 640
455 410 376 344 310 290 267 244 222 200 178 158 140 125 114 097 084 ,
010037 030 024 020 019 018 017 016 015 014 013 013 012 012 Oil Oil
008 008 007 007 006 006 005 005 004 004 003 003 002 002 001 001 001
001 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000
000 000 000 000 000 000 000 000 000 000 000 000 000 018 046 105 159
207 187 174 161 144 132 123 107 095 084 072 062 056 048 042 037 033
002021 019 017 016 015 013 012 Oil 010 009 008 007 006 005 004 003
002 002 002 002 002 002 002 002 002 002 001 001 001 001 001 001 001
001 001 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000
000 000 000 000 000 000 000 000 000 000 000 000 000 000 001 002 004
018 019 020 021 021 020 020 019 019 018 018 017 017 016 016 016 015
025^014 014 014 015 015 015 016 016 016 017 017 018 019 020 021 023
033 036 039 042 045 049 053 057 061 066 071 077 081 087 093 099 105
134 141 148 155 161 167 173 179 184 189 193 197 200 200 200 200 200
000 000 000 000 000 000 000 000 000 000 000 000 000 740 720 700 670
480 430 380 338 302 280 255 234 215 198 186 175 161 150 139 129 120 ,
084 076 070 064 057 052 048 045 042 039 036 033 030 027 024 021 018 f
006 004 004 004 004 004 003 003 003 003 003 002 002 002 002 002 001
001 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000
Decades 1-3 (R)
Rates of marriage (M) widowhood/divorce (w.d.) and remarriage (R)

















PFPP AAA RRRR K K III N N
P P A A R R K K I N N
P P A A R R K K I NN N
PPPP A A RRRR KKK I N N N
P AAAAA R R K K I N NN
P A A R R K K I N N
P A A R R K K III N N
FFFFFFFFFF 111111 LL EEEEEEEEEE 11 5555555555
FFFFFFFFFF 111111 LL EEEEEEEEEE 11 5555555555
FF II LL EE 1111 55
FF II LL EE 1111 55
FF II LL EE 11 555555
FF II LL EE 11 555555
FFFFFFFF II LL EEEEEEEE 11 55
FFFFFFFF II LL EEEEEEEE 11 55
FF II LL EE 11 55
FF II LL EE 11 55
FF II LL EE 11 55 55
FF II LL EE 11 55 55
FF 111111 LLLLLLLLLL EEEEEEEEEE 111111 555555





























































1111 00 00 00
1111 00 00 00
11 00 0000 00
11 00 0000 00
11 00 00 00 00 c
11 00 00 00 00 c
11 0000 00 0000
11 0000 00 0000
11 00 00 00




p P A A






R R K K
R R K K
RRRR KKK
R R K K
R R K K














FILEI5 12-OCT—1983 07:48 LPAO
FILE15 12—OCT—1983 07:48 LPAO


































































































































Probability (per 10^) of death (upper block) and hysterectomy
at individual years of aye - 3 decades.
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100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
9 54 69 79 85 90 93 96 97 98 99 99 99100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
46 64 76 83 88 92 95 97 98 98 99 99100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
1 36 57 71 81 87 91 94 96 97 98 99 99 99100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
-2 36 50 66 77 85 90 93 95 97 98 99 99 99100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
3 37 50 60 74 82 88 92 94 96 97 98 99 99 99100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
-4 37 50 61 69 79 86 91 94 95 97 98 99 99 99100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100




56 3S 51 61 70 76 SI 87 91 94 96 97 98 99 99 99100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
57 38 51 62 70 76 81 35 90 93 96 97 98 99 99 99100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
58 38 51 62 70 77 82 85 SS 92 95 97 98 98 99 99100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
59 38 52 62 70 77 82 86 89 91 94 96 97 98 99 99 99100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
60 38 52 62 71 77 82 86 89 91 93 95 97 98 99 99 99100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
61 38 52 62 71 77 82 86 89 91 93 95 96 98 98 99 99 99100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
62 38 52 63 71 77 82 86 89 91 93 95 96 97 98 99 99 99100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100iOO
100100100100100100100100100100100100100100100100100100100100100100100100100
63 38 52 63 71 77 82 86 B9 92 93 95 96 97 98 99 99 99100i00100i00i00i00i00i00
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
64 38 52 63 71 77 82 86 89 92 93 95 96 97 97 98 99 99 99100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
->5 38 52 63 71 77 82 86 89 92 93 95 96 97 97 98 99 99 99100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
-j6 38 52 63 71 78 83 86 89 92 94 95 96 97 98 98 98 99 99100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
■>7 38 52 63 71 78 83 86 89 92 94 95 96 97 98 98 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
>8 38 52 63 71 78 83 86 89 92 94 95 96 97 98 98 99 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
>9 39 52 63 71 78 83 87 90 92 94 95 96 97 98 96 99 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
•0 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
1 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
2 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
3 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
4 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100




76 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
77 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
78 39 52 63 71 78 33 87 90 92 94 95 96 97 98 98 99 99 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
79 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99100100100100100100
lOOlOOlOOlOOlOOlOOlOOiOOlOOlOOiOOlOOlOOlOOiOOiOOiOOlOOlOOiOOiOOlOOlOOiOOiOO
lOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOiOOlOOlOOlOOiOOiOOlOOiOOlOOiOOiOOiOOlOOlOO
30 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99100100100100100100
1001001001001001001001001001001001 OOiOOiOOiOOlOOiOOlOOiOO 1001001 OOlOOiOOiOO
100100100100100100100100100100100100100100100100100100100100100100100100100
31 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99100100100100100100
lOOlOOlQOlOOlOOlOOiOOlOOlOOlOOlOOiOOiOOiOOlOOiOOiOOiOOiOOlOOiOOlOOiOOlOOiOO
100100100100100100100100100100100100100100100100100100100100100100100100100
32 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100i00
33 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
94 39 52 63 71 78 83 87 90 92 94 95 96 97 98 98 99 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
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20 62 84 97100100100100100100100100100100100100100100100100100100100100100100
1001001OOlOOlOOlOOlOOlOOlOOlOOiOOlOOlOOlOOlOOlOOlOOlOOlOOiOOlOOlOOlOOiOOlOO
100100100100100100100100100100100100100100100100100100100100100100100100100
-21 54 74 89 98100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
-22 55 70 83 93 99100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
-23 55 69 80 88 95 99100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
-24 50 68 78 85 92 96 99100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
-25 45 62 76 83 89 94 97100100100100100100100100100100100100100100100100100100
lOOiOOiOOlOOlOOlOOlOO100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
>6 40 56 70 81 87 91 95 98100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
!7 35 51 65 76 85 90 93 96 98100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
!8 31 46 59 71 80 87 91 94 97 99100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
.'9 29 42 54 66 75 83 90 93 95 97 99100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
-*0 27 39 50 61 71 79 86 91 94 96 98 99100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
lOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOiOOlOOiOOiOOlOOiOOiOOiOOiOOlOOiOO
a 25 36 47 57 67 75 82 88 93 95 97 98 99100100100100100100100100100100100100
lOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOiOOlOOlOOiOOiOOiOOlOOlOOlOOlOOlOOiOO
100100100100100100100100100100100100100100100100100100100100100100100100100
-2 23 34 44 54 63 71 78 85 90 94 96 98 99100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
3 21 32 41 51 59 67 75 82 87 92 95 97 98 99100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
4 20 30 39 48 57 64 72 78 84 89 93 96 97 99 99100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100




36 19 27 36 44 52 60 67 73 79 34 89 93 96 98 99 99100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
lOOiOOlOOlOOlOOiOOiOOlOOlOOlOOlOOiOOlOOlOOlOOlOOlOOiOOiOOiOOiOOiOOiOOiOOiOO
37 18 27 35 43 50 58 65 71 77 82 87 91 94 97 98 99100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
38 17 26 34 41 49 56 63 69 75 SO 85 89 93 96 98 99 99100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
lOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOiOOiOOlOOlOOiOOiOO
39 17 25 33 40 48 55 61 68 73 79 84 88 91 94 97 98 93100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
lOOlOOlOOlOOlOOlOOiOOlOOiOOiOOlOOlOOlOOiOOlOOlOOlOOlOOiOOiOOiOOlOOiOOiOOiOO
40 17 24 32 40 47 54 60 66 72 77 82 87 90 93 96 98 99100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
lOOlOOlOOlOOlOOlOOlOOiOOiOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOiOOiOOiOOlOOiOOiOO
41 16 24 32 39 46 53 59 65 71 76 81 86 89 93 95 97 99 99100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
42 16 24 31 39 45 52 59 65 70 76 81 85 89 92 95 97 98 99100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
43 16 23 31 38 45 52 58 64 70 75 80 84 88 91 94 96 98 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
looiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooioo
44 15 23 30 38 45 51 57 64 69 74 79 84 88 91 94 96 98 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
45 15 23 30 37 44 51 57 63 69 74 79 83 87 91 93 96 97 98 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
46 15 23 30 37 44 51 57 63 68 74 79 83 87 90 93 95 97 98 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
47 15 22 30 37,43 50 56 62 68 73 78 83 87 90 93 95 97 98 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
48 15 22 29 36 43 49 56 62 68 73 78 82 86 90 93 95 97 98 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
49 14 21 29 36 43 49 55 62 67 73 78 82 86 90 93 95 97 98 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
60 15 22 29 36 43 50 56 63 69 74 79 83 87 90 93 95 96 98 99 99 99100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
61 16 23 30 37 45 51 58 64 70 75 80 84 88 91 94 95 97 98 98 99 99100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
62 17 24 31 38 45 52 59 65 71 76 81 85 89 92 94 96 97 98 98 99 99100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
lOOlOOiOOlOOlOOlOOlOOlOOlOOiOOiOOlOOlOOlOOlOOlOOlOOiOOlOOlOOiOOiOOiOOiOOiOO
63 17 25 33 40 46 53 60 66 72 77 82 86 90 93 95 96 97 98 98 99 99100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
iOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOlOOiOOiOOlOOlOOiOOlOOiOOlOOiOOlOOlOOiOOlOO
64 17 25 34 41 47 54 60 67 73 78 83 87 90 93 95 96 97 98 99 99 99100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100





56 17 26 34 42 49 56 62 68 74 79 S4 88 91 94 96 97 98 98 99 99 99100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
57 17 26 34 42 49 57 63 69 74 79 84 88 91 94 96 97 98 99 99 99 99100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
58 17 26 34 42 49 57 63 69 75 SO 84 88 91 94 96 97 98 99 99 99 99100100100100
1001001001001001001001001001001001001001001001001001001001001OG100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
59 17 26 34 42 49 57 63 70 75 80 85 88 92 94 96 97 98 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
60 18 26 34 42 49 57 63 70 76 81 85 89 92 94 96 97 98 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
■61 18 26 34 42 49 57 63 70 76 81 85 89 92 95 96 98 98 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
«62 18 26 34 42 50 57 63 70 76 81 86 89 92 95 96 98 98 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
■63 18 26 34 42 50 57 63 70 76 81 86 90 92 95 97 98 98 99 99 99100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
=64 18 26 34 42 50 57 64 70 76 81 85 89 93 95 97 98 98 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
•65 18 26 35 42 50 57 64 70 76 81 85 89 92 95 97 98 98 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
=66 18 26 35 43 50 57 64 70 76 81 85 89 92 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
■7 18 27 35 43 50 57 64 70 76 81 85 89 92 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
38 18 27 35 43 50 57 64 70 76 81 86 89 92 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
-»9 18 27 35 43 50 58 64 70 76 81 86 89 92 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
'0 18 27 35 43 51 58 64 71 76 81 86 89 93 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
'1 18 27 35 43 51 58 64 71 76 81 86 90 93 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
•2 18 27 35 43 51 58 64 71 76 81 86 90 93 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
3 18 27 35 43 51 58 65 71 76 81 86 90 93 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
4 18 27 35 43 51 58 65 71 76 81 86 90 93 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
5 18 27 35 43 51 58 65 71 77 82 86 90 93 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
A f 0 3
76 18 27 35 43 51 58 65 71 77 82 86 90 93 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
77 18 27 35 43 51 58 65 71 77 82 86 90 93 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
78 18 27 35 43 51 58 65 71 77 82 86 90 93 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
79 IS 27 35 43 51 58 65 71 77 82 86 90 93 95 97 98 99 99 99100100100100100100
iooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooiooioo
100100100100100100100100100100100100100100100100100100100100100100100100100
60 18 27 35 43 51 58 65 71 77 82 86 90 93 95 97 98 99 99 99100100100100100100
100100100100100100100100100100100100100100100100100100100100100100100100100
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13—OCT— 1983 08: 30 DI;
13—OCT— 1 983 08:30 DI:




NUMBER IN STATE 1 . . . 96333
NUMBER IN STATE "Jd- ... 675
NUMBER IN STATE n ... 425
NUMBER IN STATE 4 . . . 45
NUMBER IN STATE 5 . . . 98
NUMBER IN STATE 6 . . . 0
NUMBER IN STATE 7 . . . 2424
NUMBER IN STATE 8 . . . 0
NUMBER IN STATE 9 . . . 0
TOTAL POPULATION lOOOOO
YEAR 1
FROM STATE TO STATE
1 2 3 4 5 6 7 8 9
1 95026 214 3 0 0 24 136 0 380
2 152 457 21 0 0 36 1 0 3
3 2 3 369 26 0 19 3 0 3
4 0 0 0 IS 23 4 0 0 0
n;
u/ 0 0 0 0 37 0 1 o/ 1
6 0 0 0 0 0 0 0 0 0
7 0 0 0 0 0 0 2359 0 65
8 0 0 0 0 0 0 0 0 0
9 0 0 0 0 0 0 0 0 0
, 12—OCT—1983 09:13:45
THE I. A. R. C. CERVICAL CYTOLOGY SCREENING MODEL
TOTAL SCREENED THIS YEAR 4153< 467. ELLIGIBLE)
TOTAL SCREENED TO DATE 4153( 467. ELLIGIBLE)
1 2 3 4 5
TOTAL POSITIVE TESTS TO DATE 24 36 19 4 0
A tO 6
NUMBER IN STATE 1 . . . 96853
NUMBER IN STATE 2 . . . 674
NUMBER IN STATE 3 . . . 393
NUMBER IN STATE 4 . . . 44
NUMBER IN STATE 5 . . . 110
NUMBER IN STATE 6 . . . 83
NUMBER IN STATE 7 .. . 2550
NUMBER IN STATE 8 . . . 9















6 "7 8 9
1 95500 227 4 0 0 16 177 0 929
Cm 148 456 25 0 0 40 0 0 5
3 0 n\~J 341 27 0 17 1 0 4
4 0 0 0 16 21 4 nCm 0 1
5 0 0 0 0 100 0 nc. 5 3
6 25 3 nU 0 0 50 1 0 1jL
7 0 0 0 0 0 0 2487 0 63
8 0 0 0 0 0 0 0 9 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3907 < 45"/. ELLIGIBLE)
TOTAL SCREENED TO DATE 8060 ( 457. ELLIGIBLE)
1 tz. 3 4 5
TOTAL POSITIVE TESTS TO DATE 40 76 36 8 0
NUMBER IN STATE 1 . . . 97370
NUMBER IN STATE 2 . . . 689
NUMBER IN STATE 3 . . . 373
NUMBER IN STATE 4 . . . 43
NUMBER IN STATE 5 . . . 121
NUMBER IN STATE 6 . . . 127
NUMBER IN STATE ~7/ ... 2670
NUMBER IN STATE 8 . . . 14






FROM STATE TO STATE
3 4 5 6 8
1 96013 198 4 0 0 Cm Cm 170 0 963
2 137 500 21 0 0 22 1 0 8
3 0 1 326 25 0 19 0 0 Cm
4 0 0 0 19 20 4 0 0 0
5 0 0 0 0 106 0 1 12 Cm
6 14 3 1 0 0 106 0 0 3
7 0 0 0 0 0 0 2609 0 61
8 0 0 0 0 0 0 0 14 0
A10 8
0 0 u u
TOTAL SCREENED THIS YEAF
TOTAL SCREENED TO DATE
3708 ( 45"/ ELLICIBLE )
l:L76S< 45?/ ELL.IGIBLE)
TOTAL POSITIVE TESTS TO DATE
NUMBER IN STATE 1 . 97754
NUMBER IN STATE —iC. . . 702
NUMBER IN STATE 352
NUMBER IN STATE 4 44
NUMBER IN STATE 5 . . 126
NUMBER IN STATE 6 . . 173
NUMBER IN STATE / . . 2781
NUMBER IN STATE au.* . . 26















FROM STATE T 0 TATE
1 nc~ 3 4 5 6 / 8 9
1 96313 218 6 0 0 27 183 0 1007
2 156 481 26 1 0 27 4 0 7
3 1 1 306 17 0 21 1 0 5
4 0 0 0 21 20 2 0 0 1
5 0 0 0 0 115 0 1 9 1
6 23 2 2 0 0 146 0 0 0
7 0 0 0 0 0 0 2717 0 64
8 0 0 0 0 0 0 0 26 0




















NUMBER IN STATE 1 . . . 98111
NUMBER IN STATE C- ... 702
NUMBER IN STATE r>u ... 340
NUMBER IN STATE 4 . . . 39
NUMBER IN STATE 5 . . . 135
NUMBER IN STATE 6 . . . 223
NUMBER IN STATE 7 . . . 2906
NUMBER IN STATE 8 . . . 35
NUMBER IN STATE 9 1085
TOTAL POPULATION 102456
NUMBER OF BIRTHS 1618
a10 9
c a r
from state t 0 s t a t e
1 2 '3\_r 4 5 "J u /f
i 96718 258 0 0 X Z} 0 940
c~
1 -in ,107
x —r t t ex 1 0 31 i 0 ui
'"3 0 4 294 12 0 iqCX 0 0 *7
4 0 0 0 13 24 2 0 0 0
5 0 0 0 0 123 0 0 11 1
6 27 6 *•>CX 0 0 186 0cx 0 0
7 0 0 0 0 0 0 2850 0 56
8 0 0 0 0 0 0 0 35 0
9 0 0 0 0 0 0 0 0 0
total screened this year 3844 < 45% elligible)
total screened to date 19413( 45% elligible)
1 2 3 4 5
total positive tests to date 104 156 99 16 0
number in state 1 . . . 98538
number in state CX ... 765
number in state 3 . . . 330
number in state 4 . . . 26
number in state 5 . . . 147
number in state 6 . . . 257
number in state 7 . . . 3027
number in state 8 . . . 46






from state to state
3 4 5 6 8
1 97102 232 6 0 0 28 166 0 1004
2 175 523 33 0 0 27 0CX 0 5
3 0 1 289 20 0 16 0 0 4
4 0 0 0 12 14 0 0 0 0
5 0 0 0 0 132 0 0 13 ex
6 15 6 2 0 0 230 3 0 1
7 0 0 0 0 0 0 2970 0 57
8 0 0 0 0 0 0 0 46 0
9 0 0 0 0 0 0 0 0 0
total screened this year 3946< 44% elligible)
total screened to date 23359( 45% elligible)
1 2 3 4 5
A1 tO














3 . . . 330
4 ... 32








FROM STATE T 0 STATE
1 2 3 4 5 6 7 8 9
1 97418 232 nCL 0 0 17 203 0 1020
n
a. 153 528 35 ov_> 0 31 3 0 9
3 0 nCm 287 13 0 20 1 0 7
4 0 0 0 20 12 0 0 0 0
5 0 0 0 0 134 0 0 10 2
6 28 6 3 0 0 258 a. 0 4
7 0 0 0 0 0 0 3074 0 67
8 0 0 0 0 0 0 0 59 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR
TOTAL SCREENED TO DATE ;




























4 . . . 36
5 ... 146
6 ... 326
7 . . . 3283
8 ... 69




FROM STATE TO 3 T A T E
1 •-)c~ 3 4 5 •h 7 8 9
1 97822 239 £T ■i 0 .16 178 0 104 1
cL 154 540 r5 a 1 o w'C. 1 0 6
0 •->c.. 2S9 1 rjA •_/ 0 18 i 0 T
4 0 0 0 15 20 0 o 0
5 0 0 0 0 135 0 0 CD
6 i 7 3 cl i 0 300 0 1
7 0 0 0 0 0 0 OOIOuc. Ic. 0 / J.
8 0 0 o 0 0 0 0 69 0
9 0 o 0 0 0 0 0 0 o
TOTAL SCREENED THIS YEAR 3665 ( 457. ELLIGIBLE)
TOTAL SCREENED TO DATE 30937( 457. ELLIGIBLE)
1 2 3 4 5
TOTAL POSITIVE TESTS TO DATE 165 246 153 16 0
NUMBER IN STATE 1 . . . 99651
NUMBER IN STATE C- ... 784
NUMBER IN STATE 3 . . . 329
NUMBER IN STATE 4 . . . 31
NUMBER IN STATE 5 . . . 155
NUMBER IN STATE 6 . . . 366
NUMBER IN STATE 7 . . . 3394
NUMBER IN STATE 8 . . . 78
NUMBER IN STATE 9 . . . 1126
TOTAL POPULATION 104710
NUMBER OF BIRTHS 1658
YEA R 9
FROM STATE T 0 8 T A T E
1 3 4 5 6 7 8 9
1 98126 243 8 0 0 18 190 0 1066
2 161 540 38 0 0 29 3 0 13
3 0 3 289 20 0 13 1 0 3
4 0 0 0 12 16 3 0 0 0
5 0 0 0 0 139 0 0 14 2
6 16 3 1 0 0 342 Oe_ 0 2
7 0 0 0 0 0 0 3327 0 67
8 0 0 0 0 0 0 0 78 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3581 < 447. ELLIGIELE)
TOTAL SCREENED TO DATE 34518( 457. ELLIGIBLE)
1 2 3 4 5
TOTAL POSITIVE TESTS TO DATE 183 275 166 19 0
NUMBER IN STATE 1
NUMBER IN STATE 2
100029
789
NUMBER IN ST ATE 3 . . . -> i.auO
NuhbcR IN STATE 4 32
NUMBER IN STATE 5 . . . 155
NUMBER IN STATE 6 . . . 405
NUMBER IN STATE 7 . . . 3523
NUMBER IN STATE 3 . . . O'-Icu
NUMBER IN STATE 9 . . . 1153
TOTAL POPULATION 105269
NUMBER OF BIRTHS 1726
Y E A R 10
FROM STATE TO STATE
1 nCL r> 4 5 6 7 8 9
1 98587 224 12 0 0 9 153 0 1044
2 169 550 31 0 0 27 1 0 11
3 0 298 17 0 15 •->c_ 0 1
4 0 0 0 16 14 >-»CL. 0 0 0
5 0 0 0 0 147 0 0 6 -iez.
6 19 -3 0 0 374 4 0 2
7 0 0 0 0 0 0 3441 0 82
8 0 0 0 0 0 0 0 92 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 36SS ( 457. ELLIGIBLE)
TOTAL SCREENED TO DATE 38206< 457. ELLIGIBLE)
1 2 3 4 5
TOTAL POSITIVE TESTS TO DATE 192 302 181 21 0
NUMBER IN STATE 1 . . . 100468
NUMBER IN STATE ne. ... 780
NUMBER IN STATE 3 . . . 344
NUMBER IN STATE 4 . . . 33
NUMBER IN STATE 5 . . . 161
NUMBER IN STATE 6 . . . 427
NUMBER IN STATE 7 . . . 3601
NUMBER IN STATE 8 . . . 98
NUMBER IN STATE 9 . . . 1142
TOTAL POPULATION 105814
NUMBER OF BIRTHS 1693
Y E A R 11
FROM STATE TO STATE
123456789













in3 573 n i nC- 0 nn dLUC- 0 11
1 ■ 2 293 i 7 0 nn nt."« C— C- 0 7
o o 0 12 18 1 0 0 C-
o 0 0 0 151 0 0 / 3
10 5 i 0 0 402 4 0 5
0 0 0 0 0 0 3532 0 69
o 0 0 0 0 0 0 98 0
0 0 0 0 0 0 0 0 0
ED THIS YEAR 3909 ( 457. EL LIGIBL..E)
ED TO DATE 421151 457. ELLIGIBLE)
1 nCL 3 4 5







































V E A R i;




1 98577 226 9 0 0 20 221 0 1173
2 196 537 26 1 0 31 3 0 4
3 0 1 286 17 0 19 d. 0 4
4 0 0 0 16 14 0 0 0 1
5 0 0 0 0 152 0 0 16 1
6 18 4 2 0 0 436 2 0 4
7 0 0 0 0 0 0 3693 0 91
8 0 0 0 0 0 0 0 105 0

























1 . . . 99950
->
c. ... 768
3 . . . 323
4 . . . 34
5 . . . 166
6 . . . 506
7 . . . 3921
All k
NUMBER IN STATE 8
NUMBER IN STATE 9
TOTAL POPULATION 105668
NUMBER OF BIRTHS 1159
Y E A R 13
FROM STATE T 0 S T A T E
1 nc_ 4 5 6 7 8 9
1 98393 230 7 0 0 19 211 0 1090
2 142 559 30 0 0 26 Cm 0 9
3 1 4 279 14 0 19 0 0 6
4 0 0 0 16 16 1 0 0 1
5 0 0 0 0 153 0 1 7 5
6 20 5 rtv-J 0 0 471 3 0 4
7 0 0 0 0 0 0 3838 0 83
S 0 0 0 0 0 0 0 121 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3481 < 447. ELLIGIBLE)
TOTAL SCREENED TC DATE 49340( 457. ELLIGIBLE)
1 2 3 4 5
TOTAL POSITIVE TE STS TO DATE 250 381 241 23 0
NUMBER IN STATE 1 . . . 99741
NUMBER IN STATE 2 . . . 798
NUMBER IN STATE 3 . . . 319
NUMBER IN STATE 4 . . . 30
NUMBER IN STATE 5 . . . 169
NUMBER IN STATE 6 . . . 536
NUMBER IN STATE 7 . . . 4055
NUMBER IN STATE 8 . . . 128
NUMBER IN STATE 9 . . . 1 198
TOTAL POPULATION 105648
NUMBER OF BIRTHS 1185
YEA R 14
FROM STATE T 0 STATE
1 2 3 4 5 6 7 8 9
1 98125 238 7 0 0 24 CmCmCj 0 1119
2 178 552 26 1 0 31 1 0 9
3 0 3 27 5 18 0 18 3 0 OCm
4 0 0 0 9 17 4 0 0 0
5 0 0 0 0 159 0 0 6 4
















7 0 0 0 0 0 0 3978 0
8 0 0 0 0 0 0 0 1.28
9 0 0 0 0 0 0 0 0
'AL SCREENED THIS YEAR 3502 ( 44% ELLIGIBLE)
AL SCREENED TO DATE 52842< 45% ELLIGIBLE)
1 2 3 4 5
Ai_ POSITIVE TESTS TO DATE 274 412 259 27 0
NUMBER IN STATE 1 . . . 99529
NUMBER IN STATE nc- ... 797
NUMBER IN STATE rj~t ... 308
NUMBER IN STATE 28
NUMBER IN STATE 5 . . . 176
NUMBER IN STATE 6 . . . 578
NUMBER IN STATE 7 . . . 4216
NUMBER IN STATE ow ... 134
NUMBER IN STATE 9 . . . 1215
TOTAL !POPULATION 105632
NUMBER OF BIRTHS 1205
YEAR 15
FROM STATE TO STATE
1 2 3 4 5 6 7 8
1 97971 254 4 0 0 15 176 0
2 148 568 29 3 0 36 i 0
3 1 1 27 5 14 0 15 0 0
4 0 0 0 13 12 —!Cm 0 0
5 0 0 0 0 163 0 0 10
6 T~5c-cz. 6 3 0 0 537 6 0
7 0 0 0 0 0 0 4115 0
8 0 0 0 0 0 0 0 134
9 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3511< 44"/. ELLIGIBLE)
TOTAL SCREENED TO DATE 56353< 45"/. ELLIGIBLE)
1 2 3 4 5











1 . . . 99317




6 . . . 605
7 . . . 4298
8 ... 144
9 . . . 1232
105565
At t 6
NUMBER OF BIRTHS 1J.75
YEAR 16
FROM STATE T □ T A T E
1 ■..J 4 5 A 8 o
A
J. 97690 228 1 o 0 18 215 0 1165
n 171 583 36 3 0 24 o o 6
3 0 2 278 11 0 15 1 0 4
4 0 0 0 11 15 nC- 0 0 d.
5 0 0 0 0 161 0 0 10 /»
6 15 7 —>Cm 0 0 572 4 0 5
7 0 0 0 0 0 0 4204 0 94
8 0 0 0 0 0 0 0 144 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR
TOTAL SCREENED TO DATE
TOTAL POSITIVE TESTS TO DATE
3632 < 457. ELLIGIBLE)




















1 . . . 99060
2 . . . 820
3 . . . 317
4 . . . 25
5 ... 176
6 ... 631
7 . . . 4430
8 ... 154
9 . . . 1280
105459
1184
Y E A R 17
FROM STATE T 0 STATE
1 2 DuJ 4 5 6 7 8 9
1 97431 230 8 0 0 14 207 0 1 170
2 150 586 35 0 0 33 *■» 0 14
3 0 nc_ 277 18 0 16 0 0 4
4 0 0 0 8 14 3 0 0 0
5 0 0 0 0 158 0 0 11 7
6 20 3 4 0 0 598 1 0 5
7 0 0 0 0 0 0 4339 0 91
8 0 0 0 0 0 0 0 1 54 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3574 ( 457. ELLIGIBLE)
Alt 7
TOTAL SCREENED TO DATE 63559 < 457. ELLIGIDLE)
1





NUMBER IN STATE 1 ... 98820
NUMBER IN STATE nU. ... 821
NUMBER IN ST ATE 3 . . . 324
Ml M13ETO
I M 1 1JL-* t— i \ IN CTA Ti n 1 u. 'r ... 26
NUMBER IN ST ATE 5 . . . 172
NUMBER IN ST ATE 6 . . . 664
NUMBER IN STATE 7 . . . 4549
NUMBER IN STATE 8 . . . 165
NUMBER IN STATE 9 . . . 1291
TOTAL POPULATION 105376
NUMBER OF BIRTHS 1219










6 7 8 9
1 97180 246 6 0 0 21 234 0 1 133
2 158 590 rjr-yUC 1 0 31 2 0 "7/
3 0 4 278 16 0 19 4 0 3
4 0 0 0 13 10 1 1 0 1
5 0 0 0 0 153 0 0 10 9
6 14 4 1 0 0 635 3 0 7
7 0 0 0 0 0 0 4 441 0 108
8 0 0 0 0 0 0 0 165 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3440 ( 447. ELLIGIBLE)
TOTAL SCREENED TO DATE 66999( 457. ELLIGIBLE)
1 2 3 4 5


















7 . . . 4685
8 ... 175
9 . . . 1268
105277
1 179




















FROM STATE TO STATE





950 217 n; 0 0 IS 201 0




















22 3 nCm 0 o 671 0
0 0 0 0 0 0 4 583 0
0 0 0 0 0 0 0 175
0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR































7 . . . 4790
8 ... 186
9 . . . 1262
105267
1263
Y E A R 20
FROM STATE TO STATE
1 2 3 4 5 6 7 8
1 96654 278 4 0 0 18 234 0
2 184 598 21 0 0 28 2 0
3 0 Cm 285 14 0 11 0 0
4 0 0 0 13 16 1 0 0
5 0 0 0 0 146 0 0 7
6 21 3 5 1 0 698 nCm 0
7 0 0 0 0 0 0 4671 0
8 0 0 0 0 0 0 0 186
9 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3517< 457. ELLIOIBLE)
TOTAL SCREENED TO DATE 73945 ( 457. ELL 101BLE )
1 2 3 4 5
TOTAL POSITIVE TESTS TO DATE 378 595 353 36 0
All 9
NUMBER IN S TATE 1 . . . 98160
NUMBER IN STATE •->C 881
NUMBER IN STATE n 315
NUMBER IN STATE 4 . . . 28
NUMBER IN STATE 5 . . . 162
NUMBER IN STATE a ... 756
NUMBER IN STATE / ... 4909
NUMBER IN STATE p 193
NUMBER IN STATE 9 1350
TOTAL POPULATION 10521.1
NUMBER OF BIRTHS 1301
Y E A R 21
!M STATE T 0 L3 T A T E
1 -ieu 3 4 5 6 7 8 o/
1 96489 226 4 o 0 14 203 0 1224
tZ. 181 610 39 1 0 40 "5C_ 0 8
n
•_> 0 0 275 16 0 19 1 0 4
4 0 0 0 11 14 r_ 0 0 1
5 0 0 0 0 146 0 1 10 5
6 21 3 1 0 0 717 3 0 1 J.
7 0 0 0 0 0 0 4817 0 92
8 0 0 0 0 0 0 0 193 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3498 ( 44"/. ELLIGIBLE)
TOTAL SCREENED TO DATE 77443 < 457. ELLIGIBLE)
1 2 3 4 5
TOTAL POSITIVE TESTS TO DATE 392 635 372 38 0
NUMBER IN STATE 1 . . . 98062
NUMBER IN STATE 2 . . . 839
NUMBER IN STATE 3 . . . 319
NUMBER IN STATE 4 . . . 28
NUMBER IN STATE 5 . . . 160
NUMBER IN STATE 6 . . . 792
NUMBER IN STATE 7 . . . 5027
NUMBER IN STATE 8 . . . 203
NUMBER IN STATE 9 . . . 1345
TOTAL POPULATION 105227
NUMBER OF BIRTHS 1371
Y E A R 22
FROM STATE TO STATE
1 2 3 4 5 6 7 8 9
AJ 20
1 96385 240 a*_/ 0 0 16 211 0 1202
n
c. ISO 591 25 0 0 32 p 0 9
3 0 0 271 15 0 29 1 0 3
4 0 0 0 J. 4 12 1 0 0 1
5 0 0 0 0 147 0 na. 8 3
6 15 7 nC- 0 0 756 5 0 '7/
7 0 0 0 0 0 0 4917 0 1 10
8 0 0 0 0 0 0 0 203 0
9 0 0 0 0 0 0 0 0 o
AL SCREENED THIS YEAR 371S ( 467. 1ELLIGIBLE)
AL SCREENED TO DATE SI 161( 457. 1ELLIGIBLE>
1 *-)c- 3 4 5
AL POSITIVE TESTS TO DATE 408 667 401 39 0
NUMBER IN STATE 1 . . . 98014
NUMBER IN STATE nCm ... 338
NUMBER IN STATE 3 . . . 306
NUMBER IN STATE 4 . . . 29
NUMBER IN STATE 5 . . . 159
NUMBER IN STATE G ... ann~r
NUMBER IN STATE / ... 5138
NUMBER IN STATE B . . . 211





Y E A R 23
FROM STATE T 0 S TAT E
1 2 3 4 5 6 7 8 9
1 96315 242 1 0 0 16 220 0 1220
2 173 582 27 0 0 43 3 0 10
3 0 1 265 20 0 16 1 0 -i\mJ
4 0 0 0 11 14 0 0 0 4
5 0 0 0 0 145 0 1 6 7
6 18 3 3 0 0 799 5 0 6
7 0 0 0 0 0 0 5020 0 1 18
8 0 0 0 0 0 0 0 211 0


















NUMBER IN STATE 1 . . . 97897
NUMBER IN STATE nCm ... 828
NUMBER IN STATE O•mJ ... 296
NUMBER IN STATE 4 . . . 31
NUMBER IN STATE 5 . . . 159
A] 2 1
NUMBER IN STATE 6 . . 874
NUMBER IN STATE 7 . . . 5250
NUMBER IN STATE S . . . 217
NUMBER IN STATE 9 . . . 1368
TOTAL POPULATION 105335
NUMBER OF BIRTHS 1391
Y E A R 24
FROM STATE TO STATE
1 2 3 4 5 6 7 8
1 96300 252 5 0 0 15 202 0 1123
n
e. 176 532 28 1 0 28 —>Gm 0 11
3 0 CL 258 13 0 17 n 0 A
4 0 0 0 16 13 2 0 0 0
5 0 0 0 0 145 0 0 6 8
6 17 9 2 0 0 831 1 0 14
7 0 0 0 0 0 0 5122 0 128
8 0 0 0 0 0 0 0 217 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3494 ( 467. ELLIGIBL E)
TOTAL SCREENED TO DATE 88310( 457. ELLIGIBL.E)
1 2 3 4 5
TOTAL POSITIVE TESTS TO DATE 439 738 434 41 0
NUMBER IN STATE 1 . . . 97958
NUMBER IN STATE <=. ... 845
NUMBER IN STATE 3 . . . 293
NUMBER IN STATE 4 . . . 30
NUMBER IN STATE 5 . . . 150
NUMBER IN STATE 6 . . . 893
NUMBER IN STATE 7 . . . 5329
NUMBER IN STATE 8 . . . 223
NUMBER IN STATE 9 . . . 1288
TOTAL POPULATION 105506
NUMBER OF BIRTHS 1465
YEA R 25
FROM STATE TO S TATE
1 £. 3 4 5 6 / 8 9
1 96256 245 5 0 0 18 220 0 1214
n
C_ 182 584 33 1 0 35 3 0 -7/
3 0 3 259 13 0 15 1 0 Oc_
4 0 0 0 13 16 1 0 0 0
At 2 2
0 0 0 0 143 0 1 10 4
19 TV-J -)CL. 0 0 849 o 0 J '7
~7 0 0 0 0 0 0 5217 0 112
8 0 0 0 0 0 0 0 223 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3553< 467. ELLIGIBL..E)
TOTAL SCREENED TO DATE 91863< 457. ELL IG IDLE )
1 2 3 4
TOTAL POSITIVE TESTS TO DATE 457 773 449 42
NUMBER IN STATE 1 . . . 97905
NUMBER IN STATE C- ... 835
NUMBER IN STATE OvJ ... 299
NUMBER IN STATE 4 . . . 27
NUMBER IN STATE 5 . . . 159
NUMBER IN STATE o ... 918
NUMBER IN STATE *7/ ... 5445
NUMBER IN STATE 8 . . . 233





Y E A R 26
FROM STATE TO STATE
1 2 3 4 5 6 7 8 9
1 96243 244 10 0 0 16 233 0 1159
2 179 530 32 0 0 33 3 0 8
3 1 0 267 19 0 11 1 0 0
4 0 0 0 13 14 0 0 0 0
5 0 0 0 0 147 0 0 9 3
6 20 e 1 0 0 873 4 0 12
7 0 0 0 0 0 0 . 5322 0 123
8 0 0 0 0 0 0 0 233 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3485< 457. ELLIGIBL.E)
TOTAL SCREENED TO DATE 95348( 45% ELLIGIBLE)
1 2 3 4 5














4 . . . 32
5 . . . 161
6 . . . 933
7 . . . 5563
8 . . . 242
9 . . . 1305
A t 2 3
I Q • AL. POPULrtT i ON iOc?/ C'rl
NUMBER OF- BIRTHS 1453
V P •*>i i_. n R 27
FROM STATE T 0 0 T A T E
1 nCm J 4 6 UJ 9
1 96143 253 *7/ i 0 17 214 0 1266
2 187 573 27 1 0 31 O■—I 0 10
3 0 4 268 12 0 19 2 0 5
4 0 0 0 17 1.3 0 0 0 'i
5 0 0 0 0 142 0 0 14 5
6 17 6 1 0 0 894 '•>Cm 0 .1.3
7 0 0 0 0 0 0 5435 0 128
8 0 0 0 0 0 0 0 242 0
9 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3592 < 457 IELLIGISL E)
TOTAL SCREENED TO DATE 98940 < 457 1ELLIGIELE)
1 r~iCm 3 4 5
TOTAL POSITIVE TE STS TO DATE 490 837 479 42 0
NUMBER IN STATE 1 . . . 97783
NUMBER IN STATE nCm ... 836
NUMBER IN STATE 3 . . . 303
NUMBER IN STATE 4 . . . 31
NUMBER IN STATE 5 . . . 155
NUMBER IN STATE 6 . . . 961
NUMBER IN STATE 7 . . . 5656
NUMBER IN STATE 8 . . . 256
NUMBER IN STATE 9 . . . 1429
TOTAL POPULATION 105725






i 1 13D 1 1no 1CO
FROM STATE T 0 S T A T E
1 2 3 4 5 6 7 8 9
1 96066 277 4 1 0 19 243 0 1173
2 192 581 25 1 0 26 1 0 10
3 1 1 277 6 0 15 0 0 3
4 0 0 0 12 18 1 0 0 0
5 0 0 0 0 142 0 0 10 3
6 20 2 3 0 0 917 3 0 J. 6
7 0 0 0 0 0 0 5530 0 1 18
8 0 0 0 0 0 0 0 256 0












FOTAL SCREENED THIS YEAR







TOTAL POSITIVE TESTS TO DATE
NUMBER IN STATE 1 97749
NUMBER IN STATE Z) 061
NUMBER IN STATE 3 309
NUMBER IN STATE 4 . . . 20
NUMBER IN ST ATE 5 160
NUMBER IN ST ATE 6 . . . 978
NUMBER IN ST ATE / ... 5785
NUMBER IN STATE 8 . . . 266





NUMBER OF BIRTHS 1470











1 96037 238 7 0 0 14 224 0
2 173 602 36 1 0 42 n 0
3 0 nc_ 264 13 0 19 I 0
4 0 0 0 6 12 0 0 0
5 0 0 0 0 141 0 i 15
6 19 3 2 0 0 933 3 0
7 0 0 0 0 0 0 5680 0
3 0 0 0 0 0 0 0 266
9 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR 3611 ( 467. ELLIGIBLE)
TOTAL SCREENED TO DATE 106178( 457. ELLIGIBLE)
1 C- 3 4 5
TOTAL POSITIVE TESTS TO DATE 523 905 513 43 0
NUMBER IN STATE 1 . . . 97726
NUMBER IN STATE nc~ ... 845
NUMBER IN STATE 3 . . . 309
NUMBER IN STATE 4 . . . 20
NUMBER IN STATE 5 . . . 153
NUMBER IN STATE 6 . . . 1008
NUMBER IN STATE "7/ ... 5912
NUMBER IN STATE 8 . . . 281
NUMBER IN STATE 9 . . . 1371
TOTAL POPULATION 105973
NUMBER OF BIRTHS 1497
AJ 25











0- / R 9
i 96044 ci. O 1 r,u. \_' n 0 13 OCiCiL WW 0 j. 20 /
aL 192 O fa.. TDzr_ \.j .1 0 31 r:L 0 4
' "3 0 0 d. / O 10 0 20 C— 0 1
4 0 0 0 10 8 1 0 0 1
5 0 0 0 0 141 0 0 / 5
6 is 5 1 0 0 969 i 0 14
7 0 0 0 0 0 0 5759 0 153
8 0 0 0 0 0 0 0 201 0
a
/ 0 0 0 0 0 0 0 0 0
TOTAL SCREENED THIS YEAR












NUMBER IN STATE 1 . . . 97684
NUMBER IN STATE —tto. ... 849
NUMBER IN STATE nuJ ... 310
NUMBER IN STATE 4 . . . 21
NUMBER IN STATE 5 . . . 149
NUMBER IN STATE 6 . . . 1034
NUMBER IN STATE 7 . . . 5964
NUMBER IN STATE 8 . . . 288
NUMBER IN STATE 9 . . . 1385
TOTAL POPULATION 106011
NUMBER OF BIRTHS 1430
FORTRAN STOP
Job 42 entered on queue LPAO
FORTRAN STOP
Job 43 entered on queue LPAO









01: 48: 18. 17
Peak working set size:

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































<-*, 1) 0 0
<#, 2 > 11 3
<*, 3> 87 6
(*, 4) 145 24
(#, 5) 118 34
<*, 6) 111 52
<*, 7) 68 46
(*, 8) 57 31
<*, 9) 45 15
<*,101 41 13
(*,11) 37 IS
<*, 12) 22 13



































VAX/VMS SCRATCH FOROOS 13-0CT-1933 OS: 25 LPAO: 13-0CT-19S3 03: 25
VAX/VMS SCRATCH FOROOS 13-DCT-l983 03:25 LPAO: 13-0CT-19S3 08:25
VAX/VMS SCRATCH FOROOS 13-0CT-1983 OS:25 LPAO: 13-GCT-19S3 OS:25
ssss CCCC RRRR AAA
8 c R R A A
S c R R A A
sss c RRRR A A
Q c R R AAAAA
s c R R A A






















FFFFFFFFFF 000000 RR.RRRRRR 000000 000000
FF 00 00 RR RR 00 00 .00 00 08
FF 00 00 RR RR 00 00 00 00 88
FF 00 00 RR RR 00 0000 00 0000 88
FF 00 00 RR RR 00 0000 00 0000 88
FFFFFFFF 00 00 RRRRRRRR 00 00 00 00 00 00
FFFFFFFF 00 00 RRRRRRRR 00 00 00 00 00 00
FF 00 00 RR RR 0000 00 0000 00 08
FF 00 00 RR RR 0000 00 0000 00 08
FF 00 00 RR RR 00 00 00 00 88
FF 00 00 RR RR 00 00 00 00 88
FF 000000 RR RR 000000 000000















DDDDDDDD AAAAAA TTTTTTTTTT i l
DDDDDDDD AAAAAA TTTTTTTTTT i i
DD DD AA AA TT i in
DD DD AA AA TT } 111
DD DD AA AA TT l
DD DD AA AA TT i
DD DD AA AA TT i i
DD DD AA AA TT '/ l
DD DD AAAAAAAAAA TT > l
DD DD AAAAAAAAAA TT i i
DD DD AA AA TT l
DD DD AA AA TT l
DDDDDDDD AA AA TT i > 111
DDDDDDDD AA AA TT t in
ssss CCCC RRRR AAA TTTTT CCCC H H
s c R R A A T c H H
s c R R A A T C H H
sss c RRRR A A T c HHHHH
c c R R AAAAA T C H H
8 c R R A A T C 1-1 H
ssss CCCC R R A A T CCCC H H
VAX/VMS SCRATCH FOROOS 13-0CT-1983 08:25 LPAO
VAX/VMS SCRATCH F0R008 13-0CT-1983 08:25 LPAO





































































































































































































































































































































































































































































































































































































































































































































































































































































































ssss CCCC RRRR AAA TTTTT CCCC H H
s c R R A A T C H H
s c R R A A T c H H
sss c RRRR A A T c HHHHH
c> c 11 R AAiAAA T c 1 ■ { ri
c: c R R A A T c ! 1 H
coco CCCC R R A A T CCCC H H
FFFFFFFFFF 000000 RRRRRRRR 000000 000000 999999
FFFFFFFFFF GOuOOO RRRRRRRR 000000 000000 999999
FF 00 □0 RR RR GO 00 00 00 99 99
FF 00 00 RR RR 00 00 00 00 99 99
FF 00 00 RR RR 00 0000 00 0000 99 99
FF 00 00 RR RR 00 0000 00 0000 99 99
FFFFFFFF 00 00 RRRRRRRR 00 00 00 00 00 00 99999999
FFFFFFFF 00 00 RRRRRRRR 00 00 00 00 00 00 99999999
FF 00 00 RR RR 0000 00 0000 00 99
FF 00 00 RR RR 0000 00 0000 00 99
FF 00 00 RR RR 00 00 00 00 99
FF 00 00 RR RR 00 00 00 00 99
FF 000000 RR RR 000000 000000 999999
FF 000000 RR RR 000000 000000 999999
DDDDDDDD AAAAAA TTTTTTTTTT )
DDDDDDDD AAmAAA TTTTTTTTTT f
DD DD AA AA TT } 11
DD DD AA AA TT > 11
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT t
DD DD AA AA TT /
DD ' DD AAAAAAAAAA TT j
DD DD AAAAAAAAAA TT '}
DD DD AA AA TT
DD DD AA AA TT
DDDDDDDD AA AA TT } 11
DDDDDDDD AA AA TT '} 1 1
SSSS CCCC RRRR AAA TTTTT CCCC H H
s c R R A A T C H H
s c R R A A T C H H
sss c RRRR A A T C HHHHH
s c R R AAAAA T c H H
c c R R A A T c H H











LPAO: 13-OCT—1983 08: 26



































































































































































































































































































































































































































































































































































































































































































































































































































A t 3 4
VAX/VMS SCRATCH FDROiO 13-0CT-1933 03
VAX/VMS SCRATCH FDROIO 13-0CT-1983 03







SSSS CCCC RRRR AAA TTTTT CCCC H H
S c R R A A T (; H H
S c R R A A T >w' H H
SSS c RRRR A A T c HHHHH
C; c R R A A AAA 7 c H H
s c R n A A T c H i-i
SSSS ccc c R R A A T CCCC H H
FFFFFFFFFF 000000 RRRRRRRR 000000 11
FFFFFFFFFF 000000 RRRRRRRR 000000 j. 1
FF 00 00 RR RR 00 00 1111
FF 00 00 RR RR 00 00 111 1
FF 00 00 RR RR 00 0000 11
FF 00 00 RR RR 00 0000 11
FFFFFFFF 00 00 RRRRRRRR 00 00 00 11
FFFFFFFF 00 00 RRRRRRRR 00 00 00 J- J.
FF no 00 RR RR 0000 00
FF 00 00 RR RR 0000 00
FF 00 00 RR RR 00 00 11
FF 00 00 RR RR 00 00 1 L
FF 000000 RR RR 000000 1111
FF 000000 RR RR 000000 1111
DDDDDDDD AAAAAA TTTTTTTTTT i i i i 11
DDDDDDDD AAAAAA TTTTTTTTTT ; ; i i 1 1
DD DD AA A A TT > i i i 1111
DO DD AA AA TT ; ; ; ; 1 1 1 1
DD DD AA A A TT 11
DD DD AA AA TT 1 1
DD DD AA AA TT i } i i 1 1
DD DD A A AA TT i i > i
DD DD AAAAAAAAAA TT i i i ; 1 1
DD DD AAAAAAAAAA TT i > i i 1 1
DD DD AA AA TT i ; 1 1
DD DD AA A A TT ; i 1 1
DDDDDDDD AA AA TT i • 1111



















SSSS CCCC RRRR AAA TTTTT CCCC H H
s c R R A A T C H H
s c R R A A T C H H
SSS c RRRR A A T c HHHHH
o c R R AAAAA T c H H
s c R R A A T c H H



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































C This takes output from 316 (in files FOROOS, F0R009,FDROIO)
C and prints tables of incidence and mortality
C by 5 and 10 year age groups
C PLUS cumulative person-years of life lost each yesr
C ■8--B-* •* •*■«"«■■* ■«• ** -K- ***•«•*■«■ ■*• •*■»• ■»• •*■»■■«■■«•*•* ■»•»•■«••«• ■«••«• ■»••»• # *■#•# it*■»*#* -K- «■ -K- ■«■■«• ***■»••«••»•#•»•*•«••»• H- # ■» ****#** -ir *•
DIMENSION IDEAD(30.100),ICASE(30,100),PYS(30,100)
DIMENSION IVDEAD <10,20), IVCASE(10, 20)
DIMENSION IXDEAD(10, 10), IXCASE(10, 10)
DIMENSION ITDEAD(10), ITCASE(IO)
DIMENSION VDEAD(10,20),VCASE(10,20),VPYS(10,20)
DIMENSION XDEAD(10, 10), XCASE(10, 10), XPY5(10, 10)
DIMENSION TDEAD(10), TCASE(IO), TPYS(IO)
DIMENSION VDRATE(10, 20), VIRATE(10, 20)






C DATA IS YEARS FOR WHICH TABLES ARE REQUIRED EG. 10 = 1961-70, 20=1971-80
DATA IYRTAES/30, 10, 20, 30, 5, 10, 15, 20, 25, 30/
C *S*****#***************************###********■#****#•«•#* # **•«••»* **#•«••»•## *•**
C DATA FOR LIFE TABLE EXPECTATION OF LIFE 2 FORMATS!
C IMAXAGE IS MAX AGE REACHED AT AGES GIVEN e.g. 1-39=77, 40-51=78, etc
C IYRSLEFT IS eOx AT AGES GIVEN e. g. 80-82=7,83-84=6, ... etc
C * *■**************•«■**** ********************************** ***************
DATA IMAXAGE/39, 51, 59, 63, 67, 70, 73, 76, 77, 79/
DATA IYRSLEFT/82, 84, 87, 91, 95, 98, 100/
C ***** **********************************************-ft-#********************
C READ IN DATA FILES
C*******************"*******#***********************************************
5 READ(8, 801,END=10) IYR, I AG
IDEAD(IYR, IAG) = IDEAD(IYR, I AG ) + 1
GO TO 5
10 READ(9,801,END=20) IYR,IAG
ICASE(IYR,IAG) = ICASE(IYR,IAG) + 1
GO TO 10
20 DO 30 1=1,30
DO 25 J = 1, 10
IU = J * 10
IL = IU - 9









LFYRDAT(J)= (77 + I) - J
40 CONTINUE
ICOUNT = IMAXAGE(I) + 1
42 CONTINUE
DO 46 1 = 1, 7




ICOUNT « IYRSLEFT(I) + 1
46 CONTINUE
C CALCULATE & PRINT RATES FOR PERIODS DEFINED BY IYRTABS
K-0
DO 500 I = 1, 10
IF (IYRTABS(I). EQ. 0) GO TO 600
K = K + 1
IF (14 . LT. 31) GOTO 50
K = 1
50 IYR1 = 1960 + K
IYR2 = 1960 + IYRTABS(I)
WRITE<20,601) IYR1,IYR2
WRITE(20,602)
C ■a******#*#**'*-**-**##****-*#*-*-a***# **■»•*■a- -a-a-a-a-a-a-a-aaaaaaaaaaaaaaaaaaaaaaaaaaaaa
C 5 YEAR AGE GROUP TABLES
DO 200 N = 1, 20
IUA = N * 5
ILA = IUA - 4
IPL = I LA - 1
IPU = IUA - 1
DO 150 J = K,IYRTABS(I)
DO 120 M = ILA,IUA
IVDEAD(I,N) = IVDEAD(I,N) + IDEAD(J, M>
IVCASE(I,N) = IVCASE(I,N) + ICASE(J, M)




IF(VDEAD< I, N). GT. 0. 0) GOTO 160
VDRATE ( I, N) = 0. 0
GOTO 170
160 VDRATE(I,N) = <VDEAD(I,N) * 100000) / VPYS(I,N)
170 VCASE <I,N) = FLOAT <IVCASE <I,N))
IF< VCASE< I, N). GT. 0. 0) GOTO 180
VIRATE( I, N) = 0. 0
GO TO 190
ISO VIRATE(I, N) = (VCASE(I, N) * 100000) / VPYS(I,N)
190 WRITE(20, 2001)IPL, IPU, IVCASE(I, N), VIRATE(I, N), IVDEAD(I, N),
1 VDRATE(I, N)
200 CONTINUE
C aaa -a- *aaaaaaaaaaaaaaaaaaaaaaaaaaaaa -a- aaaaaaaaaaaaaaaaaaaaaaaa a*aaaaaaaaaaaaa
C TABLES FOR 10 YEAR AGEGROUPS
Caaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
WRITE(20, 602)
DO 300 N = 1,10
IUA = N-a-10
ILA = IUA - 9
IPL = ILA - 1
IPU = IUA - 1
DO 250 J = K, I YRTABS (I)
DO 220 M = ILA, IUA
IXDEAD(I, N) = IXDEAD(I,N) + IDEAD(J,M)
IXCASE(I,N) = IXCASE(I,N) + ICASE(J,M)




IF(XDEAD( I, N). GT. 0. 0) GOTO 260
Al 4 1
XDRATE ( I j N > = 0.0
GOTO 270
260 XDRATE(L N) = (XDEAD < I, N) * 100000) / XPYS(I,N)
270 XCASE(I, N) = FLOAT(IXCASE<I,N))
IF( XCASE( L N). GT. 0.0) GOTO 2S0
XIRATE!I, N) = 0. 0
GO TO 290
280 X IRATE ( L N) = (XCASE!I, N> * 100000) / XPYS(LN)
290 WRITE <20. 2001 ) I PL. IPU. I XCASE < I.N), X IRATE < I, N), I XDEAD ( I, N),
1 XDRATE<I,N)
300 CONTINUE
C CALCULATE NOS. AND RATES FOR ALL AGES
WRITE<20,602)
DO 350 J = K, IYRTABS(I)
DO 320 M = 1, 100
ITDEAD <I) = ITDEAD <I) + IDEAD(J,M)
ITCASE <I) = ITCASE <I) + ICASE<J,M)
TPYS <I) = TPYS(I) + PYS<U,M)
320 CONTINUE
350 CONTINUE
TDEAD <I) = FLOAT<ITDEAD<I))
IF(TDEAD< I ). GT. 0. 0) GOTO 360
TDRATE ( I) = 0. 0
GOTO 370
360 TDRATE <I) = (TDEAD(I) * 100000) / TPYS(I)
370 TCASE(I) = FLOAT<ITCASE<I))
IF < TCASE ( I ) . GT. 0.0) GOTO 380
TCASE < I ) = 0. 0
GO TO 390
380 TIRATE<I) = <TCASE<I) * 100000) / TPYS<I)
390 WRITE<20,2002) ITCASE<I),TIRATE<I),ITDEAD<I),TDRATE(I)
K = IYRTABS <I)
500 CONTINUE
C **■»•#**#**#■«•#****#*»■#•«■■«• *■»•■»•■**■«■■«■ **
C WRITE OUT CUMULATIVE LIFE YEARS LOST AT EACH YEAR
C ## -a"*-** ■K-^-H- -a-■»■«■•»■■»■■«•*•«■■»■*■»■■«•«•■«••«•■«■■«••«■ ■«■■»••»•#•«•«■■»■•«••«•■«••«•«■«• •«■•»•■«■* is-***###*****
WRITE<20,603)
DO 520 I = 1,30
DO 510 J = 1, 100
IPYLL <I) = IPYLL(I) + <IDEAD!I,J)*LFYRDAT!J))
510 CONTINUE
WRITE<20,2003) I,IPYLL<I)
IPYLL( 1 + 1 ) = IPYLL <I)
520 CONTINUE
600 STOP
601 FORMAT</, 3X, 'YEARS ',14,' TO ',14)
602 FORMAT < /, 3X, 'AGE',3X, 'CASES', 3X, 'INC',2X, 'DEATHS', 2X, 'RATE')
603 FORMAT!/, 2X, 'YEAR',2X, 'P-YRS LOST')
801 FORMAT < 213)
1001 FORMAT <4X, 10<F6. 1))
2001 FORMAT! IX, 12, ' - ', 12, 2< 1X, 14, 1 X, F7. 2) )
2002 FORMAT! IX, 'ALL AGE', 2< IX, 14, IX, F7. 2) )
2003 FORMAT <3X, 12, 5X, 17)
END
At * 2
VAX/VMS SCRATCH FOR020 13—OCT—1983 08: 25 LPAO : 13-OCT-1903 OS: 29
VAX/VMS SCRATCH FOR020 13-OCT-1983 08: 25 LPAO : 13-OCT-1933 08: 29
VAX/VMS SCRATCH FOR020 13-OCT-1983 03: O = LP AO : 13-OCT-1933 OS: 29
SSSS CCCC RRRR AAA TTTTT CCCC H H
3 C R R A A T C H H
S C R R A A T C H i-i
SSS C RRRR A A T c HHHHH
S C R R AAAAA T c H Pi
S C R R A A j~ c H H
SSSS CCCC R R A A } CCCC H H
FFFFFFFFFF 000000 RRRRRRRR 000000 TTTTTlCC.C.C.U.C OOOOOO
FFFFFFFFFF 000000 RRRRRRRR OOOOOO 222222 OOOOOO
FF 00 00 RR RR 00 00 22 22 00 00
FF 00 00 RR RR 00 00 OO OOCZ.CU CUCU 00 00
FF 00 00 RR RR 00 0000 22 00 0000
FF 00 00 RR RR 00 0000 22 00 0000
FFFFFFFF 00 00 RRRRRRRR 00 00 00 cucu 00 00 00
FFFFFFFF 00 00 RRRRRRRR 00 00 00 OOcue.. 00 00 00
FF 00 00 RR RR 0000 00 ppcu t— 0000 00
FF 00 00 RR RR 0000 00 oncue. 0000 00
FF 00 00 RR RR 00 00 22 00 00
FF 00 00 RR RR 00 00 22 00 00
FF 000000 RR RR OOOOOO TT-JTV OOOOOO
FF 000000 RR RR OOOOOO 2222222222 OOOOOO
DDDDDDDD AAAAAA TTTTTTTTTT
DDDDDDDD AAAAAA TTTTTTTTTT
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT
DD DD AA AA TT
DD DD AAAAAAAAAA TT
DD DD AAAAAAAAAA TT
DD DD AA AA TT
DD DD AA AA TT
DDDDDDDD AA AA TT










\U\DZJ CCCC RRRR AAA TTTTT CCCC H H
s c R R A A T c hi H
s c R R A A T c H H
SSS c RRRR A A T c HHHHH
s c R R AAAAA T c H H
s c R R A A T c H H







F0R020 13—OCT—1983 08:25 LPAO
F0R020 13-0CT-19S3 OS:25 LPAO


























































CASES INC DEATHS RATE
0 0. 00 0 0. 00
0 0. 00 0 0. 00
0 0. 00 0 0. 00







26 13. 23 3 1. 53
25 12. 86 6 3. 09
51 26. 54 20 10. 41
56 29. 94 17 9. 09
46 24. 45 41 21. 79
55 29. 50 34 18. 23
38 21. 21 32 17. 87
40 24. 44 27 16. 50
52 37. 39 41 29. 48
TO
C. i-J 26. 38 24 22. 61
23 34. 80 25 37. S3
10 31. 84 9 28. 66
1 9. 96 4 39. 84




























SES INC DEATHS RATE
0 0. 00 0 0. 00
0 0. 00 0 0. 00
0 0. 00 0 0. 00
0 0. 00 0 0. 00
1 1. 49 0 0. 00
3 4. 90 1 1. 63
9 14. 78 0 0. 00
8 12. 71 1 1. 59
21 31. 78 10 15. 13
21 31. S3 7 10. 61
23 34. 56 18 27. 05
21 31. 77 16 24. 20
24 40. 25 11 IS. 45
14 27. 40 8 15. 66
23 55. 02 14 33. 49
9 29. 28 8 26. 03
n 16. 22 2 10. 82
ry
■—/ 37. 19 1 12. 40
ah*
90 - 94 1 46. 01 1 46. 01
95 ~ 99 0 0. 00 0 0. 00
AGE CASES INC DEATHS RATE
0 - 9 0 0. 00 0 0. 00
10 - 19 0 0. 00 0 0. 00
j?o — no 4 3. 12 1 0. 78
Lu 0 1 39 17 13. 73 1 0. 81
4.0 ~~ 49 'X'P; 31. 80 17 12. 07
50 - 59 ~r "*■: vJ . i / 'O ■''! 25. 63
60 — 69 •—'• iJ? 'T . icl. 19 IT. 16*
70 — 79 Oc 44. 11 22 30. 33
SO - ooCj .' O 22. 59 3 11. 30
90 - 09 1 40. 96 1 40. 96
AGE CASES INC DEATHS RATE
ALL AGE 184 18. 00 98 9. 59
YEA RS 1971 TO 1980
AGE CASES INC DEATHS RATE
0 4 0 0. 00 0 0. 00
5 - 9 0 0. 00 0 0. 00
10 - 14 0 0. 00 0 0. 00
15 - 19 0 0. 00 0 0. 00
20 - 24 1J. 1. 44 0 0. 00
25 — 29 7. 02 4 5. 62
uJ 34 8 11. 98 3 4. 49
35 - 39 12 19. 75 cL 3. 29
40 ~ 44 14 23. 30 3 4. 99
45 - 49 16 25. 99 3 4. 87
50 - 54 8 12. 56 8 12. 56
55 - 59 18 28. 90 11 17. 66
60 - 64 5 8. 19 7 11. 46
65 — 69 16 27. 63 11 IS. 99
70 - 74 16. 33. 38 14 29. 21
75 - 79 9 25. 51 7 19. 84
SO - 84 14 63. 11 15 67. 61
65 - 89 4 36. 99 4 36. 99
90 - 94 0 0. 00 3 82. 77
95 - 09 0 0. 00 0 0. 00
AGE CASES INC DEATHS RATE
0 - 9 0 0. 00 0 0. 00
10 - 19 0 0. 00 0 0. 00
20 - 29 6 4. 27 4 2. 85
30 - 39 20 15. 68 5 3. 92
40 - 49 30 24. 66 6 4. 93
50 - 59 26 20. 64 19 15. 08
60 - 69 21 17. 65 18 15. 13
70 - 79 25 30. 05 21 25. 24
SO - 89 IS 54. 55 19 57. 58
90 — 99 0 0. 00 3 71. 92
AGE CASES INC DEATHS RATE
ALL AGE 146 13. 92 95 9. 05
YEARS 1981 TO 1990
AGE CASES INC DEATHS RATE






























































i ^ 25. 91
.16 27. 54
9 15. 40


















































CASES INC DEATHS RATE
134 12. 78 95 9. 06
1961 TO 1965
SES INC DEATHS RATE
0 0. 00 0 0. 00
0 0. 00 0 0. 00
0 0. 00 0 0. 00
0 0. 00 0 0. 00
0 0. 00 0 0. 00
1 3. 30 0 0. 00
4 13. 02 0 0. 00
6 18. 54 1 3. 09
14 41. 24 4 11. 78
13 40. 03 4 12. 32
IS 51. 71 10 28. 73
14 43. 16 6 18. 50
12 41. 74 7 24. 35
7 28. 45 3 12. 19
13 63. 97 5 24. 61
5 33. 86 5 33. 86
1 11. 67 0 0. 00
0 0. 00 0 0. 00
0 0. 00 1 115. 07


























































0 0. 00 0 0. 00
'j 1. 63 0 0. 00
1 0 15. 85 1 1. 58
ri. / 40. 65 8 12. 04
32 47. 59 16 23. 79
19 35. 61 10 18. 74
13 51. 30 10 28. 50
i 8. 2? 0 0. 00
0 0. 00 1 101. 73
ASES INC DEATHS RATE
103 21. 43 46 9. 13
1966 to 1970
:ases inc deaths rate
0 0. 00 0 0. 00
0 0. 00 0 0. 00
0 0. 00 0 0. 00
0 0. 00 0 0. 00
•1
i 2. 77 0 0. 00
o
cr- 6. 46 1 3. 23
5 16. 57 0 0. 00
c. 6. 54 0 0. 00
/ 21. 78 6 18. 67
8 23. 88 3 8. 95
B 15. 75 8 25. 20
20. 79 10 29. 70
12 38. 86 4 12. 95
/ 26. 42 5 18. 87
i o 46. 54 9 41. 89
4 25. 04 3 18. 78
'"3 20. 17 2 20. 17
65. 62 1 21. 87
1 76. 66 0 0. 00










































30 - 34 7 22. 66 2 6. 48
■JiZ) •Ji'"/ 5 16. 6 6 a. £j. O CJ
40 - 4 4 9 29. 68 0 0. 00
45 — 4 9 / 22. 10 1 3. 16
50 - 54 oc. 6. 10 4 12. 21
55 - 59 o 29. 41 3 9. 80
60 - 64 4 12. 51 4 12. 51
65 - 69 6 21. 07 5 17. 55
70 - 74 10 43. 29 8 34 . 63
~? —; *"7 Q j 17. 65 4 77 r~\
SO - 84 ~7 65. 07 5 46. 48
85 - 89 n 58. 42 o 58. 42
90 - 94 o 0. 00 3 174. 37
95 - 99 0 0. 00 0 0. 00
AGE CASES INC DEATHS RATE
0 - 9 0 0. 00 0 0. 00
10 - 19 0 0. 00 0 0. 00
20 - 29 5 7. 02 2 2. 81
30 - 39 12 19. 70 4 6. 57
40 - 49 16 25. SI 1 1. 61
50 - 59 1 1 17. 36 7 1 1. 05
60 - 69 10 16. 54 9 14. 89
70 - 79 13 32. 42 12 29. 93
80 - 89 10 62. 92 8 50. 34
90 - 99 0 0. 00 3 154. 36
AGE CASES INC DEATHS RATE
ALL AGE 77 14. 65 46 8. 75
YEARS 1976 TO 1980
AGE CASES INC DEATHS RATE
0-4 0 0. 00 0 0. 00
5-9 0 0. 00 0 0. 00
10 - 14 0 0. 00 0 0. 00
15 - 19 0 0. 00 0 0. 00
20 - 24 0 0. 00 0 0. 00
25 - 29 1 2. 84 2 5. 69
30 - 34 1 2. 78 1 2. 78
35 - 39 *7/ 22. 77 0 0. 00
40 - 44 5 16. 80 3 10. 08
45 - 49 9 30. 1 1 2 6. 69
50 - 54 6 19. 40 4 12. 93
55 - 59 9 28. 41 8 25. 26
60 - 64 1 3. 44 3 10. 31
65 - 69 10 33. 98 6 20. 39
70 - 74 6 24. 16 6 24. 16
75 - 79 6 32. S3 3 16. 41
80 - 84 7 61. 25 10 87. 50
85 - 89 1 17. 61 1 17. 61
90 - 94 0 0. 00 0 0. 00
95 - 99 0 0. 00 0 0. 00
AGE CASES I NO DEATHS RATE
0-9 0 0. 00 0 0. 00
10 - 19 0 0. 00 0 0. 00
20 - 29 1 1. 45 2 2. 89
30 - 39 8 12. 00 1 1. 50
40 - 49 14 23. 47 5 8. 38
50 - 59 15 23. 96 12 19. 17
AI 4 8
60 - 4. IT; I 1 1 8. 7 w 9. 15. 38
70 - 79 1 T 27. 34 9 20. 88
SO - 89 8 4 6. 76 11 64. 30
90 - 99 0 0. 00 0 0. 00
rVcrC CASES INC DEATHS RATE
ALL AiGE 69 13. 18 49 9. 36
vcr a
' u.. n p c 1981 TO 1905
AGE CASES INC DEATHS RATE
0 — 4 0 0. 00 0 0. 00
5 - 9 0 0. 00 0 0. 00
10 - 14 0 0. 00 0 0. 00
15 - 19 0 0. 00 0 0. 00
20 - 24 0 0. 00 0 0. 00
25 - 29 1 2. 95 0 0. 00
30 - 34 ACJ 17. 12 0 0. 00
35 - 39 o 8. 39 1 2. 80
40 - 44 / 22. 94 5 16. 38
45 - 49 12 40. 85 3 10. 21
50 - 54 10 34. 26 3 10. 28
55 - 59 7 23. 46 5 16. 76
60 - 64 5 16. 64 5 16. 64
65 - 69 1 3. 72 2 7. 44
70 - 74 ~7/ 27. 14 7 27. 14
75 - 79 5 25. 59 6 30. 71
SO — 84 24. 35 2 16. 24
S5 — 89 *"5c. 33. 20 1 16. 60
90 - 94 0 0. 00 0 0. 00
95 - 99 0 0. 00 0 0. 00
AGE CASES INC DEATHS RATE
0 - 9 0 0. 00 0 0. 00
10 - 19 0 0. 00 0 0. 00
20 - 29 1 1. 38 0 0. 00
30 - 39 9 12. 71 1 1. 41
40 - 49 19 31. 72 8 13. 36
50 - 59 17 28. 80 8 13. 56
60 - 69 6 10. 54 7 12. 30
70 - 79 12 26. 47 13 28. 68
SO - 89 5 27. 26 3 16. 36
90 - 99 0 0. 00 0 0. 00
AGE CASES INC DEATHS RATE
ALL AGE 69 13. 19 40 7. 64
YEARS 1986 TO 1990
AGE CASES INC DEATHS RATE
0 — 4 0 0. 00 0 0. 00
5 - 9
r<
u 0. 00 0 0. 00
10 - 14 0 0. 00 0 0. 00
15 - 19 1 2. 74 0 0. 00
20 - 24 0 0. 00 0 0. 00
25 - 29 1 2. 62 0 0. 00
30 - 34 *"3VJ 3. 83 0 0. 00
35 - 39 O£. 5. 73 Cm 5. 73
40 - 44 9 25. 38 nCm 5. 64
45 - 49 ~7/ 23. 23 4 13. 27
50 - 54 5 17. 41 12 41. 79
75 - 79 5 24. 29 w 14. 53
SO — 34 3 22. 91 6 45. 33
85 - 39 1 15. 39 3 46. 16
90 - 94 0 0. 00 0 0. 00
95 - 99 0 0. 00 0 0. 00
AG E CASES INC DEATHS RATE
0 - 9 0 0. 00 0 0. 00
10 - 19 i 1. 52 0 0. 00
20 - 29 1 1. 28 0 0. 00
30 - 39 5 7. 28 2 2. 91
40 - 49 16 24. 40 6 9. 15
50 - 59 14 24. 58 14 24. 58
60 — 69 13 23. 13 15 26. 69
70 - 79 11 24. 92 9 20. 39
80 - 89 4 20. 42 9 45. 94
90 - 99 0 0. 00 0 0. 00
AGE CASES INC DEATHS RATE
ALL AGE 65 12. 37 55 10. 47
YEAR P-YRS LOST
1 151
2 235
3 504
4 750
5 966
6 1274
7 1507
8 1639
9 1909
10 2056
11 2203
12 2444
13 2542
14 2675
15 2856
16 3061
17 3245
18 3417
19 3643
20 3771
21 3973
22 4089
23 4168
24 4313
25 4539
26 4665
27 5002
28 5217
29 5476
30 5573
